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OGTT oral glucose tolerance test
p probability or pico - ,  xlO-12
PBS phosphate buffered saline
PEG polyethylene glycol
PI proinsulin
QC quality control
r correlation coefficient
RIA radioimmunoassay
RPMI Roswell Park Memorial Institute
S APU Scottish Antibody Production Unit
SD standard deviation
SP solid-phase
TEA triethylamine
TEA trifluoroacetic acid
Th helper T lymphocyte
Ts suppressor T lymphocyte
U units
UV ultraviolet
v/v volume/volume
w/v weight/volume
WHO World Health Organisation
yr year
p. micro xlO-9
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HENRY DAVID THOREAU
SUMMARY
Production of high titre, high avidity, polyclonal antisera to insulin was attempted in 
a number of animal species but was only successful in guinea-pigs. In particular, 
the use of Strain 2 guinea-pigs resulted in a 100% success rate (Chapter 3).
Ten murine monoclonal antibodies (McAbs) were produced using porcine insulin 
and human proinsulin as immunogens. Six reacted with insulin and proinsulin, one 
with C-peptide and proinsulin, and three with proinsulin only (Chapter 4).
The detection of McAbs specific for proinsulin required the preparation of 
monoiodinated 125I-proinsulin. This involved the development of a reverse-phase 
high performance liquid chromatography (HPLC) technique to separate the various 
iodinated species of 125I-proinsulin (Chapter 5, Section 1.2).
A two-site immunoradiometric assay (IRMA) for human insulin was developed 
using the guinea-pig anti-insulin in conjunction with an insulin McAb raised using 
porcine insulin as immunogen. Proinsulin cross-reacted in the assay to a degree 
dependent upon the form being measured and its concentration (Chapter 5, 
Section 2).
Initial evaluation suggested that the avidity of the C-peptide McAb was too low to 
provide a proinsulin IRMA of the required sensitivity (Chapter 5, Section 4). 
Subsequent reassessment with the previously unavailable NIBSC proinsulin 
standard and a higher avidity insulin McAb suggested that a potentially useful assay 
could be developed (Chapter 5, Section 6.3).
The highest avidity proinsulin-specific and insulin McAbs, raised using human 
proinsulin as immunogen, were used in a two-site IRMA to measure human 
proinsulin. The presence of insulin interfered with the initial assay developed 
(Chapter 5, Section 5) and the protocol was modified to abolish this effect
2 9
(Chapter 5, Section 6). The assay measured intact, 65-66 split and des 64-65 
proinsulin.
Clinical validation of the assays developed was performed by measuring insulin and 
proinsulin concentrations in serum from normal adult subjects under a variety of 
conditions (Chapter 6, Section 1). The release of proinsulin relative to insulin was 
found to be delayed in response to an increase in blood glucose concentrations.
Serum proinsulin and insulin concentrations were also measured in patients in 
various states of altered or patho-physiology. Measurement of fasting proinsulin 
compared to insulin concentrations provided improved discrimination in the 
diagnosis of insulinoma (Chapter 6, Section 2.3).
The reported association between cirrhosis of the liver and glucose intolerance, 
hyperinsulinaemia and hyperproinsulinaemia was confirmed although the data 
suggested that only hyperinsulinaemia was truly secondary to the development of 
cirrhosis. The hyperinsulinaemia appeared to be due to reduced degradation rather 
than hypersecretion (Chapter 6, Section 2.5).
Data is presented which supports the role of insulin resistance in the development of 
impaired glucose tolerance in pregnancy (Chapter 6, Section 2.2) and the high 
circulating concentration of insulin in a boy with Mendenhall's Syndrome 
(Chapter 6, Section 2.4). However, an abnormal pattern of insulin secretion in the 
basal state also appears to contribute to the hyperinsulinaemia in Mendenhall's 
Syndrome.
The glucose intolerance has also been shown to be due to an abnormal pattern of 
insulin release in response to increased blood glucose concentrations in patients 
with non-insulin dependent diabetes mellitus (NIDDM) (Chapter 6, Section 2.1) and 
cirrhosis of the liver (Chapter 6, Section 2.5).
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From the clinical data presented in this thesis, it is hypothesised that two pools of 
insulin exist, only one of which contains intact proinsulin. It is hypothesised that 
the pattern of release of insulin from these pools varies in the basal and stimulated 
states, and that various pathophysiological conditions, including insulin and non­
insulin dependent diabetes mellitus, exhibit altered patterns of secretion which are 
characteristic of the underlying disease mechanism.
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1 PROINSULIN, INSULIN AND C-PEPTIDE
1.1 H istorical Background
The Islets of Langerhans were first described in 1869 (1), approximately fifty years 
before the discovery of insulin (2). In 1889, von Mering and Minkowski showed 
that pancreatectomy produced diabetes in dogs (3), but it was not until 1921 that 
insulin was isolated from the pancreas of dogs in a relatively pure form by Banting 
and Best (2).
Since its discovery, research involving insulin has resulted in an impressive list of 
firsts. It was the first protein to be crystallised (4), sequenced (5), quantitated by 
radioimmunoassay (RIA) (6), synthesised by chemical techniques (7), shown to be 
synthesised as a larger precursor molecule (8), quantitated by immunoradiometric 
assay (IRMA) (9) and prepared for commercial use by recombinant DNA 
technology (10).
1.2 Biosynthesis
The processes involved in the biosynthesis of insulin have been reviewed in detail 
(11) and a summary is given here.
Insulin is initially synthesised as pre-proinsulin on the rough endoplasmic reticulum 
of the (3 cells in the pancreas. The signal sequence is then removed prior to transfer 
of the proinsulin molecule to the Golgi apparatus where it is packaged into clathrin- 
coated secretory granules. These granules provide the environment for the 
conversion of proinsulin to insulin and C-peptide by converting enzymes. The 
conversion process is accompanied by the shedding of the clathrin coat such that 
non-coated granules are formed which contain equimolar amounts of insulin and C- 
peptide as well as a residual amount (approximately 3% in molar terms) of 
proinsulin (12). It is in these mature secretory granules that insulin is stored until it 
is released in response to an appropriate stimulus.
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1.3 Amino Acid Sequence and Species Variation
The amino acid sequence of proinsulin (13) is shown in Figure 1.1. It is converted 
to insulin and C-peptide by removal of the two dibasic linking residues which 
connect the A and B chains of insulin to C-peptide. The species variation in amino 
acid sequence of proinsulin is a reflection of that observed in insulin and in 
particular C-peptide.
The amino acid sequences of twenty-eight insulins (14) including human (15) have 
been determined. The most highly variable residues are A8-A10 and B30 
(Table 1.1). Changes in these residues do not appear to affect the tertiary structure 
of insulin where they are located in close proximity on the surface of the molecule 
and affect properties such as solubility and crystallisation but not receptor 
binding (14).
In contrast to insulin which is a highly conserved molecule in evolutionary terms, 
C-peptide molecules from different species are very heterogeneous, both in length 
and amino acid sequence (Table 1.2) (16). However, there are a number of 
conserved residues and these are proximal to residues in insulin that are also 
conserved, suggesting that interactions between these residues are highly probable. 
The residues in insulin that interact with C-peptide are principally those thought to 
be important for the biological activity of the insulin molecule (16).
1.4 Secretion
Insulin and C-peptide are released from the p cell in equimolar amounts together 
with approximately 3% proinsulin in molar terms (12). However, in the peripheral 
circulation the ratio of C-peptide to insulin is much higher and proinsulin may 
account for as much as 20% immunoreactive insulin (17). This is due to the marked 
differences in the hepatic extraction of these peptides.
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TABLE 1.1
AMINO ACID SEQUENCE OF INSULIN IN VARIOUS SPECIES AT 
RESIDUES A8-A10 AND B30
Species
insu lin A8 A9 A10 B30 O ther residues*
Human Thr Ser He Thr
Porcine Thr Ser He Ala -
Rabbit Thr Ser He Ser -
Equine Thr Gly He Ala -
Bovine Ala Ser Val Ala -
Ovine Ala Gly Val Ala -
Chicken H is Asn Thr Ala B l, B2, B27
Guinea-pig Thr G ly Thr Asp A4, A12, A13, 
A14, A17, A18, 
B3, B4, BIO, 
B14, B17, B20, 
B21, B22, B27
* Other residues different from human insulin.
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The major physiological stimulus for insulin secretion is glucose. Other molecules 
also affect secretion and these can be divided into three main groups: substrates, 
hormones and neurotransmitters. A summary of the main substances in each group 
thought to be important physiologically, is given in Table 1.3 (18).
1.5 Physiological Effects
The biological activity of proinsulin is qualitatively similar to insulin but 
considerably less potent. The exact percentage activity attributed to proinsulin 
relative to insulin varies with the assay system used and has been quoted as ranging 
from approximately 5-25% (19). It has also been shown that the split and des- 
amino forms of proinsulin exhibit greater biological activity than the intact molecule 
(19, 20).
C-peptide does not appear to have any intrinsic biological activity although it does 
inhibit the biological activity of proinsulin by interacting with a number of the 
residues in the insulin moiety which are involved with receptor binding (16). The 
main function of C-peptide however, appears to be in facilitating the correct folding 
of the A and B chains of insulin such that the disulphide bridges are correctly 
formed (21).
Insulin regulates carbohydrate, protein and lipid metabolism to promote an anabolic 
state. The major target organs are the liver, muscle and adipose tissue, and a 
summary of the metabolic effects of insulin on these tissues is given in 
Table 1.4 (22).
1.6 M etabolism
It has been estimated that the half-lives of proinsulin, insulin and C-peptide, as 
measured by the disappearance of these hormones in the serum of patients following 
pancreatectomy, are 17.2, 4.8 and 11.1 minutes respectively (17, 23). Similar
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TABLE 1.3
THE MAJOR PHYSIOLOGICAL FACTORS REGULATING INSULIN 
SECRETION
G roup Factor Action on insulin secretion
Substrates Glucose Stimulate
Amino acids Stimulate
Free fatty acids Stimulate
Hormones Glucagon Stimulate
Gastric inhibitory 
polypeptide (GIP) Stimulate
Somatostatin Inhibit
Neurotransmitters Cholinergic Stimulate
a-adrenergic* Inhibit
P-adrenergic* Stimulate
♦The overall effect of sympathetic (adrenergic) innervation in vivo is to 
depress insulin release.
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estimates were obtained following suppression of endogenous insulin and C-peptide 
secretion by somatostatin. The half-lives measured were 3.9 minutes for insulin and
10.2 minutes for C-peptide (24).
The primary organs involved in the clearance of insulin from the circulation and 
degradation of the hormone are, in order of importance, the liver, kidney and muscle 
(25). The liver is the predominant organ, extracting 50-75% of insulin after its 
release into the portal vein prior to its appearance in the peripheral circulation, and a 
further 40-60% of all the insulin which reaches the periphery (26). The greater part 
of the insulin remaining is metabolised by the kidney (27).
In contrast, the kidney appears to be the main organ responsible for the clearance of 
both proinsulin and C-peptide from the circulation (28). Proinsulin is also 
metabolised by the liver to an extent which reflects its biological activity in this 
organ, but C-peptide does not appear to be extracted by the liver (26).
1.7 Assays
Measurement of proinsulin, insulin and C-peptide by immunoassay techniques is 
complicated by the structural similarities between proinsulin and both insulin and C- 
peptide. Polyclonal antisera raised against all three hormones contain antibodies 
which react with one or both of the other hormones. Insulin antisera generally cross- 
react with proinsulin 50-90% on a molar basis while C-peptide antisera usually 
cross-react to a lesser extent (29). In contrast, although proinsulin antisera cross- 
react with both insulin and C-peptide, it is possible to absorb out the antibodies with 
these specificities such that only antibodies specific for proinsulin remain (30, 31). 
Radioimmunoassays developed using these antisera inevitably show the same 
patterns of cross-reaction.
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The introduction of both monoclonal antibody technology and two-site IRMA 
techniques has overcome some of the problems mentioned above, and the assay 
methodology available at the present time for each hormone is detailed below.
C-Peptide
The measurement of C-peptide has been unaffected by the recent advances described 
above. No McAbs have been produced which are specific for C-peptide and as yet 
the development of a two-site IRMA for this analyte has not been reported. 
However, measurement of C-peptide is least affected by cross-reaction as proinsulin 
reacts with the best available polyclonal antiserum at a level of only 30% in molar 
terms and it is present in serum at a much lower molar concentration than C-peptide 
in the majority of conditions (29). In cases where high concentrations of proinsulin 
are suspected or proven, a separation step to remove proinsulin from the sample 
prior to C-peptide assay should be performed.
Insulin
Monoclonal antibodies have facilitated the assay of insulin by two-site IRMA 
techniques. This has resulted in a reduction of the percentage cross-reaction of 
proinsulin in the measurement of insulin when compared to RIA's. Recently 
however, a major advance in the assay of insulin has been made with the production 
of a McAb specific for insulin and its use in a two-site IRMA which measures 
insulin without cross-reaction with proinsulin (32).
Proinsulin
The original assays developed for the measurement of proinsulin utilised polyclonal 
antisera to insulin and C-peptide in RIA (33) and IRMA (34) techniques. However, 
their use was limited due to the shortage of a well-defined human proinsulin 
standard. The availability of biosynthetic human proinsulin resulted in the more
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widespread development of RIA's for proinsulin which utilised either insulin and C- 
peptide (35, 36) or proinsulin-specific polyclonal antisera (30, 31, 37, 38). A two- 
site IRMA based on proinsulin-specific and insulin McAbs has also been 
reported (39).
The main problem remaining in the assay of proinsulin is the fact that it is present in 
more than one form in human serum (40). Depending upon the assay, the 
individual conversion intermediates of proinsulin are measured to various degrees or 
not at all (30, 35, 37, 39). A recent major advance has been the development of 
two-site IRMA's, utilising McAbs, which allow the measurement of intact 
proinsulin and each of the conversion intermediates (32). The application of these 
assays should provide valuable information on the physiology and pathophysiology 
of the different forms of proinsulin.
2 POLYCLONAL ANTIBODY PRODUCTION 
2.1 Introduction
The production of both polyclonal and monoclonal antibodies for use as reagents in 
immunoassay techniques exploits the humoral immune response which forms part 
of the natural protection of vertebrates against invading organisms. This protection 
is conferred by the immune system which functions by discriminating self from 
non-self, and comprises various mechanisms to eliminate foreign cells, viruses and 
macromolecules. A basic understanding of the components of the immune system 
and their functions is required therefore, to successfully manipulate this natural 
defence mechanism and produce antibodies with defined characteristics.
2.2 The Immune System
The vertebrate immune system is capable of mediating immunity in both a non­
specific and specific manner. Non-specific, innate, immunity is mediated by
4 0
physical and chemical barriers (skin, mucus and lysozyme), as well as cellular 
components which are collectively referred to as the reticuloendothelial system. 
This type of immunity is not enhanced by repeated exposure to antigen but does play 
an important role in the development of acquired immunity (41).
Specific, acquired, immunity is enhanced by repeated exposure to antigen and is 
mediated by a group of cells called lymphocytes. Lymphocytes are part of the 
lymphoid system and can be divided into two groups based on the primary 
lymphoid organs in which they are produced (42). In mammals, B cells originate 
from the foetal liver and bone marrow while T cells originate from the thymus. It is 
in this environment that the lymphocytes acquire their repertoire of specific antigen 
receptors and therefore become committed to a single antigenic specificity for their 
life-span (43). They also learn to discriminate between self and non-self. Mature T 
and B cells migrate to the secondary lymphoid organs which include the spleen and 
lymph nodes, and it is in this environment that they interact with macrophages and 
each other to mount an immune response. It has recently been shown that cells 
other than macrophages are capable of interacting, in a similar manner, with T 
lymphocytes in the course of an immune response. Collectively these cells are 
known as antigen-presenting cells (APC's) (44).
2.3 The Humoral Immune Response
A humoral immune response is one which results in the production of antibodies by 
B lymphocytes. The activity of the B lymphocytes is regulated directly or indirectly 
by two sub-sets of T lymphocytes known as T-helper (Th) and T-suppressor (Ts) 
cells (45, 46).
The initial stages in an antibody response involve transport of the antigen from the 
periphery, via the lymphatics, to the local lymph node. At some stage of this 
journey the antigen will be engulfed non-specifically by macrophages. Once 
internalised it is partially degraded (47, 48) and fragments of it appear on the cell
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surface complexed with I region associated (la) antigens (49) which are coded for 
by the I region of the major histocompatibility complex (MHC) (50). These antigen 
fragment-Ia antigen complexes then interact with receptors, on the surface of Th 
cells, which are specific for both components of the complex (51). The bound Th 
cells are thus stimulated to proliferate resulting in the clonal expansion of the 
selected Th cells. These are now primed and will only interact with B cells which 
present simultaneously antigen and la antigen in the same format as originally 
presented on the macrophage (52). This phenomenon is known as MHC restriction 
and appears to be antigen-specific.
Antigen is also taken up by B cells, but unlike macrophages this process is specific 
and is mediated by immunoglobulin on the B cell surface (53). Free antigen is 
bound by the surface immunoglobulin and the complex internalised. Here the 
antigen is degraded (54, 55) before fragments of it appear on the cell surface 
complexed to la antigens (52). The antigen fragment-Ia antigen complexes on B 
cells are identical to the analogous complexes on the macrophages involved in the 
priming of the appropriate Th cells (56). This interaction between Th and B 
lymphocytes provides the stimulus that leads to the differentiation of B cells into 
either plasma cells, which are short-lived and devoted to the production of antibody, 
or memory cells, which are long-lived and do not secrete antibody.
2.4 Primary and Secondary Responses
The first time a particular foreign antigen is encountered by the immune system, the 
response observed is weak and slow compared to subsequent encounters. This is 
because only a small number of the total lymphocyte population will be capable of 
interacting with the antigen. As explained in the previous section, after the initial 
contact, both T and B lymphocytes are subject to clonal selection and expansion 
such that on re-exposure to the same antigen there are relatively more reactive 
lymphocytes present resulting in a quicker and stronger response.
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2.5 Genetic Control of the Murine Immune Response
Autosomal dominant genes controlling the immune response to various antigens, 
particularly those involving synthetic polypeptides and 'weak' antigens closely 
related to self, have been reported (57). These immune response (Ir) genes have 
been mapped to the I region of the MHC ( H-2 in the mouse) (58). The la antigens, 
which also map to the I region of the MHC, are the products of these genes (59) and 
are expressed predominantly on B lymphocytes and macrophages (60) where they 
effect the antigen-specific MHC restriction of T cells. A number of different 
theories to account for the antigen-specific effects of la antigens on the immune 
response have been proposed, but it is unclear which one(s) are correct (59).
2.6 Immunogenicity
The immunogenicity of a molecule refers to the ability to induce an immune 
response, ie, produce antibodies, whereas antigenicity relates only to the ability to 
combine with antibody.
In general, the greater the phylogenetic distance between the immunogen and the 
recipient the more vigorous the immune response. Responses against highly 
conserved proteins tend to be weak as they are limited by the structural differences 
between the immunogen and the host's self-proteins and therefore by host 
regulatory mechanisms (61).
In addition, to be immunogenic a molecule must possess two distinct epitopes (62): 
one which can combine with surface antibody on B cells and is therefore displayed 
on the intact antigen, and another, which after degradation of the immunogen inside 
the B cell/macrophage can bind simultaneously to both the la antigens on the B 
cell/macrophage surface and the T cell receptor (63). The former epitope determines 
the specificity of the antibodies produced and is an absolute requirement in eliciting 
an antibody response.
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These requirements for immunogenicity can be divided into two categories : those 
properties which are intrinsic to the molecule and those which are extrinsic (64). 
The intrinsic properties relate to the epitope which binds to the B cell and include 
accessibility and hydrophilicity. The extrinsic properties relate to the la antigen-T 
cell receptor binding site, recognition of which is restricted by a number of variables 
all of which are a function of the host and therefore change depending on the species 
or individual chosen for immunisation.
Antigens tend not to be immunogenic for one of two reasons (for explanation see 
above).
(i) They are too small to possess an la antigen-T cell receptor binding site in 
addition to an epitope recognised by B lymphocytes and as such are 
classified as haptens.
(ii) They share a high degree of homology with a recipient molecule and as such 
are not recognised as foreign due to MHC restriction of the immune 
response.
Both of these problems can be circumvented by conjugating the antigen to an 
immunogenic carrier molecule. This provides the la antigen-T cell receptor binding 
site which was not present in case (i) and is an alternative to the one present, but not 
recognised as foreign, in case (ii). In the latter case, immunisation of a number of 
different inbred strains of animal may be an additional or alternative solution.
2.7 Immunisation
There are no generally accepted guidelines for the production of antisera, therefore 
the immunisation schedule adopted tends to reflect personal preferences. The 
variables which should be considered prior to starting an immunisation programme 
are as follows.
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(i) The immunogen. Is the antigen immunogenic or does it need to be 
coupled to an immunogenic carrier protein?
(ii) The choice of animal species and strain. This will be dependent on 
the immunogen to be used ie, differences in sequence/structure between it 
and various species molecules; the volume of antiserum required; and 
practical considerations such as facilities for housing animals.
(iii) The quantity of immunogen to inject. Doses have been 
recommended which range from as little as 1-50 pg for mice (65) up to 
several mg for larger animals (66). In the majority of cases however, doses 
of 100-500 |ig should suffice for larger animals.
(iv) The route of immunisation and number of sites. The most common 
routes are intramuscular, subcutaneous, intraperitoneal and intradermal. It is 
commonly accepted practice to use several sites for each route of inoculation 
except for intraperitoneal where one site is usually preferred.
(v) The use of adjuvant. This is the only generally accepted practice. The 
most commonly used adjuvant is Freunds which comes in two forms, 
complete (FCA) and incomplete (FIA). Freunds complete adjuvant contains 
Mycobacterium tuberculosis of which the active component is muramyl 
dipeptide (MDP) (67). The mechanisms of action of adjuvants are complex 
but most incorporate two components. Firstly, they form a depot which 
protects the antigen from catabolism and releases it slowly over an extended 
period of time. Secondly, they stimulate the immune response in a non­
specific manner. For FCA this involves local formation of granulomas 
which are rich in macrophages and immunocompetent cells (68). Normally 
FCA is used for the primary immunisation with FIA being used for 
subsequent booster injections.
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(vi) Timing of injections and bleeding. A four weekly injection regime is 
recommended with bleeds being taken seven to fourteen days after a booster 
injection (66). The protocols used in this thesis (Chapter 2, Section 6) were 
based on those conditions found to be optimal by the Scottish Antibody 
Production Unit (SAPU) (69, 70).
3 MONOCLONAL ANTIBODY PRODUCTION 
3.1 Introduction
Polyclonal antibodies are complex mixtures of different antibodies of varying 
specificity and avidity. The relative amounts of a single antibody within this mixture 
are subject to change at different times during an immunisation schedule for any one 
animal, and comparisons of antisera raised in different animals even of the same 
species may show the presence or absence of particular subsets of antibodies. This 
results in practical difficulties in providing a continuous supply of polyclonal 
antibodies as a standard reagent for use in immunoassay techniques.
However, Kohler and Milstein (71) developed a technique which allows the growth 
of clonal populations of cells in vitro which secrete antibodies of a defined 
specificity and avidity. This allows the continuous supply of standard homogeneous 
reagents known as monoclonal antibodies. The technique involves isolating 
antibody-secreting plasma cells from immunised animals (these cannot normally be 
grown in vitro) and fusing them with a myeloma cell-line. The resulting hybrid 
cells, or hybridomas, retain the capacity of the myeloma cell to grow indefinitely in 
vitro together with the ability of the plasma cell to secrete antibody.
3.2 Immunisation
The choice of mouse strain for immunisation is determined by the responsiveness of 
a particular strain for a given antigen. If there is no good reason for choosing
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otherwise, BALB/c mice are preferable as all available myeloma cell lines are 
derived from BALB/c mice and this therefore allows the resulting hybridomas to be 
grown in this strain. Immunisation of a different strain requires the use of Fi hybrid 
animals to grow the hybridomas in vivo.
The serum titre in the immunised animal is related to the number of McAbs 
eventually produced and the range of avidities and specificities observed reflects 
those present in the serum prior to fusion. Therefore if McAbs of particular 
specificities are desired, it may be advantageous to screen for the presence of these 
antibodies in the serum of a number of immunised animals such that the most 
suitable may be chosen for fusion.
3.3 Plasma Cells
The plasma cells used for fusion are isolated from a lymphoid organ, usually the 
spleen, of an immunised animal. The larger spleen cells which have recently 
undergone antigen stimulation and blast transformation appear to fuse preferentially 
with myeloma cells (72). This can be achieved by giving large doses of antigen 
intravenously without adjuvant, to an animal which has been immunised by 
conventional means, on each of the 3-4 days preceding fusion (73). Other workers 
have found that a single boost 3-4 days prior to fusion results in the greatest 
number of positive hybrids (74).
3.4 Myeloma Cells
Myelomas are malignantly transformed antibody-secreting cells and can be induced 
in a few strains of mice by injecting mineral oil into the peritoneum. The most 
commonly used fusion partners today are derived from myelomas isolated from 
BALC/c mice (75). However, these early myelomas secreted antibody and 
subsequent cell lines have been selected which are non-functional in this respect. A 
further refinement has been the selection of cell lines which are selectively killed
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when grown in medium containing hypoxanthine, aminopterin and thymidine 
(HAT). Normal cells have two pathways for the synthesis of nucleotides, the de 
novo and salvage pathways. Cells lacking one of the enzymes involved in the 
salvage pathway, hypoxanthine-guanine phosphoribosyl transferase (HGPRT), can 
be selected for with 8-azaguanine. The addition of HAT to medium blocks the de 
novo synthesis pathway (aminopterin) and forces cells to use the salvage pathway 
(utilising HT) which requires the presence of HGPRT. Therefore, the use of a 
myeloma cell line lacking this enzyme allows unfused myeloma cells to be 
selectively killed by growing the fusion products in HAT medium. The myeloma 
cells which have fused with plasma cells (ie, hybridomas) will not be affected as the 
salvage pathway will be contributed by the plasma cell (76). The ability to kill 
selectively myeloma cells is necessary because fusion efficiency is low. Therefore 
hybrid cells are greatly outnumbered by unfused myeloma cells which if not killed 
will result in the death of the hybridomas due to overgrowth. The cell line used in 
the work presented in this thesis, X63. Ag 8. 653 (77) lacks the enzyme HGPRT 
and is non-functional with respect to antibody synthesis.
3.5 Fusion Procedure
Most fusions designed to produce hybridomas use polyethylene glycol (PEG) as 
fusogen. The optimum concentration is in the region of 35-50%, but there is some 
variation with cell line (78). The mechanism of fusion is complex and involves cell 
agglutination, membrane fusion and cell swelling (79).
3.6 Cell Growth and Cloning
The fusion products are grown in medium containing HAT to kill selectively 
unfused myeloma cells (Section 3.4). Unfused plasma cells will not survive in 
culture for more than a few days. The remaining hybridomas are a heterogeneous 
mixture of which only a small number may be producing antibody of the desired 
specificity. It is therefore necessary to clone cells as soon as possible after the
4 8
detection of positive cultures. Cloning is also necessary as non-producer variants 
may arise due to chromosome loss, particularly during the early stages of hybrid 
growth. At least two cloning steps should be performed to ensure that a monoclonal 
cell line has been obtained. There are two main cloning techniques, that of limiting 
dilution or cloning in soft agar. The former method is more frequently used.
Cloning by limiting dilution is based on the Poisson distribution:
f(0) = e -*
where f(0) is the fraction of wells with no growth and X is the average number of 
clones per well. If X = 1, then f(0) = 0.37, ie, if at least 37% of wells show no 
growth then the probability is that those that do show growth contain true 
monoclonal hybridomas (80).
3.7 Expansion of Cloned Hybridomas
Cloned hybridomas can either be grown in vitro producing antibody as culture 
supernatant or in vivo producing antibody as ascitic fluid.
The latter technique makes use of the fact that mice primed with mineral oils are 
more susceptible to the development of spontaneous mineral oil induced 
plasmacytomas (MOPC's) and this is used to encourage hybridoma growth in vivo 
(75). The mice are primed with an intraperitoneal injection of pristane (2, 6,10,14- 
tetramethyl pentadecane) prior to the intraperitoneal inoculation of hybridoma cells. 
The optimal interval between priming and inoculation to maximise the amount of 
antibody produced and also result in a high percentage of responding mice, has 
been reported to range from 10 days (81) to 3-4 weeks (82).
3.8 Screening Assays
The assays used for both the evaluation of serum in the immunised animal and 
screening of the fusion products should be as similar as possible to the type of assay
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in which the McAb will ultimately be used (83). Apart from this the assay chosen 
should be sensitive enough to detect the concentrations of antibody found in culture 
supernatant (<1 |ig/ml). It should also be simple and rapid, such that large numbers 
of samples can be handled at one time.
If a fusion yields large numbers of positive cultures it may be necessary to assign 
priorities. This can be achieved by screening not only for the presence of antibody, 
but also for particular specificities or avidities. It should also be noted that coupling 
an antigen to solid-phase or labelling with enzymes or radioactive molecules may 
destroy or make inaccessible particular epitopes. Whereas this may not be noticed 
with a polyclonal antiserum, it may lead to the preferential selection of McAbs of 
particular specificities which may not necessarily correlate with the desired 
specificities.
3.9 Advantages and Disadvantages of Monoclonal Antibodies 
Advantages
Once a stable cell line has been established it is possible to produce a continuous 
supply of a homogeneous reagent with defined characteristics. Unlike polyclonal 
antiserum which contain 15-20 mg/ml immunoglobulin of which as little as 1% may 
be specific for the immunising antigen (74), McAbs can be produced in vitro or in 
vivo such that the majority of immunoglobulin present is specific for the 
immunising antigen. This usually circumvents the requirement for affinity 
purification of antibody prior to labelling for use in immunometric assay techniques.
The specificity of McAbs ie, they react with a single epitope on an antigen, can be 
advantageous in assays where the measurement of a particular antigen is complicated 
by the presence of closely related molecules.
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Disadvantages
Monoclonal antibodies tend to be low avidity compared to polyclonal antibodies. 
The production of such antibodies reflects their preponderance in the serum of 
immunised animals. Also, the avidity of polyclonal antisera in part depends on co­
operative effects between antibodies of differing specificities and as such is greater 
than would be anticipated from the individual avidity of each antibody present.
In certain situations the specificity of McAbs may not be advantageous. This arises 
from the same property that makes them particularly useful, ie, that they can 
distinguish between different forms of the same antigen. Thus problems may occur 
when attempting to measure the concentration of molecules which are genetically 
polymorphic or heterogeneous.
Finally, individual McAbs may differ markedly in their stability to procedures such 
as freezing and thawing, in their susceptibility to changes dependent on procedures 
such as labelling with enzymes or radioactive molecules and coupling to solid- 
phase, and the optimum conditions for their use.
Conclusion
The use of McAbs in immunoassay techniques does offer distinct advantages over 
polyclonal antibodies in particular situations. However, it should be realised that 
they do have their disadvantages and therefore their use should be viewed as 
complementary to, rather than as a replacement for, polyclonal antisera.
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4 IMMUNOASSAY METHODOLOGY
4.1 In troduction
The basic principle underlying immunoassay techniques is the Law of Mass Action. 
Assuming a reversible reaction, this can be represented by the equation:
ka
Ag + Ab AgAb ... (1)
kd
where ka and are the association and dissociation constants respectively. The 
equilibrium constant K can then be expressed as:
Keq = k^ = fAgAb]
kd [Ag][Ab] ... (2)
where [Ag], [Ab] and [AgAb] represent the concentrations of free and complexed 
antigen and antibody in the final equilibrium mixture (84).
From equation (1) it can be seen that if either of the two reactants is present at 
limiting concentration then the other distributes between the free and bound states. 
If the non-limiting reactant is labelled, its distribution can be measured. 
Radioimmunoassay (6) employs radioactively labelled antigens whereas the 
immunoradiometric (9) and two-site immunoradiometric assays (85) employ 
radioactively labelled antibodies. A simplified representation of the three assay 
techniques is shown in Figure 1.2.
4.2 Radioim m unoassay
Purified antigen is required for radioactive labelling, which when labelled, should be 
recognised by the antibody as identical or very similar to the analyte. Labelled 
antigen is incubated with a limiting amount of antibody, such that at equilibrium all 
the antibody, but only a percentage of the labelled antigen, reacts to form the bound
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A. RADIOIMMUNOASSAY
Ag + *Ag + A b^^^Ag Ab + *Ag Ab
B. IMMUNORADIOMETRIC ASSAY
Ag + Ab* ^ 5=^Ag Ab*
C. TW O-SITE IMMUNORADIOMETRIC ASSAY
Ag + Ab* + S P -A b ^S P -A b  Ag Ab*
Figure 1.2
A simplified representation of the three immunoassay techniques employing 
radioactive labels.
Ag = antigen; *Ag = iodinated antigen; Ab = antibody; Ab* = iodinated antibody; 
SP-Ab = solid-phase coupled antibody.
fraction. Addition of unlabelled antigen reduces the proportion of antibody-bound 
labelled antigen in a dose dependent fashion. Thus separation of the antibody- 
bound from the free labelled antigen, followed by measurement of the bound 
fraction, yields a dose-response curve where the percentage bound has an inverse 
relationship to the amount of unlabelled antigen added (Figure 1.3A).
The sensitivity of an RIA is governed by four factors (86):
(i) The equilibrium constant of the antigen-antibody interaction ie, the avidity of 
the antiserum.
(ii) The experimental error involved in the measurement of antibody-bound and 
free antigen.
(iii) The specific activity of the labelled antigen.
(iv) The misclassification of the bound and free antigen.
In practice, factors (i) and (ii) impose the major constraints on assay sensitivity (86) 
while factor (iv) is a major cause of experimental imprecision and bias (87).
4.3 Immunoradiometric Assay
The immunoradiometric assay differs from the radioimmunoassay in that it 
employs labelled antibodies rather than antigens, and requires the use of excess 
rather than limiting amounts of antibody.
Antigen is incubated with excess labelled antibody such that at equilibrium, with a 
high avidity antibody, most of the antigen, but only a percentage of the labelled 
antibody, reacts to form the bound fraction. Free labelled antibody is separated by 
the addition of solid-phase coupled antigen. The amount of labelled antibody bound 
to antigen (not coupled to solid-phase) is directly proportional to the amount of 
antigen present (Figure 1.3B).
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Figure 1.3
Representative dose-response curves for a radioimmunoassay 
(A) and an immunoradiometric assay (B).
It has been suggested that the potential sensitivity of IRMA's is less dependent on 
the antibody avidity than RIA (86) but it has been shown, with the use of 
monoclonal antibodies, that while this is true, the avidity of the antibody is still a 
major determinant in the final sensitivity achieved (88, 89). The ultimate sensitivity 
of IRMA's however, derives more from the specific activity of the moiety used for 
labelling the antibody and the zero dose binding levels which can be achieved (86).
The disadvantages of this technique are the requirement for large amounts of 
antigen, and specific antibody which requires immunoaffinity purification (90, 91). 
This technique also fails to achieve the low zero dose binding levels that are required 
to maximise the sensitivity of IRMA's (86). This is due to the presence, in any 
labelled preparation, of radioactive material which is not immunoreactive, and thus 
in this case cannot be removed by the solid-phase coupled antigen (90). This 
unbindable fraction of the labelled antibody increases the zero dose binding count 
against which specific antibody binding is measured thus limiting the sensitivity 
which can be obtained.
4.4 Two-Site Immunoradiometric Assay
This modification of the conventional IRMA, described above, replaces the solid- 
phase coupled antigen with a solid-phase coupled antibody capable of binding to the 
antigen to be measured simultaneously with the labelled antibody. As with the 
conventional IRMA, the amount of labelled antibody bound to the antigen is directly 
proportional to the amount of antigen present (Figure 1.3B).
IRMA techniques have a number of advantages compared with RIA. They are 
faster, have a wider working range and are potentially more sensitive (74). The 
two-site IRMA's also have the potential for improved specificity due to the 
recognition by antibodies of two distinct epitopes on the molecule (90).
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While the two-site IRMA still requires large amounts of antibody, one of which 
requires immunoaffinity purification, there is no longer the requirement for antigen 
in the separation step (90).
4.5 Polyclonal or Monoclonal Antibodies
Radioimmunoassay
While monoclonal antibodies offer the potential advantages of increased specificity 
and an unlimited supply of a standardised reagent (89) they are, in general, of lower 
avidity than the polyclonal antisera which can be raised to the same antigen (89,92). 
Such antibodies produce RIA’s of poor sensitivity. High avidity McAbs may 
approach but do not significantly improve on, the sensitivity of assays achieved with 
polyclonal antisera (89).
Two-Site Immunoradiometric Assay
The major contribution of McAbs has been in the wider application of the two-site 
IRMA and in the realisation of the full potential of such techniques (74). Until the 
introduction of McAbs, there was a lack of evidence to support the theoretical and 
practical advantages which had been proposed for IRMA techniques (88).
Polyclonal antisera have been employed to develop IRMA's for a number of 
hormones and proteins (93) but their application has been relatively restricted due to 
a number of factors (74). The main disadvantages of polyclonal antibodies have 
been the requirements for large quantities of immunoaffinity purified material, and 
for two antibodies capable of binding simultaneously to the antigen to be measured 
(polyclonal antisera usually exhibit substantial overlap in their epitope 
reactivity) (74).
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Conclusion
While polyclonal antisera remain the reagents of choice for the majority of RIA's, 
the use of McAbs alone or in conjunction with polyclonal antisera have proved 
essential for the realisation of the advantages proposed for IRMA techniques.
5 OBJECTIVES
The objectives of this project were:
(i) To raise high avidity, high titre polyclonal antisera to insulin.
(ii) To raise high avidity, high titre polyclonal antisera to C-peptide.
(iii) To produce high avidity monoclonal antibodies reactive with insulin,
proinsulin and C-peptide.
(iv) To develop a two-site IRMA for human insulin.
(v) To develop a two-site IRMA for human proinsulin.
(vi) To develop either an RIA or two-site IRMA for human C-peptide.
(vii) To establish proinsulin concentrations under physiological conditions in the 
fasting state and during a variety of dynamic function tests.
(viii) To investigate proinsulin concentrations under pathophysiological conditions 
in the fasting state and during a variety of dynamic function tests.
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CHAPTER 2 
MATERIALS AND METHODS
1 MATERIALS
All chemicals used were analytical grade unless otherwise stated. 
Anti-immunoglobulin and animal sera
BSA standard
Cell culture media and reagents 
Charcoal (activated)
DMSO 
FCA, FIA
Folin-Ciocalteu reagent 
GelBondR film
Glutaraldehyde (electron microscopy grade) 
Insulin (various species)
Ovalbumin 
PEG 1500
Proinsulin (intact and intermediates)
RosilR (C l8, 3 |im)
SephacrylR S300 (unmodified)
SephadexR G50 and G75 
SepharoseR 6B and CL-4B 
Strain 2 guinea-pigs
TSK DEAE 5 PW column
SAPU
Pierce Chemical Co.
Flow Laboratories 
Sigma Chemical Co.
Sigma Chemical Co.
Difco Laboratories 
Sigma Chemical Co.
Sigma Chemical Co.
Sigma Chemical Co.
Sigma Chemical Co.
Sigma Chemical Co.
BDH
Gift from Dr B.H.Frank, Eli Lilly 
Research Laboratories
Alltech Associates/Applied Science
Pharmacia Fine Chemicals
Pharmacia Fine Chemicals
Pharmacia Fine Chemicals
Animal Unit, Southampton General 
Hospital
Anachem
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2 BUFFERS
2.1 Charcoal Reagent
Used as described in Section 5.5 of this chapter.
B uffer: NaH2P 0 4 . 2H20 3.1 g
Thiomersal 0.12 g
BSA 2.5 g
The above chemicals were dissolved in less than 500 ml distilled water and the pH 
adjusted to 7.4 prior to the addition of further distilled water to give a final volume 
of 500 ml.
Charcoal reagent: 10 ml buffer
10 ml donkey serum 
1 g activated charcoal
The above reagents were mixed together and stirred for at least 20 minutes before 
use.
2.2 EPPS Buffer
Assay buffer for immunoradiometric assays.
EPPS 25.23 g
Sodium azide 0.5 g
Sheep semm 5 ml
Tween 20 2 ml
The above reagents were dissolved in less than 1 litre distilled water and the pH 
adjusted to 8.0 prior to the addition of further distilled water to give a final volume 
of 1 litre. Due to problems with heterophilic antibodies (Chapter 6, Section 1.5) it 
was subsequently necessary to add 1% (v/v) mouse serum to this buffer.
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2.3 1% TEATFA pH 3.0
Column buffer for reverse-phase HPLC of 125I-proinsulin (Section 5.2 of this 
chapter).
A 1% (v/v) solution of trifluoroacetic acid (TFA) in distilled water was prepared and 
the pH adjusted to 3.0 with triethylamine (TEA).
3. GENERAL METHODS
3.1 Protein Estimation
A modification of the Lowry protein assay (94) was used to measure protein in 
solution or coupled to solid-phase.
Reagents
(i) Alkaline copper reagent was prepared by mixing 10 g sodium carbonate in 
50 ml 1 mol/1 sodium hydroxide with 100 mg sodium potassium tartrate 
dissolved in 2-3 ml distilled water and 50 mg cupric sulphate similarly 
dissolved in 2-3 ml distilled water. The volume was then adjusted to 100 ml 
with distilled water.
(ii) Stock Folin-Ciocalteu reagent was diluted 1:25 with distilled water to 
provide a working solution.
(iii) Bovine serum albumin (BSA) standard (Pierce) was diluted in the 
appropriate buffer to give standards of 0.5, 0.4, 0.3, 0.2 and 0.1 mg/ml.
Method
Protein estimations were carried out in duplicate by mixing 200 p.1 protein standard 
or sample with 200 p.1 alkaline copper reagent, vortexing and incubating at room 
temperature for 10 minutes. 1 ml working strength Folin-Ciocalteu reagent was then
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added, the tubes vortexed and placed in a water bath at 55°C for 5 minutes, after 
which rapid cooling was achieved by placing the tests in cold water for 1-2 minutes. 
The absorbance was measured at a wavelength of 650 nm within 30 minutes. A 
standard curve was constructed and used to determine the protein content of the 
samples.
3.2 Immunogen Preparation
Immunogens were prepared either as water-in-oil (95) or multiple (96) emulsions. 
Water-in-Oil Emulsions
One volume antigen and nine volumes adjuvant, in separate glass syringes, were 
emulsified by repeated passage through a 19 g needle fitted with twin Luer hubs.
Multiple Emulsions
Antigen and adjuvant (1:1, v/v) were homogenised, using a Silverston laboratory 
mixer, to give a water-in-oil emulsion. An equal volume of 2% Tween 80/0.9% 
saline was then added and the mixture rehomogenised to form a multiple emulsion.
3.3 Serum Separation
Human blood was allowed to clot for 30 minutes at room temperature before 
centrifugation (1000 g, 10 min, 20°C). Blood from all other species was incubated 
either overnight at 4°C or 2 hours at 37°C prior to centrifugation as above. The 
serum was then decanted, divided into aliquots where appropriate and stored at 
-20°C.
3.4 Conjugation of Insulin to Carrier Proteins
Insulin was conjugated to either human immunoglobulin G (IgG) or ovalbumin 
using a two-step glutaraldehyde technique (97), followed by size-exclusion 
chromatography on Sephadex G75 to remove free insulin.
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Method
Porcine insulin (2 mg in 200 fil 0.01 mol/1 hydrochloric acid) was diluted with 
750 \i\ 6.7 mmol/1 phosphate buffered saline (PBS) pH 7.3 prior to the addition of 
glutaraldehyde to a final concentration of 1.25%. The mixture was then rolled 
overnight at room temperature. The activated insulin was diluted 1:4 with 0.1 mol/1 
sodium carbonate/0.5 mol/1 sodium chloride pH 9.2 (carbonate buffer) and dialysed 
against the same overnight at room temperature. Human IgG (10 mg) or ovalbumin 
(6 mg) in carbonate buffer ( 1ml) were then added to the activated insulin and the 
mixture rolled overnight at room temperature. The reaction was terminated by the 
addition of 1 ml 1 mol/1 lysine in carbonate buffer.
Unconjugated insulin was removed by size-exclusion chromatography on a 
Sephadex G75 column (30 x 1 cm) equilibrated and eluted in carbonate buffer. The 
conjugate eluted first followed by unreacted insulin. The conjugate was assessed 
for human IgG or ovalbumin reactivity by immunodiffusion (Section 4.1 of this 
chapter) using the appropriate antisera and the quantities of conjugated and 
unconjugated insulin were measured by RIA. The ratio of insulinrcarrier protein 
was calculated assuming that all the carrier protein was conjugated.
3.5 Ion-Exchange HPLC of Murine Ascitic Fluid
The purity of McAbs obtained from ascitic fluid by caprylic acid fractionation was 
assessed by anion-exchange HPLC on a TSK DEAE 5PW column (7.5 x 0.75 cm). 
The column was equilibrated in 20 mmol/1 Tris-HCl pH 7.7 and samples were 
dialysed against the same before application to the column. Elution was performed 
at a flow rate of lml/min using a gradient of 0.5 mol/1 sodium chloride/20 mmol/1 
Tris-HCl pH 7.7 from 0-30% over 40 min, increasing to 100% from 40-50 min 
and returning to 0% at 60 min. Eluted protein was measured using a flow-through 
UV absorbance monitor (280 nm) which was connected to a chart recorder.
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4. IMMUNOCHEMICAL METHODS
4.1 Immunodiffusion
Immunodiffusion was performed according to the method of Ouchterlony (98). 
Agarose (1% w/v) in Tris-HCl (0.05 mol/1, pH 8.6) containing 1% w/v PEG 4000 
was melted, poured into plastic Petri dishes to a depth of 2-3 mm and left to set at 
room temperature. A pattern consisting of one central well and six peripheral wells 
was cut out of the gel and the wells filled with antigen or antiserum as appropriate. 
The plates were then left in a moist chamber in the dark for 24-48 hours before 
examination.
To stain, gels were washed for a minimum of 48 hours in 0.15 mol/1 sodium 
chloride, press-dried on to GelBondR film, air or oven-dried and stained with 
Crowle's double stain (99). To destain, the plates were soaked in 3% v/v acetic acid 
until all excess stain was removed, washed under running tap water and air or oven- 
dried.
4.2 Immunoadsorbent Preparation
Immunoadsorbents were prepared according to the method of Wright & Hunter 
(100). The required volume of SephacrylR S300 (unmodified), measured after the 
slurry had settled out in a measuring cylinder, was washed thoroughly with distilled 
water before resuspension in 4.5 volumes 5 mmol/1 sodium meta-periodate / 
0.1 mol/1 sodium acetate pH 5.0 and mixed on a roller for one hour at room 
temperature in a closed vessel. Glycerol (10% v/v) was then added and the gel 
mixed for a further hour. The activated SephacrylR was washed with either excess 
0.1 mol/1 sodium bicarbonate pH 9.0 if coupling was to proceed immediately, or 
excess 0.02 mol/1 sodium phosphate pH 6.2 containing 0.1% sodium azide if the 
activated gel was to be stored before use.
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Protein (10 mg/ml in 0.1 mol/1 carbonate pH 9.0) and activated gel were mixed at 
equivalent volumes for 16 hours at room temperature. Uncoupled protein was 
removed by filtration at negative pressure on a sintered glass funnel and kept for 
future use. The immunoadsorbent was resuspended in two volumes 6.7 mmol/1 
PBS pH 7.3 and allowed to settle for 30 minutes before decanting the supernatant 
to remove fines. The solid-phase was resuspended in a final volume seven times 
that of the settled gel and solid sodium borohydride added (132 mmol/1). After 
30 minutes the gel was transferred to a sintered glass funnel and washed with 
PBS pH 7.3 followed by 0.02 mol/1 sodium phosphate pH 6.2 containing 
0.1% sodium azide. The solid-phase was stored in the latter buffer at 4°C.
4.3 Immunoglobulin Fractionation
The IgG fraction of antisera and ascitic fluid from all species, except guinea-pig, 
was prepared by caprylic acid precipitation (101). Guinea-pig IgG was isolated by 
affinity chromatography using anti-guinea-pig IgG coupled to Sephacryl S300 
(Section 4.2 of this chapter). Chicken egg yolk IgG was purified according to the 
method of Jensenius et al (102).
Caprylic Acid Precipitation
One volume serum was mixed with two volumes 0.06 mol/1 sodium acetate pH 4.0 
and 7.5 ml caprylic acid added for every 100 ml original serum volume. The 
caprylic acid was added dropwise with vigorous stirring and the preparation mixed 
for 30 minutes before centrifugation (1000 g, 30 min, 20°C). The supernatant was 
filtered through Whatman grade 4, qualitative filter paper and dialysed against 
several changes of a buffer appropriate to further studies. The resulting IgG fraction 
was concentrated by ultrafiltration in an Amicon stirred cell using a PM30 
membrane.
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Affinity Chromatography
Antiserum and solid-phase coupled anti-guinea-pig IgG (v/v) were mixed for 
2 hours at room temperature. The slurry was then poured into a column and 
unbound protein washed through with 0.02 mol/1 sodium phosphate pH 6.2, 
followed by elution of non-specifically bound protein with 2 molA sodium chloride 
in the same buffer. Guinea-pig IgG was eluted with 0.1 mol/1 glycine pH 2.6 and 
collected in an equal volume of 1 mol/1 sodium phosphate pH 6.2. Protein was 
concentrated by ultrafiltration as described above.
Purification of Egg Yolk IgG
The egg yolk was separated from the white, the membrane cut open and the yolk 
poured into a measuring cylinder. Nine volumes of distilled water were added and 
after mixing, the pH of the diluted egg yolk was adjusted to 7 with 0.1 mol/1 sodium 
hydroxide prior to freezing at -20°C. The egg yolk was then thawed at 37°C and 
precipitated lipid removed by centrifugation (1000 g, 30 min, 20°C). The IgG was 
precipitated by the addition of solid ammonium sulphate to a concentration of 2 mol/1 
and the mixture stirred for 30 minutes followed by centrifugation (1000 g, 30 min, 
20°C) to recover the IgG. The precipitate (IgG) was dissolved in 0.5 volumes
6.7 mmol/1 PBS pH 7.3 and stored at -20°C until required.
5 IMMUNOASSAY TECHNIQUES
5.1 Preparation of Hormone-Free Serum
The relevant hormones (ie, proinsulin, insulin and C-peptide) were removed from 
pooled normal human serum by absorption with agarose coated charcoal.
Charcoal (activated Norit PN5), was coated with agarose by heating a 5% (w/v) 
agarose solution to 70°C and adding 20 g activated charcoal per 100 ml agarose. 
The slurry was allowed to cool to 50°C before being poured into 200 ml acetone, in
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a fume hood, with vigorous stirring. The granular precipitate formed was filtered 
through Whatman grade 4, qualitative filter paper and air-dried overnight.
Serum was rendered hormone-free by mixing 10 g agarose-coated charcoal with 
100 ml serum overnight at room temperature. Hormone-free serum was recovered 
by centrifugation (1600 g, 15 min, 20°C) and stored in suitable aliquots at -20°C.
5.2 Protein Iodination
Antigens and antibodies were labelled with 125I using a solid-phase lactoperoxidase 
technique (103). Iodinated protein was separated from unreacted iodide by either 
gel filtration chromatography or reverse-phase high performance liquid 
chromatography.
Iodination Protocol
Antigens (5-10 |Lig in 10 |il) or antibodies (20-40 |!g in 10 |il) were iodinated by the 
addition of:
10 |il 0.5 mol/1 sodium phosphate pH 7.4
10 |il (excess) solid-phase lactoperoxidase (prepared locally)
5 or 10 (il 125I, carrier-free (18.5 or 37 MBq respectively)
10 p.1 hydrogen peroxide (30% w/v stock diluted 1:20,000
with distilled water)
The mixture was vortexed and incubated at room temperature for 30 minutes, with a 
second 10 |il aliquot of hydrogen peroxide being added after the first 15 minutes. 
The reaction was terminated by the addition of 200 |il column buffer.
Gel Filtration Chromatography
Labelled antibodies and antigens were purified on SepharoseR 6B (25 x 1.5 cm) or 
SephadexR G50 (30 x 1 cm) columns respectively. Both columns were equilibrated 
and eluted with 0.1 molA sodium phosphate/0.154 mol/1 sodium chloride pH 7.4
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containing 1% BSA and 0.1% sodium azide, at a flow rate of 10 ml/hour. 
1 ml fractions were collected and radioactivity measured in a gamma counter.
Small amounts of aggregated material eluted in the column void volume, followed 
by iodinated protein and then unreacted iodide (Figure 2.1). After counting, the 
relevant fractions were pooled, diluted in column buffer, divided into aliquots and 
stored at 4°C or -20°C.
Reverse-Phase HPLC
Proinsulin was the only protein which required this method of purification to 
provide a suitable tracer.
After the iodination reaction had been terminated, the mixture was centrifuged 
(1000 g, 5 min, 20°C), to remove the solid-phase lactoperoxidase. A stainless 
steel column (4.6 x 250 mm) packed with RosilR (C l8, 3 }im) was equilibrated and 
eluted with 1% TEATFA pH 3.0 (Section 2.3 of this chapter) containing 
34% acetonitrile, at a flow rate of 1 ml/minute and a back pressure of 3500 psi. 
100 |il iodination mixture was injected on to the column per run with 1 ml fractions 
being collected and counted on a gamma counter.
After each run the column was regenerated by running 1% TEATFA pH 3.0 
containing 95% acetonitrile until a stable baseline was achieved. Re-equilibration 
was carried out by washing through with at least three column volumes 
equilibration/elution buffer.
The last major peak on the chromatogram (Figure 2.2, peak 6) was pooled, diluted 
with an equal volume of 0.1 mol/1 sodium phosphate/0.154 mol/1 sodium chloride 
pH 7.4 containing 1% BSA and freeze-dried to remove the acetonitrile and 
trifluoroacetic acid. The tracer was reconstituted to the original pool volume with 
distilled water, divided into aliquots and stored at -20°C.
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Figure 2.1
Representative elution profiles for 125I-insulin (A) and 125I- 
monoclonal antibody (B).
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5.3 Solid-Phase Preparation
SepharoseR CL-4B was activated by a carbodiimide technique (104) for use in RIA 
and IRMA.
SepharoseR CL-4B was calibrated by pouring the gel into a measuring cylinder, 
allowing it to settle overnight and adding sufficient distilled water to give a 50% v/v 
suspension.
One volume calibrated gel was dehydrated by washing successively with
2.5 volumes distilled water; 30%, 50% and 70% (v/v) acetone, prepared with 
distilled water; 100% acetone in a sintered glass filter funnel under negative 
pressure. The gel was not allowed to dry out at any stage as this resulted in a 
tendency to flocculate.
The dehydrated SepharoseR was transferred, in acetone, to a conical flask and 
further acetone added to make up the original calibrated volume. Activation was 
accomplished by adding carbonyldiimidazole to 0.15 mol/1, sealing the flask and 
mixing the contents for one hour. Activated gel was rehydrated in the same manner 
as before by successive washes with 2.5 volumes 100% acetone; 70%, 50% and 
30% (v/v) acetone, prepared with distilled water; 0.1 mol/1 EPPS pH 8.0 (coupling 
buffer). The gel was transferred to a polycarbonate bottle containing the protein to 
be coupled (in coupling buffer) and further coupling buffer added to give the 
original calibrated volume. Coupling was achieved by gentle mixing for 18 to 
24 hours at room temperature.
Unbound protein was recovered by centrifugation (1200 g, 15 min, 20°C) and used 
again for future solid-phase preparations. The gel was then extensively washed 
with various buffers (v/v) and recovered by centrifugation (1200 g, 15 min, 20°C) 
between each wash cycle as follows:
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(1) 0.5 mol/1 sodium bicarbonate pH 8.0, rotate 20 minutes; (2) repeat; (3) 0.1 mol/1 
sodium acetate pH 4.0, rotate 60 minutes; (4) 0.1 mol/1 sodium acetate pH 4.0, 
rotate 16-20 hours; (5) 0.154 mol/1 sodium chloride, rotate 20 minutes; (6) repeat.
The solid-phase was then adjusted to the original calibrated volume with 0.154 mol/1 
sodium chloride containing 0.1% sodium azide and stored at 4°C.
SepharoseR coupled anti-immunoglobulin was prepared using 25 ml neat antiserum 
per 200 ml calibrated gel, whereas primary antibodies were coupled as IgG fractions 
(Section 4.3). Polyclonal anti-insulin and monoclonal anti-proinsulin were coupled 
at ratios of 0.05 mg and 0.024 mg IgG per mg gel respectively.
5.4 Evaluation of Anti-Immunoglobulin Solid-Phase for RIA
Various solid-phase coupled anti-immunoglobulins (ie, anti-rabbit IgG, anti-mouse- 
y-globulin, anti-guinea-pig IgG and anti-sheep/goat IgG) were evaluated for use as 
separating reagents in RIA utilising primary antibodies to a variety of antigens raised 
in the appropriate species. The first incubation conditions were held constant 
(ie, dilution of antiserum, mass of label, incubation time and temperature) while the 
effects of varying the mass of solid-phase coupled second antibody added and the 
incubation time were observed. The solid-phase was added at 0.25, 0.5, 1.0 and
2.0 mg/tube while the incubation times were 15, 30, 60, 90 and 120 minutes.
Usually a 60 minute incubation with 1 mg solid-phase/tube gave optimum binding 
as can be seen in Figure 2.3 which shows the pattern of results normally obtained.
5.5 RIA for Antibody Detection and Evaluation
Polyclonal and monoclonal antibody production were monitored by RIA. A solid- 
phase second antibody separation technique was used except for chicken and 
donkey test bleed evaluation which employed a charcoal separation technique.
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Figure 2.3
Determination of optimum mass and incubation time for 
SepharoseR CL-4B coupled second antibody.
Polyclonal Antiserum Evaluation
Antibody dilution curves were constructed for all test bleeds and donations 
(Figure 2.4). The test system was as outlined below:
100 pi hormone-free serum
100 pi antiserum (various dilutions)
All species except 
chicken and donkeys
1
100 pi 125I-antigen (5 000 or 10 000 cpm)
incubated (3 h, room temperature)
Added 200 pi (1 mg) SepharoseR CL-4B 
coupled anti-immunoglobulin
incubated (1 h. continuous mixing)
Added 3 ml 0.2% Tween 20/  ^
0.9% sodium chlorideI
Centrifuged 
(1000 g, 20°C, 1 min)I
Aspirated supernatant
I____________
Repeated
twice
Chicken and donkeys
Added 400 pi charcoal 
reagent and mixed
I
incubated (10 min, 
room temperature)
Centrifuged 
(1000 g, 4°C, 30 min)
1
Removed 400 pi supernatant 
into clean tubes
Counted on gamma counter
69
Reciprocal antiserum dilution
Figure 2.4
A representative antiserum dilution curve.
Monoclonal Antibody Detection
Monoclonal antibodies were detected in culture supernatants according to the 
following protocol:
50 ]Lil culture supernatant 
+
200 p.1125I-antigen (10 000 cpm)
incubated (overnight, room temperature)
T
Added 200 jii (1 mg) SepharoseR CL-4B coupled anti-mouse-y-globulin 
incubated (1 h, continuous mixing)
I
Washed solid-phase as described for polyclonal antibody evaluation 
1
Counted on gamma counter
Culture supernatants were considered to be 'antibody-positive' if they bound more 
than 10% of the added label.
Ascitic fluid containing monoclonal antibody was evaluated either as above or as 
described for polyclonal antisera except that hormone-free serum was not added to 
the primary incubation.
5.6 Displacement Studies
Single Dose Displacement Curves
Single dose displacement curves were constructed for both polyclonal and 
monoclonal antibodies prior to Scatchard analysis and specificity determinations.
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The method was as outlined below:
100 p.1 antibody (various dilutions)
+
100 |il buffer or standard (at appropriate concentration)
+
100 jil 125I-antigen (5 000 or 10 000 cpm)
incubated (3 h, room temperature)
▼
Added 200 pi (1 mg) SepharoseR CL-4B coupled anti-immunoglobulin 
incubated (1 h, continuous mixing)
T
Washed as described for polvclonal antibody evaluation 
1
Counted on gamma counter.
Results were calculated as described for polyclonal antiserum evaluation 
(Section 5.5) and antibody dilution curves in the presence and absence of cold 
antigen plotted together (Figure 2.5).
Further studies were performed using the dilution of antibody which exhibited 
maximum displacement with between 30 and 50% of the added label bound in the 
absence of standard (i.e. 50% > B0 > 30%).
Specificity Determ ination
The specificity of monoclonal antibodies reactive to insulin was determined using 
various species insulins while those reactive to proinsulin and C-peptide were 
evaluated with different forms of split and des-amino proinsulins. The same general 
assay protocol was used for all specificity determinations and is described over.
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Figure 2.5
A representative single dose displacement curve.
100 fil antibody (B0 = 30-50%)
+
100 jliI buffer or standard (range of concentrations)
+
100 jil 125I-antigen (5 000 or 10 000 cpm)
incubated (3 h, room temperature)
▼
Solid-phase added, incubated, washed and counted 
as described in previous sections.
Results were calculated in terms of label bound in the presence of standard 
expressed as a percentage of label bound in the absence of standard (% B/B0) and 
plotted against the corresponding standard concentration. The displacement curves 
generated for each antibody using various antigens were plotted as a single graph 
(Chapter 4, Sections 2.2 and 2.3).
Determ ination of 125I-Antigen Specific Activity
The specific activity of 125I-labelled antigens was measured by self-displacement in 
an RIA as described below:
100 jil antibody (B0 = 30-50%)
+
100 jil 125I-antigen (various masses)
OR
100 fil antigen (various concentrations)
+
100 jil 125I-antigen (5 000 cpm)
^  incubated (3 h, room temperature)
Solid-phase added, incubated, washed and counted as described previously.
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Results were calculated in terms of 125l-antigen bound expressed as a percentage of 
the total amount added (% bound), and the displacement curves in the presence of 
labelled and unlabelled antigen plotted together. Representative curves for 125I- 
labelled proinsulin and insulin are shown in Figure 2.6 parts A and B respectively. 
The doses of labelled and unlabelled antigen required to achieve half-maximal 
displacement were determined from these curves and the specific activity of the 
labelled antigen calculated. The specific activities of the 125I-labelled proinsulin and 
insulin shown in Figure 2.6 were 11.8 MBq/pg and 5.3 MBq/|ig respectively.
Scatchard Analysis
Scatchard analysis was performed according to the protocol outlined in the previous 
section with various masses of unlabelled antigen and a known mass of 125I-labelled 
antigen added to a limiting amount of the antibody under evaluation. Results were 
plotted as the ratio of bound/free 125I-antigen (B/F) at each antigen concentration 
([H]). The avidity constant of the antibody was then calculated according to the 
method of Scatchard (105).
5.7 Immunoradiometric Assay of Human Proinsulin
Standards and serum samples (200 |il) were incubated with 200 Jil SepharoseR 
CL-4B coupled PH5/B5 (1 mg) for 30 minutes at room temperature. The solid- 
phase was then washed six times with assay buffer (0.1 mmol/1 EPPS pH 8) prior 
to the addition of 100 jn.1 125I-PH4/B1 (0.37-0.56 MBq/pg; 200 000 cpm) and a 
further incubation of 1 hour at room temperature. After a further six washes with 
0.2% Tween 20/0.9% sodium chloride, the bound radioactivity was quantitated on a 
gamma counter. Both incubations were performed on an orbital mixer. Results 
were calculated as the amount of 125I-PH4/B1 bound expressed as a percentage of 
the total amount added. A standard curve was constructed and used to determine the 
proinsulin concentration of the samples.
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Figure 2.6
Determination of the specific activity of 125I-proinsulin (A) and 
12^ I-insulin (B).
5.8 Immunoradiometric Assay of Human Insulin
Standards and serum (100 p.1) were incubated with 100 jil 125I-ID1/C10 (0.37- 
0.56 MBq/|ig; 200 000 cpm) for two hours at room temperature prior to the addition 
of 200 |il SepharoseR CL-4B coupled guinea-pig anti-insulin and a further 
incubation of 1 hour at room temperature. The solid-phase was then washed four 
times with 0.2% Tween 20/0.9% saline and the bound radioactivity quantitated on a 
gamma counter. The incubation in which solid-phase was present was performed on 
an orbital mixer. Results were calculated as described in Section 5.7 of this chapter.
6 POLYCLONAL ANTIBODY PRODUCTION
6.1 General Guidelines
The following guidelines for polyclonal antibody production were followed except 
where stated otherwise.
(i) A multiple emulsion technique was used for immunogen preparation.
(ii) FCA was used for immunisation with FLA being used for subsequent boosts.
(iii) Boosts were given at four-weekly intervals.
(iv) Test bleeds and blood donations were taken seven days after boosting.
(v) Test bleeds and blood donations were evaluated by RIA.
6.2 Guinea-Pigs
Strain 2 guinea-pigs over three months of age (ie, immunologically competent), 
were immunised and boosted with porcine insulin. Each animal received a dose of 
50 |ig in a final volume of 1 ml evenly distributed over two intramuscular and two 
subcutaneous sites. Test bleeds were obtained by spotting blood from an ear vein 
on to filter paper. The paper was air-dried, a 3 mm diameter circle punched out and 
eluted in 1 ml isotonic saline overnight at room temperature. The sample eluted 
from this size of disc was equivalent to 2 p.1 of serum ( Chapter 3, Section 1.2).
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When a serum titre similar to that of the commercially available Wellcome anti­
insulin was achieved, animals were exsanguinated by cardiac puncture. Serum was 
separated (Section 3.3 of this chapter) and stored frozen for future use.
Ascitic fluid containing specific antibody was produced in two immunised animals 
by weekly intraperitoneal injection of either 0.5 ml FCA with 50 (ig porcine insulin 
as a water-in-oil emulsion, or 0.5 ml FCA alone (106). Animals were weighed 
weekly and ascitic fluid collected, using a 5 ml syringe fitted with a 19 g needle, 
when present, (ie, an increase in weight suggested the presence of ascitic fluid). 
After ascites production had ceased, these guinea-pigs were also exsanguinated.
6.3 Rabbits
High responder semi-lop New Zealand White rabbits were immunised and boosted 
with a porcine insulin-human IgG conjugate (4:1). Each animal received 100 jig 
conjugate in a final volume of 1 ml, evenly distributed over two intramuscular and 
two subcutaneous sites. Test bleeds were taken from the marginal ear vein, 
processed as described in Section 3.3 of this chapter, and tested by 
immunodiffusion, to allow the detection of antibodies to human IgG, and by RIA to 
determine the specific anti-insulin titre.
6.4 Sheep
Sheep were immunised and boosted with either human insulin or a human insulin- 
ovalbumin conjugate (16:1). Each animal received 100 pg protein (5 ml), evenly 
distributed over six intramuscular and four subcutaneous sites. Test bleeds were 
taken from the jugular vein, the serum separated and tested by immunodiffusion to 
detect antibodies to ovalbumin, and by RIA to measure specific insulin antibody.
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6.5 Mice
Mice were immunised and boosted intraperitoneally with 6-10 p.g antigen prepared 
as a water-in-oil emulsion. Test bleeds were taken from the tail vein on to filter 
paper and prepared for assay as described in Section 6.2 of this chapter. When a 
stable serum titre was achieved, mice were rested until required as spleen donors for 
the production of monoclonal antibodies (Section 7.5 of this chapter). Three days 
prior to hybridisation, 6-10 fig antigen (in 0.1 ml saline) was administered 
intravenously via the tail vein.
6.6 Chickens
Chickens were immunised and boosted with porcine insulin prepared as a water-in- 
oil emulsion. Each animal received 50 fig in a final volume of 1 ml, evenly 
distributed between two sites in the breast muscle. Test bleeds were taken from a 
wing vein and the plasma separated and tested by RIA to determine the anti-insulin 
titre.
Chickens were injected and bled by Dr P Sharp, Institute of Animal Physiology and 
Genetics Research, Roslin, Edinburgh.
6.7 Donkeys
Donkeys were immunised and boosted initially with a human insulin-ovalbumin 
conjugate (16:1), followed by several booster injections with porcine insulin. Each 
animal received 100 |ig protein in a final volume of 5 ml, evenly distributed over six 
intramuscular and four subcutaneous sites. Test bleeds were taken from the jugular 
vein and the serum separated and tested by RIA to determine the specific anti-insulin 
titre.
7 6
7 MONOCLONAL ANTIBODY PRODUCTION
Murine McAbs were produced by the fusion (hybridisation) of spleen cells from 
immunised BALB/c mice with the myeloma cell line X63.Ag 8.653, according to 
local adaptations of the method of Kohler and Milstein (71).
7.1 Media
HEPES buffered RPMI 1640 was used throughout. Myeloma cells were grown in 
1 x RPMI 1640 containing 20 mmol/1 HEPES, 2 mmol/1 glutamine, fungizone 
(2.5 [ig/ml), penicillin (100 IU/ml), streptomycin (100 (J-g/ml) and 10% foetal calf 
serum (FCS). Hybridomas were maintained in the same medium except that HAT 
(100, 0.4 and 16 (imol/1 respectively) was added and the FCS was raised to 20%. 
Mouse peritoneal macrophages were used as feeder cells as required (e.g. fusion 
and clone plates).
7.2 Preparation of Mouse Peritoneal Macrophages
Peritoneal macrophages were collected from stock mice which had been killed by 
administration of excess diethyl ether. This was the method used routinely for 
killing mice.
The peritoneal cavity of each mouse was rinsed with 5 ml 1 x RPMI containing 
20 mmol/1 HEPES (referred to as medium in future), using a syringe and 19 g 
needle. Washes from individual mice were pooled, centrifuged (800 g, 10 min, 
20°C) and the pellet resuspended in complete medium (ie, medium containing 
glutamine, fungizone, penicillin/streptomycin, FCS and HAT) at 3 x 104 cells/ml.
Unless otherwise stated, cells were always centrifuged at 800 g for 10 minutes at 
20°C.
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7.3 Maintenance of Myeloma Cells
The murine myeloma cell line X63. Ag 8.653 was maintained in logarithmic growth 
at a viability of greater than 95% for a minimum of 7 days before hybridisation. 
Cell counts were performed in a Neubauer haemocytometer using trypan blue 
(0.5% in 0.85% sodium chloride;v/v, dyeicell suspension) to assess cell viability.
7.4 PEG Preparation
Polyethylene glycol (M.W. 1500) was melted in a water bath at 55°C and medium 
added to give a 50% solution (w/v). The pH was adjusted to approximately 7 with 
0.3 mol/1 sodium hydroxide using the phenol red in the RPMI as an indicator and 
the solution filtered through a sterile 0.2 pm filter unit (Millipore).
7.5 Preparation of Spleen Cells
Immediately prior to hybridisation, an immunised mouse, which had been boosted 
intravenously three days previously (Section 6.5 of this chapter), was killed and the 
spleen removed using aseptic techniques. All further manipulations were carried out 
in a sterile laminar flow cabinet.
In a small petri dish containing fresh medium, the spleen was dissected free from 
fatty tissue, cut in half and the cells teased from the capsule with scalpel blades. 
Clumps of cells were dispersed by pipetting up and down with a 10 ml pipette 
before transfer to a 50 ml centrifuge tube. After debris had settled, the spleen cell 
suspension was decanted and centrifuged. The pellet was washed twice with 
medium, resuspended in 10 ml of the same and an aliquot taken for counting as 
described for myeloma cells (Section 7.3 of this chapter).
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7.6 Hybridisation Protocol
The day before hybridisation, complete medium containing peritoneal macrophages 
was dispensed into fifteen 96-well flat-bottomed microtitre plates (100 fil/well).
Immediately prior to hybridisation myeloma cells were counted, washed once with 
medium and mixed with spleen cells (1:1). This suspension was divided into three 
aliquots, each of which was used in a separate hybridisation experiment.
The myeloma/spleen cell suspensions were centrifuged and the supernatants 
discarded. To each pellet, 800 |il 50% PEG was added over one minute with 
stirring, and the mixture stirred for another 90 seconds prior to the addition of 10 ml 
medium over 5 minutes. After centrifugation, the cells were resuspended in 50 ml 
complete medium and plated out over five 96-well plates (100 |il/well) containing a 
feeder layer as described above. Three hybridisations from each mouse spleen 
provided a total of fifteen 96-well plates. The plates were sealed with sellotape, 
placed in a 37°C incubator and left untouched, except to monitor cell growth, until 
the initial screen 10-14 days later (Section 5.5 of this chapter).
7.7 Cloning Procedure
The cells from each antibody-positive well on the original fusion plates were cloned 
at least twice before attempting the production of antibody in vivo (ie, ascitic fluid). 
Cells were routinely cloned from 96-well plates, either the original fusion plate or a 
previous clone plate, by the method of limiting dilution.
The cells from one well of a 96-well plate were diluted in 1.5 ml complete medium 
in a 2 ml well. This cell suspension was then dispensed into the first column 
(8 wells, 100 ql/well) of a 96-well plate previously seeded with 100 ql/well 
complete medium containing peritoneal macrophage feeders. Using a multichannel 
pipette the cells were double diluted across the plate, and complete medium
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(100 (ll/well) added to columns 1-11. Complete medium (800 (il) was also added 
to the cells remaining in the 2 ml well. These cells were expanded and frozen to 
insure against cloning failure. Each clone plate was sealed with sellotape, placed in a 
37°C incubator and left untouched, except to monitor cell growth, until screening 
1-3 weeks later (Section 5.5 of this chapter).
Hybrids from three wells in the last one or two columns in which all wells 
supported cell growth, were further expanded and/or cloned.
7.8 Screening Protocols for Antibody Detection
In an initial screening procedure, monoclonal antibodies to insulin were detected by 
simple binding of 125I-porcine insulin and separation with solid-phase coupled anti- 
mouse-y-globulin. Displacement studies were then performed with human insulin 
to discriminate high and low avidity antibody producing clones. For proinsulin 
monoclonal antibodies the screening protocol used 125I-human proinsulin in the 
primary screen. Positive supernatants were retested with 12^ I-porcine insulin while 
supernatants from all hybridomas which proved stable through two cloning steps 
were tested for reactivity with 125I-labelled insulin and proinsulin as well as 125I-C- 
peptide.
7.9 Expansion of Hybridomas in vitro
Hybridomas were routinely expanded from fusion and clone plates to provide 
safeguard frozen stocks, and from second clone plates to provide sufficient cell 
numbers for the production of antibody in vivo.
Expansion was achieved by the transfer of cells sequentially to 2 ml wells, 25 cm2 
flasks and 75 cm2 flasks, with feeder cells being added at each transfer step. The 
cell density was maintained at 10^-10^ cells/ml.
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7.10 Expansion of Hybridomas in vivo
BALB/c mice were primed by the intraperitoneal injection of 0.5 ml pristane (2, 6, 
10 ,14-tetramethylpentadecane) ten days before the injection (intraperitoneal) of 106 
hybridoma cells (500 jil, washed and resuspended in medium) as described by 
N. Hoogenraad et al. (81).
The time interval between the injection of hybridoma cells and the production of 
ascitic fluid was variable (2-6 weeks). When present, ascites was collected (tapped) 
from mice anaesthetised with diethyl ether, using a 19 g needle, allowing the ascitic 
fluid to drain under gravity. Mice were tapped several times over a period of days 
or weeks, after which they were killed and any remaining ascitic fluid removed.
7.11 Storage and Recovery of Cells
All cell lines were stored frozen in liquid nitrogen. Cells were centrifuged and 
resuspended at 1-5 x 106 cells/ml in 10% DMSO/90% FCS. 1 ml aliquots were 
dispensed into cryovials and frozen slowly in a polystyrene box at -70°C. After a 
minimum of twelve hours, usually overnight, the vials were transferred to liquid 
nitrogen for long-term storage.
Recovery of cells was achieved by rapid thawing at 37°C, after which the contents 
of the cryovial were immediately diluted in 20 ml medium and centrifuged. The 
pellet was resuspended in 1 ml complete medium and transferred to a 25 cm2 flask 
containing 4 ml complete medium previously seeded with peritoneal macrophages.
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CHAPTER 3 
POLYCLONAL ANTIBODY PRODUCTION
1 GUINEA-PIGS
1.1 Comparison of Outbred and Inbred Animals
A group of twelve outbred guinea-pigs was immunised and boosted with porcine 
insulin. Two animals died after the primary immunisation (200 |ig insulin) from 
suspected hypoglycaemia and the dose was lowered to 100 |ig for subsequent 
boosts. One animal died after the first boost but no cause of death was established. 
Test bleeds were taken by cardiac puncture which resulted in two further deaths. 
After three boosts, anti serum dilution curves from the remaining seven guinea-pigs 
were compared with a commercially available antiserum (Wellcome) and the results 
shown in Figure 3.1. The highest titre antiserum raised in outbred guinea-pigs was 
a hundred-fold lower than the titre of the commercial antiserum, with two animals 
showing no serum antibody response.
An inbred strain of guinea-pigs, Strain 2, was then purchased and the animals 
immunised as described in Chapter 2, Section 6.2. Figure 3.2 shows the range of 
responses observed in comparison with the outbred group after the same number of 
boosts. The lowest responders in the inbred group produced similar antiserum titres 
to the highest responders in the outbred group. Subsequently, inbred guinea-pigs 
were adopted for immunisation.
The avidity of a pool of insulin antiserum raised in Strain 2 guinea-pigs was 
compared to that of the Wellcome antiserum by displacement of 125I-porcine insulin 
with human insulin standards (Figure 3.3). Although the antiserum raised in Strain 
2 guinea-pigs was of a lower titre than the commercial one (1:20 000 vs 1:60 000 
initial dilution) the avidity was comparable. To date, sixty Strain 2 guinea-pigs have 
been immunised with insulin and all have produced high titre, high avidity antisera 
suitable for use in RIA and IRMA techniques.
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Figure 3.1
Comparison between insulin antisera raised in outbred guinea- 
pigs and a commercially available antiserum (Wellcome).
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Figure 3.2
Comparison of the range of insulin antibody responses observed 
in outbred and inbred guinea-pigs.
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Figure 3.3
Insulin RIA standard curves constructed with Wellcome 
Strain 2 guinea-pig antisera.
1.2 Evaluation of Blood Spots for Test Bleeding Guinea-Pigs
The high risk of mortality associated with taking test bleeds by cardiac puncture was 
unacceptable and a safer method, that of collecting small volumes of blood 
(<100 pi) from a peripheral vein on to filter paper, was assessed.
Six blood spots were taken from each of two guinea-pigs immediately before 
exsanguination and eluted in 2 ml saline as described in Chapter 2, Section 6.2. 
Samples eluted from blood spots were arbitrarily designated as 'neat'. The results 
from each series of blood spot dilution curves were pooled and plotted, as mean and 
standard deviation, together with the corresponding serum dilution curve 
(Figure 3.4). Similar percentage binding was achieved with a serum dilution 
approximately 1000 times greater than the arbitrary dilution assigned to the blood 
spots. Therefore, the sample volume eluted from the original blood spots into 2 ml 
saline was probably 2 pi to result in a 1:1000 dilution.
This method of test bleeding has been used successfully to monitor accurately serum 
antibody levels in both guinea-pigs and mice.
1.3 Avidity Constants of Antiserum for Insulin and Proinsulin
The avidity constants of the insulin antiserum, raised in Strain 2 guinea-pigs, for 
insulin and proinsulin were 1.6 x 1011 - 1.0 x 1012 1/mol and 1.1 x 1010 1/mol 
respectively. The relevant Scatchard plots are shown in Figure 3.5.
1.4 Ascites Production
Production of ascitic fluid containing specific antibody was attempted (Chapter 2, 
Section 6.2) in two guinea-pigs which exhibited a good serum titre of anti-insulin 
following a series of ten boosts. One of the animals was humanely killed prior to 
any ascitic fluid production. The second guinea-pig produced approximately 40 ml 
ascites over a one month period after which it was exsanguinated (Table 3.1).
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Figure 3.4
Antiserum dilution curves prepared from blood spots and serum 
from each of two guinea-pigs.
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Figure 3.5
Scatchard plots of the insulin antiserum raised in Strain 2 guinea- 
pigs with insulin (A) and proinsulin (B) standards.
TABLE 3.1
IMMUNISATION SCHEDULE FOR THE PRODUCTION OF ASCITIC FLUID 
IN GUINEA-PIGS
Guinea-pig A Guinea-pig B
Date Treatment
Weight (g) Volume
of
Weight (g) Volume
o f
Pre* Post*
ascites
(ml) Pre Post
ascites
(ml)
10.6.86 FCA/Insulin _ _ _
17.6.86 FCA/Insulin - - - - -
24.6.86 FCA 820.3 - - 770.6 - -
1.7.86 FCA 794.2 - - 769.3 - -
8.7.86 FCA 690.2 - - 764.5 - -
15.7.86 FCA/Insulin 652.8 - - 722.1 - -
22.7.86 FCA 501.5 - - 723.8 709.9 15
Animal humanely killed
28.7.86 - - - 733.6 729.4 5
29.7.86 FCA/Insulin - - 734.5 732.6 2
31.7.86 - - - 679.4 669.5 10
5.8.86 FCA - - 675.7 672.9 3
8.8.86 - - - 660.3 - 5
Animal exsanguinated
*Pre and post refer to the weights of the guinea-pigs before and after ascitic fluid 
was removed.
The ascitic fluid obtained from this guinea-pig was pooled and assessed in 
conjunction with the corresponding serum collected at exsanguination. The 
antibody titre was lower in ascites than serum (Figure 3.6) and the higher avidity 
antibodies appeared to be missing as indicated by the higher doses of insulin 
required to achieve the same displacement of 125I-insulin from the antibody present 
in ascitic fluid compared with serum (Figure 3.7).
Post-mortem examinations performed on both animals showed a marked 
inflammatory reaction which involved the whole of the peritoneum in guinea-pig B, 
but was localised to the area surrounding, but not involving, the pancreas in guinea- 
pig A (Figure 3.8A). The inflammatory cell infiltrate comprised abundant 
epithelioid macrophages and lymphocytes (Figure 3.8B). Examination of the 
peritoneum revealed a dense infiltrate of immunoglobulin-secreting plasma cells 
deep to the peritoneal surface (Figure 3.8C).
1.5 Discussion
Guinea-pigs have been the species of choice for the production of high avidity 
antisera to insulin due to the large number of amino acid differences in the primary 
structure of guinea-pig and mammalian insulins (14). However, the immune 
response of guinea-pigs to insulin has been shown to be under the control of 
immune response genes (108) and therefore only animals of the appropriate 
haplotype will respond. The data presented in Figure 3.2 support this observation 
as only some of the outbred compared with all of the inbred guinea-pigs immunised 
with insulin responded. The use of Strain 2 guinea-pigs has resulted in the 
reproducible production of anti-insulin with all the animals immunised producing 
antisera suitable for use in immunoassay techniques.
The T cells of Strain 2 guinea-pigs are known to recognise the A-chain loop 
determinant on the insulin molecule (108). The data presented here suggest that the
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Figure 3.6
Comparison of serum and ascites anti-insulin dilution curves.
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Figure 3.7
Comparison of insulin RIA standard curves prepared with anti­
insulin present in serum and ascitic fluid.
Figure 3.8
Effect of intraperitoneal injection of Freunds complete adjuvant in guinea-pigs.
A Guinea-pig A. The pancreas on the left is normal. Omental fat on the right 
contains a marked inflammatory cell infiltrate.
Haematoxylin and eosin; x 25
B Guinea-pig A. High power of the inflammatory cell infiltrate. There are 
abundant epithelioid macrophages and lymphocytes, and a Langhan's giant cell 
is present. This reaction is typical of a response to mycobacteria (107).
Haematoxylin and eosin; x 400
C Guinea-pig B. High power of the peritoneum. Immediately deep to the 
peritoneal surface there is a dense infiltrate of immunoglobulin-secreting 
plasma cells.
Haematoxylin and eosin; x 500
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antibody response may also reflect the immunodominance of this epitope over others 
on the insulin molecule in this strain of guinea-pig. Scatchard analysis of the anti­
insulin raised in Strain 2 guinea-pigs resulted in a typical polyclonal curve against 
insulin but gave a straight line, characteristic of a McAb, when evaluated with 
proinsulin (Figure 3.5). This suggests that the antiserum reacts with a single 
epitope on the proinsulin molecule. Evidence that this epitope may be the A-chain 
loop or an epitope in close proximity to this is presented in Chapter 5, Figure 5.13. 
Two McAbs to insulin, one of which reacted with the A-chain loop (PH4/B1), were 
assessed for use in an insulin IRMA in conjunction with the guinea-pig anti-insulin. 
No binding was observed over the standard curve when the McAb recognising the 
A-chain loop was used, thus suggesting that both antibodies recognised the same or 
spatially close epitopes.
The attempt to increase the yield of antiserum obtained per guinea-pig by the 
production of ascitic fluid in pre-immunised animals was successful in terms of the 
volume of reagent harvested. However, the avidity of the anti-insulin in the ascitic 
fluid was lower than that in the serum and therefore this technique was not pursued.
2 RABBITS
Three rabbits were immunised and boosted once with a porcine insulin-human IgG 
conjugate (Chapter 2, Section 3.4). The resulting antiserum had a strong anti­
human IgG reactivity but no detectable insulin antibody. Due to the strength of the 
immune response to human IgG it was decided that further boosting would be 
unproductive and the experiment was terminated.
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Figure 3.9
Antiserum dilution curves prepared from test bleeds taken from 
sheep immunised with human insulin (A) or a human insulin- 
ovalbumin conjugate (B).
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Figure 3.10
Comparison of test bleeds taken from a sheep boosted with a 
human insulin-ovalbumin conjugate and one month later with 
human insulin.
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Comparison erf antisenmi dilution curves prepared with l25I-
labelled bovine and porcine insulins, from sheep immunised 
with either human insulin (A) or a human insulin-ovalbumin 
conjugate (B) and a commercial sheep anti-insulin (€).
3 SHEEP
3.1 Comparison of Immunisation with Human Insulin or Human 
Insulin-Ovalbumin Conjugate
Two groups of two sheep were immunised and boosted three times with either 
human insulin (Humulin) or a human insulin-ovalbumin conjugate (Chapter 2, 
Section 3.4). In both experiments a single sheep responded to produce a significant 
titre of insulin antibody (Figure 3.9). However, both sheep immunised with the 
conjugate showed a strong response to ovalbumin. The two sheep immunised with 
the conjugate were given a final boost with human insulin alone in an attempt to 
improve the anti-insulin titre by specifically stimulating the appropriate B 
lymphocytes. Unfortunately, a lower titre of insulin antibody was observed in the 
test bleeds taken after this boost compared to those taken after the previous boost 
with conjugate (Figure 3.10).
3.2 Epitope Specificity of Antisera
A commercial sheep anti-insulin (The Binding Site) was evaluated in conjunction 
with the above antisera in terms of antiserum dilution curves performed with both 
porcine and bovine iodinated insulins (Figure 3.11). The commercial antiserum and 
the one raised using human insulin as immunogen exhibited a preference for 125I- 
porcine insulin. Since the insulin in these two species differ only by two amino 
acids, at the A-chain loop (amino acids 8-10 on the A chain), this pattern of binding 
suggests that these antisera are directed, at least primarily, against this epitope. 
Human and porcine insulins are identical at these positions. In contrast, the 
antiserum raised using the conjugate as immunogen, does not distinguish between 
12^ I-labelled porcine and bovine insulins suggesting that it reacts with an epitope 
outside the A-chain loop.
8 6
3.3 Discussion
It is probable that the immune response of sheep to insulin is under the control of 
Ir genes, for whilst both sheep showed a strong response to ovalbumin, only one 
exhibited a significant response to insulin (Figure 3.9).
The apparent difference in specificity of the insulin antisera raised using either 
insulin or an insulin-ovalbumin conjugate (Figure 3.11) suggest that the A-chain 
loop determinant of the insulin molecule is immunodominant in sheep. The data 
also suggest that the conjugation of insulin to ovalbumin masked this epitope, 
resulting in the immune response being directed against a different epitope. In this 
respect, it would have been interesting to evaluate in a similar manner the tests 
bleeds, taken from a single sheep, after a booster injection with an insulin- 
ovalbumin conjugate one month and with insulin the following month 
(Figure 3.10). The lower titre of the test bleed taken after the booster injection with 
insulin may reflect the production of a previously unstimulated population of 
antibodies.
4 MICE
4.1 Immunisation with Porcine Insulin
Initially, a group of four BALB/c and New Zealand Black Fi hybrid mice was 
immunised with porcine insulin (Chapter 2, Section 6.5). After three boosts there 
was no detectable serum antibody response and the experiment was terminated. 
Five BALB/c mice were then immunised according to the same schedule and all 
responded. This difference in response was due to differences in the major 
histocompatibility complex between each group of mice (Chapter 1, Section 2.5). 
The antiserum dilution curves obtained after two boosts are shown in Figure 3.12. 
Mouse number 5 was used as the spleen cell donor for the fusion which generated
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Figure 3.12
Antiserum dilution curves prepared from test bleeds taken from 
mice immunised with porcine insulin.
McAbs ID 1/CIO, ED4/E5 and ID 1/A4 (Chapter 4). Monoclonal antibody ID1/C10 
was used to develop the insulin IRMA in conjunction with the polyclonal anti­
insulin raised in Strain 2 guinea-pigs (Chapter 5, Section 2).
4.2 Immunisation with Human Proinsulin
Four BALB/c mice were immunised and boosted once with human proinsulin before 
test bleeds were taken and antiserum dilution curves constructed (Figure 3.13). The 
serum response remained unchanged after two further boosts and the best responder 
(mouse 4) was used as the spleen cell donor for the hybridisation experiment 
performed on 19.7.85, which produced no stable antibody-secreting hybridomas 
(Chapter 4, Table 4.1).
The above experiments were performed using a heterogeneous 125I-human 
proinsulin preparation purified by gel filtration chromatography. Proinsulin 
contains four tyrosine residues, each of which is available for iodination, and one of 
these (B26) lies very close to the immunodominant epitope recognised by McAbs 
specific for proinsulin (the B-C chain junction). Iodination of proinsulin at this 
position could possibly inhibit the binding of McAbs with the desired specificity. It 
has been shown that iodination of proinsulin at the A 14 tyrosine residue does not 
inhibit the binding of proinsulin-specific antibodies (109) and a method for 
separating the various iodinated species of proinsulin was developed using reverse- 
phase HPLC (Chapter 5, Section 1.2).
The original test bleeds from the four BALB/c mice were then retested with 125I- 
proinsulin prepared by reverse-phase HPLC (Figure 3.14). The results indicated 
that four of the five mice had responded to the immunisation schedule confirming 
that the original iodinated proinsulin, purified by gel filtration chromatography, 
could not bind to all the antibodies present in the serum of these animals.
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Figure 3.13
Serum antibody response of mice immunised with human 
proinsulin (assessed using l25I-proinsulin purified by gel 
filtration chromatography).
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Mouse 1, which had been rested for 11 months, was then boosted, a test bleed taken 
and antiserum dilution curves constructed with both ^^I-labelled proinsulin and 
insulin (Figure 3.15). This animal was sacrificed and its spleen removed for the 
fusion experiment performed on 6.6.86, which yielded one McAb reactive against 
the C-peptide moiety of proinsulin (PD4/H4) and two reactive to both insulin and 
proinsulin (PF1/B9 and PF2/B5). The McAb PD4/H4 proved to be of inadequate 
avidity for the development of a sensitive proinsulin IRMA (Chapter 5, Section 4).
A subsequent group of eight BALB/c mice was immunised with human proinsulin 
in an attempt to produce higher avidity proinsulin-specific McAbs from a short 
immunisation schedule. Test bleeds were taken after two boosts and antiserum 
dilution curves constructed with iodinated proinsulin and insulin. Representative 
results from two mice are shown in Figure 3.16. The mouse giving the results 
shown in Figure 3.16A was used as the spleen cell donor for the fusion which 
generated three proinsulin-specific McAbs (PH5/B5, PI2/G4 and PI3/B10) and one 
which reacted with insulin and proinsulin (PH4/B1). Monoclonal antibodies 
PH5/B5 and PH4/B1 were used to develop the final proinsulin IRMA (Chapter 5, 
Section 6).
4.3 D iscussion
The immune response of mice to insulin is known to be under the control of Ir genes 
(110,111, 112) and this explains the non-responder status of the first group of mice 
immunised.
The difference in the observed serum antibody response of a group of mice 
immunised with human proinsulin, when tested with two different 125I-proinsulin 
preparations (Figure 3.14) emphasises the importance of establishing a suitable 
screening system for the evaluation of mouse serum prior to fusion and the 
subsequent detection of McAbs (Chapter 4, Section 3).
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Figure 3.15
Serum antibody response to proinsulin and insulin of the mouse 
used as spleen cell donor for the fusion which produced McAbs 
PD4/H4, PFI/B9 and PF2/B5.
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Figure 3.16
Representative serum antibody responses to proinsulin and 
insulin from two mice immunised with human proinsulin.
The production of high avidity proinsulin-specific McAbs from a short 
immunisation schedule appeared to be successful. This approach was based on the 
assumption that the dose of proinsulin used for immunisation was not small enough 
to only stimulate the highest avidity clones of plasma cells secreting antibody of the 
desired specificity. To have proved the validity of this argument, a considerable 
amount of work would have been required which was not directly relevant to the 
aims of this thesis.
5 CHICKENS 
5.1 Immunisation of Two Strains of Chicken with Porcine Insulin
Five ISA Brown chickens were immunised and boosted with porcine insulin. Two 
birds died after the first boost and a post-mortem examination revealed streptococcal 
infection of the liver. Test bleeds taken from the remaining three birds after four 
boosts were compared with the antiserum raised in Strain 2 guinea-pigs 
(Figure 3.17). A different strain of chicken, Dwarf Broilers, was then immunised 
according to the same protocol. Representative dilution curves from five of the ten 
birds immunised are shown in Figure 3.18 together with those of the highest and 
lowest responders from the ISA Brown group. The titre of the antisera raised in 
both strains was similar but 100-1000 fold lower than that of the guinea-pig 
antiserum. The avidities of the antisera from each of the chickens was assessed in 
conjunction with the guinea-pig antiserum by performing single dose displacement 
studies (200 mU/1 insulin) at three serum dilutions (Table 3.2). Chicken 28/4 
produced the highest avidity antiserum and was later evaluated for use as a solid- 
phase coupled reagent in an IRMA to measure insulin (Section 5.3).
5.2 Antibody Levels in the Eggs of an Immunised Chicken
The antibody titre present in the yolk of eggs laid by an immunised chicken (28/5) 
was approximately half that present in the plasma of the same bird (Figure 3.19).
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This titre was maintained for four weeks after a boost. This was assessed by the 
binding of 125I-porcine insulin by egg yolk antibody, at two dilutions, from eggs 
collected from a single chicken (28/5) over this period (Figure 3.20).
5.3 Evaluation of Antiserum in an IRMA to Measure Insulin
Purified IgG was prepared from the egg yolks of eggs laid by chicken 28/4 which 
produced the highest avidity antiserum (Chapter 2, Section 4.3). The IgG was 
coupled to SepharoseR CL-4B and compared with solid-phase coupled guinea-pig 
anti-insulin for use in an IRMA to measure insulin, in conjunction with two 12^ I- 
labelled McAbs reactive with insulin but with different epitope specificities. The 
chicken antiserum did not bind insulin over the range of concentrations tested, 
suggesting poor avidity.
5.4 Discussion
The immune response of chickens is known to be under the control of Ir genes 
(113). Although particular strains of chicken were used in this project, they were 
not inbred with respect to Ir genes and it was not surprising therefore, that a range 
of antibody titres and avidities was observed in the birds immunised with insulin.
At the outset, the use of chickens for the production of antisera to insulin was 
thought likely to succeed due to the relatively large number of amino acid differences 
between avian and mammalian insulins. However, as was shown with guinea-pigs 
(Section 1.5 of this chapter) success probably depends upon immunising the 
appropriate inbred strain. If this problem could be overcome, the use of chickens 
for immunisation with insulin would provide a feasible alternative to guinea-pigs 
especially as large quantities of specific antibody can be obtained from the yolks of 
eggs laid by immunised chickens. This is an important consideration in the 
development of immunometric assay techniques which require the use of excess 
antibody reagents.
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Figure 3.17
Comparison of insulin antisera raised in ISA Brown chickens 
and Strain 2 guinea-pigs.
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Figure 3.18
Comparison of responses of ISA Brown and Dwarf Broiler 
chickens to immunisation with porcine insulin.
TABLE 3.2
COMPARISON OF AVIDITIES OF CHICKEN ANTISERA IN RELATION 
TO A GUINEA-PIG ANTISERUM
Chicken % Displacement ± SD
identification __________________________
Dilution of antisera
1:50 1:100 1:500
28/3 0 7.2±7.l 1.4±1.9
28/4 36.5±2.l 55.1±0.1 38.6±0.1
28/5 0 6.6±1.8 21.5±30.4
65/1 27.4±6.6 41.4±2.3 33.6±6.5
65/2 28.4±0.8 16.0±5.4 0
65/3 0 18.0±4.2 32.3±1.3
65/4 5.1±1.6 0 0
65/5 6.9±0.2 12.9±1.6 0
65/6 0 3.6±2.5 7.0±0.2
65/7 15.5±1.7 29.9±8.8 26.8±4.0
65/8 18.4±1.3 13.9±3.0 26.7±1.3
65/9 15.8±21.5 0 4.4±0.8
65/10 0 4.7±2.8 0
Guinea-pig* 55.4±0.8 66.1±1.4 49.5±1.8
*Multiply dilutions by 103
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Figure 3.19
Comparison of antibody titre in the plasma and egg yolk of 
ISA Brown chicken (28/5) immunised with porcine insulin.
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6 DONKEYS
Two donkeys were immunised and boosted three times with a human insulin- 
ovalbumin conjugate (Chapter 2, Section 3.4) before test bleeds were taken and 
compared with the guinea-pig antiserum (Figure 3.21 A). No response was 
obtained. The animals were boosted three times with porcine insulin and further test 
bleeds taken. The antisera produced were of low titre (Figure 3.21B) and low 
avidity as indicated by the percentage displacements achieved with 200 mU/1 human 
insulin (Table 3.3). The IgG fraction of the antiserum raised in donkey 42 was 
coupled to SepharoseR CL-4B and assessed in an IRMA to measure insulin as 
described for the chicken antiserum (Section 5.3). Similar results were obtained, 
ie, no binding of insulin over the range of insulin concentrations tested.
The data presented in Figure 3.21 suggest that the epitope required for an antibody 
response to insulin in donkeys is masked by conjugation to ovalbumin. From the 
observations made in Section 3.3 of this chapter, it would appear that, as with 
sheep, the A-chain loop is immunodominant in donkeys.
9 2
60
50
40
30
20
10
-o—  Guinea-pig
-□----- Donkey 41
-■----- Donkey 42
3-------- -
Q L i i i i i ml.  i i i 11 ml < . . . . . . .  I . .   i
101 102 103 104 10;
Reciprocal antiserum dilution
60
50
40
30
20
10
0 42 1010
Reciprocal antiserum dilution
Figure 3.21
Comparison of insulin antisera raised in Strain 2 guinea-pigs, 
and donkeys after three boosts with a human insulin-ovalbumin 
conjugate (A) and three further boosts with porcine insulin (B).
TABLE 3.3
COMPARISON OF AVIDITIES OF DONKEY ANTISERA IN 
RELATION TO A GUINEA-PIG ANTISERUM
Donkey num ber
% Displacement ±SD
Dilution of antisera
1:10 1:50 1:100
41 0 0 0
42 0.8±0.3 11.5±9.7 24.2±4.7
Guinea-pig* NA 55.4±0.8 66.1±1.4
NA = not assessed * Multiply dilutions by 103
CHAPTER 4
PRODUCTION AND CHARACTERISATION OF MONOCLONAL
ANTIBODIES
1 PRODUCTION OF MONOCLONAL ANTIBODIES
Monoclonal antibodies were produced as described in Chapter 2, Section 7.
Table 4.1 summarises the relevant details of four hybridisation experiments which 
generated a total of ten antibody secreting cell lines, all of which have maintained 
antibody production both in culture and in regenerated frozen stocks to date. More 
than 60% of hybridomas detected in the initial screen were lost prior to and at the 
primary cloning step due to either cell death or loss of antibody production. No 
hybridomas were lost at or after the second cloning.
Six monoclonal antibodies reactive to both insulin and proinsulin were produced 
using either porcine insulin (3 McAbs) or human proinsulin (3 McAbs) as 
immunogen. Three of the remaining four antibodies generated using human 
proinsulin as immunogen, were specific for proinsulin and one was directed against 
the C-peptide moiety of proinsulin.
The initial hybridisation experiment with human proinsulin as immunogen did not 
yield any antibody-secreting hybridomas which were stable through two cloning 
steps. This failure was attributed in part to the poor quality 125I-human proinsulin, 
purified by gel filtration, used for screening. This label was unstable when stored at 
4°C (Chapter 5, Section 1.2) and shown to be incapable of binding to all the 
antibodies present in the serum of mice immunised with proinsulin (Chapter 3, 
Section 4.2). The remaining two fusions were screened using l^i-proinsulin  
which had been purified by reverse-phase HPLC.
The results from the first of the three proinsulin fusions also differed in the pattern 
of epitope specificity observed in the antibody-positive supernatants. The apparent 
low level of antibodies reactive to the insulin moiety of proinsulin was almost 
certainly due to the inadvertent use of iodinated bovine rather than porcine insulin 
in the screening assays. The commercial source of this preparation provided random 
batches of either porcine or bovine insulin without prior notification. This could
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have caused the misclassification of some antibodies as unreactive to insulin because 
the amino acid differences between porcine and bovine insulin occur in the region 
where anti-insulin McAbs, raised using proinsulin as immunogen, would be likely 
to bind (Section 2.2 of this chapter).
2 CHARACTERISATION OF MONOCLONAL ANTIBODIES 
2.1 General
Monoclonal antibodies were characterised for antigen binding specificity by RIA 
with 125I-labelled human proinsulin, porcine insulin and human C-peptide 
(Table 4.2). Six antibodies bound both insulin and proinsulin, three proinsulin 
only and one C-peptide and proinsulin. Antibodies within each group have been 
classified as anti-insulin, anti-proinsulin and anti-C-peptide respectively throughout 
the remainder of this thesis.
Details of the isotypes of all the antibodies and the avidity constants of four are 
shown in Table 4.3. Eight of the antibodies were of the IgGi and two of the IgG2a 
subclass. The avidity constants, calculated from the Scatchard plots shown in 
Figures 4.1 and 4.2, ranged from 1.2 x 108 to 2.1 x 109 1/mol.
2.2 Anti-Insulin Monoclonal Antibodies
Displacement curves with porcine insulin were performed to determine the relative 
avidities of the six insulin McAbs (Figure 4.3). Two groups of three antibodies 
were clearly distinguished and the division correlated with the hormone used for 
immunisation:porcine insulin resulted in the higher avidity (approximately 109 1/mol) 
and human proinsulin in the lower avidity (approximately 108 1/mol) groups.
This same division of the antibodies was apparent when species specificity studies 
were carried out to assess epitope recognition. Figure 4.4 shows the pattern of 
results obtained for the three McAbs raised using porcine insulin. Porcine, human,
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TABLE 4.2
BINDING OF MONOCLONAL ANTIBODIES TO 125I-LABELLED  
PROINSULIN, INSULIN AND C-PEPTIDE
A ntibody
% Bound ± SD
125I-P ro insu Iin 125I-InsuIin 125I-C -pep tide
ID1/C10* 65.6±0.5 48.8±0.5 NA
ID4/E5 78.3+0.7 58.2±0.5 NA
ID1/A4 75.2±0.6 59.7+0.3 NA
PD4/H4 31.6±0.9 1.1+0.1 16.6+0.5
PF1/B9 53.3±0.5 42.3+0.6 1.1+0.0
PF2/B5 49.4±0.3 39.8+0.7 1.1+0.1
PH5/B5** 74.2±0.0 0.9+0.0 0.6+0.0
PI2/G4 30.0±2.1 0.7+0.0 0.7+0.1
PI3/B10 58.2±1.8 0.9+0.1 0.7+0.0
PH4/B1** 81.2±0.6 61.2+0.4 0.6+0.1
NSB 1.6±0.0 1.1+0.1 0.7+0.1
NA = not assessed *used in insulin IRMA **used in proinsulin IRMA
125j_2aU)elleci proinsulin and insulin were prepared as described in Chapter 2, 
Section 5.2. 125I-C-peptide was obtained from Novo. Details of the method are 
given in Chapter 2, Section 5.5.
TABLE 4.3
ISOTYPES AND AVIDITY CONSTANTS OF MONOCLONAL ANTIBODIES 
PRODUCED
Antibody
code
Antigen
specificity
Isotype Avidity constant 
(1/mol)
ID1/C10* — IgGi 2.1 x 109
ID4/E5 IgGi 2.1 x 109
ID1/A4 IgGi NA
PF1/B9 Insulin/Proinsulin IgGi NA
PF2/B5 IgGi NA
PH4/B1** — IgG2a 1.2 x 108
PI2/G4 — IgGi NA
PI3/B10 Proinsulin IgG2a NA
PH5/B5** — IgGi 1.3 x 108
PD4/H4 C-peptide/Proinsulin IgGi NA
NA = not assessed *used in insulin IRMA ** used in proinsulin IRMA
Isotyping was performed by the Ouchterlony double diffusion technique (Chapter 2, 
Section 4.1) with sheep anti-mouse class and subclass specific antisera (Serotec). 
Affinity constants were determined by Scatchard Analysis (Chapter 2, Section 5.6).
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Figure 4.1
Scatchard plots of three anti-insulin monoclonal antibodies.
Scatchard analysis was performed as described in Chapter 2,
Section 5.6
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Figure 4.3
Relative avidities of the anti-insulin monoclonal antibodies for 
porcine insulin.
Details of the method are outlined in Chapter 2, Section 5.6
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Figure 4.4
Species inhibition curves of the three anti-insulin monoclonal 
antibodies raised using porcine insulin as immunogen.
Details of the method are outlined in Chapter 2, Section 5.6.
equine, bovine and ovine insulins were equally effective in displacing 125I-porcine 
insulin from two of the three antibodies. Monoclonal antibody ID4/E5 required 
slightly higher doses of bovine and ovine insulins to cause a similar level of 
displacement to the other three insulins. As equine, bovine and ovine insulins differ 
from porcine at the A chain loop (ie, amino acid positions 8-10 on the A chain) by 
1, 2 and 3 amino acids respectively, these antibodies do not react with this epitope. 
There may be some interaction of ID4/E5 with this portion of the insulin molecule 
but later results (Chapter 5, Section 2.2) suggest that this is not the complete binding 
site for this antibody. The carboxyl terminal of the B chain also appears not to be 
involved in epitope recognition as porcine and human insulin differ by one amino 
acid at position B30.
In contrast, evaluation of two of the three McAbs raised using human proinsulin as 
immunogen resulted in a pattern of binding suggesting that they were directed 
against the A chain loop (Figure 4.5). Increasing concentrations of porcine and 
human, equine, bovine and ovine insulin were required to cause the same 
displacement of 125I-porcine insulin from these antibodies.
An important feature of all the species specificity curves is the parallelism observed 
between the curves for any one antibody. This suggests that the antibody under 
evaluation was binding to the same site on each of the different species insulin.
2.3 Anti-Proinsulin/C-Peptide Monoclonal Antibodies
The relative avidities of the four McAbs in this group, for intact human proinsulin, 
are shown in Figure 4.6. The doses of proinsulin required to achieve displacement 
are of the correct order of magnitude (ie, nmol) but are not accurate due to the use of 
a secondary standard material prior to the acquisition of the primary proinsulin 
standard WHO 84/611. The assay was not repeated when the NIBSC standard 
became available since comparative information could be extracted from the results 
as presented.
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Figure 4.5
Species inhibition curves of two of the three anti-insulin 
monoclonal antibodies raised using human proinsulin as 
immunogen.
Details of the method are outlined in Chapter 2, Section 5.6
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Figure 4.6
Relative avidities of the three anti-proinsulin and one anti-C- 
peptide monoclonal antibodies for intact human proinsulin.
Details of the method are outlined in Chapter 2, Section 5.6.
The displacement of 125I-intact human proinsulin from antibody PH5/B5 by intact, 
split and des-amino proinsulins is shown in Figure 4.7. Complete displacement 
curves were not achieved due to the scarcity of these materials. However, it is 
possible to detect an emerging pattern of specificity since only the 32-33 split and 
des 31-32 forms failed to cause displacement, suggesting specificity at the B-C 
chain junction, ie, B chain of insulin and C-peptide. This observation was 
confirmed during specificity studies on the final proinsulin IRMA, developed using 
this antibody (Chapter 5, Figure 5.51 and Table 5.15). Epitope studies were not 
attempted on the other three low avidity antibodies.
Iodinated human proinsulin and C-peptide were not displaced from the C-peptide 
McAb (PD4/H4) with doses of cold proinsulin and C-peptide up to 60 nmol/1 and 
5 nmol/1 respectively.
3 DISCUSSION
The hybridisation experiments performed resulted in small numbers of antigen- 
specific antibody-producing hybridomas being detected at the initial screen, and a 
subsequent low yield of stable hybridomas following cloning. This observation is 
in agreement with the reported yields of other groups raising McAbs to insulin and 
proinsulin (39, 114, 115, 116, 117).
Within each fusion, the antibodies produced exhibited very similar specificities for 
insulin, proinsulin or C-peptide. This suggests that the antibody response of mice 
to small molecules such as insulin and proinsulin may in practice be limited to a 
single or small number of epitopes. A similar observation was made in Chapter 3 
following the immunisation of larger animals with insulin. It was also noted that in 
the two fusions in which proinsulin was used as immunogen, either C-peptide or 
proinsulin-specific McAbs were obtained. It is suggested that this might reflect 
subtle differences in the antibody response of individual mice to a particular
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Figure 4.7
Specificity of monoclonal antibody PH5/B5 for split and des- 
amino proinsulins.
immunogen, even within an inbred strain. If this was the case, screening of mice 
prior to fusion to ascertain the presence of particular subsets of antibodies, as has 
been advocated previously (74), would be advantageous.
The importance of establishing a screening procedure which is capable of detecting 
the antibodies of interest is highlighted by the failure of the initial hybridisation 
experiment which was attributed to the use of an unsuitable 125I-proinsulin 
preparation (Chapter 3, Section 4.3).
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CHAPTER 5 
ASSAY DEVELOPMENT
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1 REAGENT PRODUCTION
1.1 Immunoglobulin Fractionation
Monoclonal antibodies were routinely purified from ascitic fluid by caprylic acid 
fractionation (Chapter 2, Section 4.3) prior to iodination or coupling to SepharoseR 
CL-4B. The purity of these antibodies was assessed by anion-exchange HPLC 
(Chapter 2, Section 3.5). Representative elution profiles of ascitic fluid before and 
after fractionation are shown in Figure 5.1 A and B respectively. All ascitic fluid 
evaluated contained transferrin and albumin in addition to the McAb, but the ratio of 
the three proteins varied. The McAb shown in part B was estimated to be greater 
than 90% pure.
1.2 Iodination of Proinsulin 
Gel Filtration Chromatography
Initially, 125I-labelled proinsulin was purified by gel filtration chromatography on 
Sephadex G50 (Chapter 2, Section 5.2). A typical elution profile is shown in 
Figure 5.2. The immunoreactivity of this preparation was evaluated by constructing 
dilution curves with a polyclonal (guinea-pig) and monoclonal (ID4/E5) anti-insulin 
and comparing them with a dilution curve constructed using 12^ I-insulin and the 
monoclonal anti-insulin (Figure 5.3). The maximum binding of 12^ I-proinsulin 
purified in this way was 30% (polyclonal) and 25% (monoclonal) compared with 
60% (monoclonal) for the 125I-insulin. Aliquots of this preparation were stored at 
4°C or -20°C for one week and re-evaluated with the two insulin antibodies as 
described above (Figure 5.4). The dilution curves obtained indicated that the 
aliquot stored at 4°C had lost all immunoreactivity after one week and therefore 
storage at -20°C was recommended.
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Figure 5.1
Elution profiles, from HPLC on an anion-exchange column, of
ascitic fluid containing monoclonal anti-insulin before (A) and
after (B) caprylic acid fractionation.
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Figure 5.2
Representative elution profile of 125I-proinsulin on Sephadex
G50.
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Figure 5.3
Assessment of 125I-proinsulin, purified by gel filtration
chromatography, using a polyclonal and monoclonal anti­
insulin.
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Figure 5.4
Dilution curves prepared with a polyclonal (A) and monoclonal 
(B) anti-insulin and 125I-proinsulin stored at 4°C or -20°C.
125I-proinsulin, prepared as described above, was found to be unsuitable for use as 
a screening reagent for the detection of antibodies reactive to proinsulin in the serum 
of mice immunised with proinsulin, (as described in Chapter 3, Section 4.2), and 
also for the detection of proinsulin-specific McAbs in hybridisation experiments 
(as described in Chapter 4, Section 1). Therefore, an alternative method of 
purification, reverse-phase HPLC, was investigated.
Reverse-Phase HPLC
Starting conditions for the purification of 125I-proinsulin by reverse-phase HPLC 
were based on published results of similar work on 125I-insulin (118). Details of the 
column and elution buffers used are given in Chapter 2, Section 5.2. Fractions of 
the column eluant were collected at one minute intervals and the appropriate peak 
fractions pooled and tested for proinsulin immunoreactivity. The results are 
presented in tabular form as the percentage bound of each pool at a single dilution of 
polyclonal (guinea-pig) and monoclonal (ID4/E5) anti-insulin. The percentage of 
iodinated insulin bound by both antibodies is also shown for reference purposes. 
The only factor changed between experiments was the concentration of acetonitrile.
Initially, a concentration of 31.5% acetonitrile was used as this was between the 
concentrations, 31.2% and 32.5%, previously shown to elute split and intact 
proinsulins respectively from a similar C18 column (119). The elution profile 
obtained is shown in Figure 5.5. From Table 5.1, it can be seen that peaks 1-3 did 
not show any proinsulin reactivity and these were assumed to contain unreacted 
iodine. Pools 4-9, collected from 60-230 minutes at 31.5% acetonitrile, all showed 
proinsulin immunoreactivity as did peaks 10 and 11 collected while cleaning the 
column with 95% acetonitrile.
The concentration of acetonitrile was raised to 32.5% and a freshly iodinated aliquot 
of l25l-proinsulin applied (Figure 5.6 and Table 5.2). Peaks 1-5 appeared to
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Figure 5.5
Purification of 125I-proinsulin by reverse-phase HPLC at 31.5%
acetonitrile.
TABLE 5.1
ASSESSMENT OF 125I-PROINSULIN PREPARED BY REVERSE-PHASE
HPLC AT 31.5% ACETONITRILE
P ro insu lin
pool
% Bound±SD
Polyclonal
anti-insulin
M onoclonal
anti-insu lin
Insulin* 58.3±0.8 40.2±0.4
1 0.5±0.1 0.6±0.0
2 0.7±0.1 0.7±0.1
3 1.2±0.1 1.0±0.0
4 47.8±0.2 56.6±0.7
5 33.0±0.5 37.4±1.7
6 51.0±3.8 63.9±0.9
7 68.0±1.0 80.0±0.2
8 60.2±1.9 70.0±0.8
9 60.8±0.3 69.1+03
10 62.9±0.9 70.6±2.7
11 22.1±0.5 24.1±0.9
*125I-labelled porcine insulin prepared as described in Chapter 2, Section 5.2
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Figure 5.6
Purification of 125I-proinsulin by reverse-phase HPLC at 32.5%
acetonitrile.
TABLE 5.2
ASSESSMENT OF 125I-PROINSULIN PREPARED BY REVERSE-PHASE
HPLC AT 32.5% ACETONITRILE
P ro insu lin
pool
% Bound±SD
Polyclonal
anti-insulin
M onoclonal
anti-insulin
Insulin* 66.4±0.1 52.0±0.7
1 0.6±0.1 0.6±0.0
2 0.7±0.0 0.8±0.0
3 1.1±0.0 1.1±0.1
4 1.1±0.1 1.1±0.3
5 1.2±0.0 1.0±0.1
6 1.2±0.0 1.0+0.1
7 59.2±1.0 65.7±0.1
8 54.3±0.3 56.4±1.0
*l25i-labelled porcine insulin prepared as described in Chapter 2, Section 5.2
contain unreacted iodine. No further peaks were detected up to 95 minutes at 
32.5% acetonitrile and the concentration was increased to 37.2%. Two peaks 
eluted, the first of which appeared to be unreacted iodine (peak 6) while the second 
(peak 7) contained ^^I-proinsulin. A final peak of ^^I-proinsulin was eluted in 
95% acetonitrile. The lower recovery of the ^^I-proinsulin from the column 
during this run compared with the previous run (31.5% acetonitrile) suggested that 
the iodination had been unsuccessful, with poor incorporation of 125I into the 
proinsulin. However, the time taken to elute the unreacted iodine from the column 
appeared to be similar for both runs suggesting that a higher concentration of 
acetonitrile was necessary to elute the 125I-labelled proinsulin in a shorter time.
A further aliquot of proinsulin was iodinated and the concentration of acetonitrile 
adjusted to 33%. Peaks 1 and 2 appeared to contain unreacted iodine while peaks 
3-8 showed proinsulin reactivity (Figure 5.7 and Table 5.3). The peak eluted in 
95% acetonitrile was not collected.
Increasing the acetonitrile concentration from 31.5% to 33% appeared to decrease 
the number of peaks containing unreacted iodine from three to two and also 
appeared to result in most of the 125I-labelled proinsulin being eluted by 70 minutes 
as opposed to 230 minutes. Therefore, the acetonitrile concentration was increased 
further to 34%. This resulted in the first elution profile in which distinct peaks were 
observed (Figure 5.8). The pools of 125I-proinsulin collected in this experiment 
were evaluated using a proinsulin-specific McAb (Dr K Siddle, Cambridge), in 
addition to the two insulin antibodies. Peaks 1 and 2 contained unreacted iodine 
while peaks 3-12 contained 125I-proinsulin (Table 5.4). The majority of the 125I- 
labelled proinsulin was eluted by 60 minutes. Peak 6 exhibited the highest 
percentage binding with all three antibodies and these fractions were collected in 
subsequent runs to provide a 2^^I-proinsulin preparation suitable for use in 
screening procedures for the detection of antibodies reactive to proinsulin (Chapter 
3, Section 4.2 and Chapter 4, Section 1).
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Figure 5.7
Purification of 125I-proinsulin by reverse-phase HPLC at 33%
acetonitrile.
TABLE 5.3
ASSESSMENT OF 125I-PROINSULIN PREPARED BY REVERSE-PHASE
HPLC AT 33% ACETONITRILE
Proinsulin
pool
% Bound± SD
Polyclonal
anti-insulin
Monoclonal
anti-insulin
Insulin* 64.2±0.9 43.2±1.5
1 0.4±0.0 0.4±0.1
2 0.5±0.3 0.5±0.1
3 30.4±1.3 35.7±0.8
4 56.7±0.9 67.6±1.0
5 58.0±0.7 70.2±0.1
6 61.6±0.7 73.4±0.8
7 63.1±0.2 74.5±1.5
8 53.3±1.0 61.2±1.5
*125]_iabelled porcine insulin prepared as described in Chapter 2, Section 5.2
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Figure 5.8
Purification of 125I-proinsulin by reverse-phase HPLC at 34%
acetonitrile.
TABLE 5.4
ASSESSMENT OF 125I-PROINSULIN PREPARED BY REVERSE-PHASE
HPLC AT 34% ACETONITRILE
Proinsulin
pool
% Bound!SD
Polyclonal
anti-insulin
Monoclonal
anti-insulin
Monoclonal
anti-proinsulin
Insulin* 65.9±0.4 58.2±0.5 1.1±0.2
1 l.Q±0.1 1.1±0.2 1.0±0.3
2 2.6±0.0 2.8±0.1 2.3±0.2
3 44.0±1.1 51.5±0.7 43.2±0.2
4 47.4±0.1 54.9±0.1 44.9±0.7
5 58.3±0.4 68.2±1.3 55.1±0.5
6 66.6±1.1 78.3±0.7 61.8±1.2
7 58.3±l.l 69.0±0.4 61.5±0.6
8 48.1±0.1 54.4±2.0 44.9±0.6
9 53.6±1.0 64.9±0.2 55.3±2.3
10 57.1±0.3 65.4+1.1 56.9±2.1
11 54.3±0.4 62.3±1.0 53.3±1.4
12 27.4±0.1 30.4±0.5 33.1±0.0
*125I-labelled porcine insulin prepared as described in Chapter 2, Section 5.2
The elution profile obtained with 34% acetonitrile appeared to be similar to that 
presented in the only report in the literature for the preparation of 125I-labelled 
proinsulin purified by reverse-phase HPLC (120). This paper was unavailable at 
the time these experiments were started. The column packing described was similar 
to the one used above (C l8) but the buffer system and concentration of acetonitrile 
differed. The elution buffer was 29.5% acetonitrile in 0.2 mol/1 ammonium 
acetate pH 5.5 compared with the above elution buffer of 34% acetonitrile in 
1% trifluoroacetic acid with the pH adjusted to 3 with triethylamine 
(1% TEATFA pH 3).
The elution profile of 125l-proinsulin, from the column used for the previous 
experiments, using 29.5% acetonitrile in 0.2 mol/1 ammonium acetate pH 5.5 
(ie, the conditions described in reference 120) is shown in Figure 5.9 with the 
relevant results shown in Table 5.5. Peaks 1 and 2 appeared to contain unreacted 
iodine while pools 3-8 contained 125I-proinsulin. Under these conditions 
proinsulin was not eluted from the column as distinct peaks. Similar percentage 
binding of the various pools of 125I-proinsulin was achieved using this separation 
system as with that shown in Figure 5.8, but the maximum binding was observed at 
60 minutes compared to 30 minutes respectively. There did not appear to be any 
obvious advantage in adopting the buffer system described in reference 120 as this 
would have necessitated re-optimisation of the concentration of acetonitrile. 
Therefore, an elution buffer of 34% acetonitrile in 1 % TEATFA pH 3 was adopted.
1.3 Evaluation of Anti-Insulin Ascites for Use as Labelled Antibody
Ascitic fluid was produced as described in Chapter 2, Section 7.10 for each 
hybridoma. Taps of ascitic fluid from individual mice at the same stage were pooled 
to yield taps 1, 2, 3 etc. The antibody content of each pool was evaluated by 
constructing dilution curves with l^I-insulin and the results for two anti-insulin 
hybridomas, ID 1/C 10 and ID4/E5, are shown in Figure 5.10 parts A and B
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Figure 5.9
Purification of 125I-proinsulin by reverse-phase HPLC at 29.5%
acetonitrile in 0.2 mol/1 ammonium acetate pH 5.5.
TABLE 5.5
ASSESSMENT OF 125I-PROINSULIN PREPARED BY REVERSE-PHASE
HPLC USING 0.2 MOL/L SODIUM ACETATE pH 5.5 CONTAINING
29.5% ACETONITRILE
Proinsulin
pool
% Bound±SD
Polyclonal
anti-insulin
Monoclonal
anti-insulin
Insulin* 56.4±0.9 43.1±0.3
1 0.5±0.0 0.5+0.1
2 0.9+0.2 0.6±0.1
3 34.0±0.5 39.0±0.3
4 60.5±0.3 71.3±1.1
5 68.5±1.0 78.8±0.5
6 69.1 ±0.7 80.8±0.7
7 68.8±0.1 77.6±1.4
8 27.6±1.2 29.8±0.2
* 125I-labelled porcine insulin prepared as described in Chapter 2, Section 5.2
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Figure 5.10
Dilution curves of sequential ascitic fluid taps from two anti­
insulin hybridomas.
A - ED1/C10 B - ID4/E5
respectively. Ascitic fluid produced by hybridoma E01/C1Q appeared to show an 
increase in antibody content up to tap 3 after which there did not seem to be any 
further increase. In contrast, the antibody content of the ascites produced by 
hybridoma ID4/E5 appeared to increase up to the fourth tap. Aliquots of each of 
these ascites taps for each antibody were fractionated using caprylic acid and the 
protein content of the supernatants (>90% McAb as shown in Section 1.1 of this 
chapter) measured by a modified Lowry protein assay (Chapter 2, Section 3.1). 
The pattern of results obtained from this experiment (Table 5.6) were similar to 
those shown in Figure 5.10.
Aliquots of the purified McAb from each of the four taps of ascitic fluid produced by 
hybridoma ED4/E5 were iodinated and assessed in an immunoradiometric assay in 
conjunction with solid-phase coupled polyclonal anti-insulin (Figure 5.11, details as 
for Figure 5.1, Section 2.2 of this chapter). The specific radioactivities of the 
iodinated taps 1-4 were 0.65, 0.35, 0.37 and 0.32 MBq/p.g respectively. A lower 
maximum binding was achieved with tap 1 (20%) compared with the subsequent 
three taps (40%). This could either be due to iodination damage to the antibody or 
the presence of non-specific host IgG in the ascitic fluid. The second, third and 
fourth taps all resulted in maximum binding levels of approximately 40%, but the 
rate of change in binding of the standard curve obtained with the second tap was less 
than that achieved with the third and fourth taps which were similar. This suggests 
the presence of non-specific IgG in tap 2. Therefore, subsequent experiments made 
use of tap number 3 onwards for the production of l^^I-labelled monoclonal 
antibodies.
1.4 Discussion
The antibody content (Table 5.6) and antibody titre (Figure 5.10) increased in 
sequential taps of ascitic fluid obtained from two hybridomas. This is in agreement 
with published work (82). When the taps from one hybridoma (ID4/E5) were
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TABLE 5.6
MONOCLONAL ANTIBODY CONCENTRATION IN SEQUENTIAL 
TAPS OF ASCITIC FLUID PRODUCED BY TWO ANTI-INSULIN 
HYBRIDOM AS
Tap Protein concentration (mg/ml)
num ber ______________________________
ID 1/C 10 ID4/E5
1 1.68 2.04
2 2.28 4.44
3 3.96 5.76
4 3.96 7.92
5 4.20
Insulin (mU/L)
Figure 5*11
Insulin IRMA standard curves prepared with iodinated sequential
taps of anti-insulin (ID4/E5).
iodinated and evaluated in an IRMA to measure insulin, the maximum binding 
increased with successive taps but the rate of rise of the standard curve at the lower 
end also increased even after the maximum possible binding had been achieved. 
Thus, the maximum binding achieved was not the only factor important in deciding 
which taps were suitable for use in IRMA techniques as has previously been 
suggested (88).
It was hoped that the results obtained in Figure 5.11, the comparison of iodinated 
sequential taps of insulin McAb ID4/E5, would correlate with either the protein 
concentration (>90% IgG) recovered by caprylic acid fractionation (Table 5.6) or the 
dilution curves performed (Figure 5.10B). However, neither set of results 
suggested that taps 3 and 4 would yield identical standard curves in the insulin 
IRMA and therefore were of no predictive value.
Due to the time which would be involved in iodinating IgG from each tap of ascitic 
fluid from each hybridoma to be assessed, it was subsequently assumed that IgG 
prepared from ascitic fluid collected at or after a third tapping, would result in 
optimal labelled antibody preparations.
2 INSULIN IRMA
2.1 General Guidelines on IRMA Development
The following points are common to all the assays discussed in this chapter unless 
otherwise stated.
(i) Monoclonal antibodies were labelled with 125I to a specific activity of 0.37- 
0.56 MBq/pg.
(ii) The solid-phase matrix used was SepharoseR CL-4B.
(iii) Solid-phase was added to assay tubes in a volume of 200 pi.
(iv) Incubation steps in the presence of solid-phase were mixed continuously on an 
orbital shaker (Denley).
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(v) All incubations were at room temperature.
(vi) 12^ I-labelled antibody was added to standard or sample in a primary incubation 
step prior to a secondary incubation with solid-phase coupled antibody.
(vii) Prior to counting, the solid-phase was washed three times with 0.2% 
Tween 20/0.9% sodium chloride as described in Chapter 2, Section 5.5.
(viii) Radioactivity was quantitated using a Nuclear Enterprises gamma 
counter (NE1600).
(ix) Results were calculated as the amount of label bound expressed as a 
percentage of the total label added (% bound).
2.2 Evaluation of Monoclonal Antibodies for Use in an Insulin IRMA
Separate aliquots of the six anti-insulin McAbs were radiolabelled or coupled to 
solid-phase. Each antibody was then paired, either as label or solid-phase, with 
each of the other five antibodies to determine those McAbs compatible for a two-site 
immunoradiometric assay (Table 5.7). No two antibodies were capable of binding 
to the insulin molecule simultaneously. Therefore, all subsequent experiments 
compare the various McAbs in conjunction with a solid-phase polyclonal anti-insulin 
raised in guinea-pigs (Chapter 3, Section 1).
Figure 5.12 shows the standard curves obtained with 12^ I-labelled ID1/C10 and 
ID4/E5. Both antibodies gave similar results but ID 1/C 10 resulted in a slightly wider 
linear working range. The third McAb (ID1/A4) in this group (raised using porcine 
insulin as immunogen) gave poor incorporation of 12^ I, and was not evaluated 
further. Monoclonal antibody ID 1/C 10 was also compared with PH4/B1, one of the 
three McAbs raised using human proinsulin as immunogen. These two antibodies 
have different avidity constants (2.1xl09 and 1.2xl08 1/mol respectively) and bind 
to different regions of the insulin molecule. No binding of 12^I-PH4/B1 was 
observed over the range of insulin concentrations tested (Figure 5.13). This 
suggested that either the avidity of this antibody was inappropriately low for use in
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Figure 5.12
Comparison of two anti-insulin monoclonal antibodies in an 
insulin IRMA.
Standard(200 j l l I )  and 125I-McAb (100 000 cpm in 100 jil) were 
incubated for 2 h followed by a 1 h incubation with solid-phase 
coupled polyclonal anti-insulin (1 mg).
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Figure 5.13
Evaluation of a third anti-insulin monoclonal antibody in an 
insulin IRMA.
Details as for Figure 5.12
the development of a clinically useful IRMA or the epitope recognised was similar to 
that of the polyclonal antiserum. Further development of the insulin IRMA was 
performed therefore, with and solid-phase coupled guinea-pig anti­
insulin as described below.
2.3 Assay Optimisation
The optimum conditions for various parameters of the insulin IRMA were 
determined as follows.
Incubation Times
The primary incubation involved mixing 100 pi aliquots of standard and 125I- 
labelled ID1/C10 (100 000 cpm) with the addition of solid-phase coupled polyclonal 
anti-insulin (1 mg) for the second incubation. The optimum reaction times for the 
primary and secondary incubation steps were 2 h and 1 h respectively (Figure 5.14).
In subsequent graphs the rate of change in the percentage bound at the lower end of 
the standard curve is less. This is due to the use of a pool of antiserum from several 
animals which exhibited a range of avidities in their individual sera. The overall 
avidity of this pool was lower than that of the antiserum from the single guinea-pig 
which had been used previously.
Solid-Phase Coupled Antibody
Five solid-phases were prepared at different coupling ratios of IgGrgel. The amount 
of IgG coupled per mg gel increased as the amount offered increased, but the overall 
percentage uptake of IgG by the gel decreased at first and appeared to reach a plateau 
(Table 5.8). These solid-phases were then evaluated in the insulin IRMA as 
described above, using the optimum incubation times. Assay sensitivity, arbitrarily 
calculated as the dose of insulin resulting in a percentage bound twice that of the 
zero dose, was optimal at a coupling ratio of 0.05 mg IgG/mg gel (Figure 5.15A).
1 0 5
100
■os
o
CQ
£
0.5h
10 1000 1000
Insulin (mU/L)
100
o
CQ
0.5h
1.5h
10 100 10000
Insulin (mU/L)
Figure 5.14
Optimisation of the primary (A) and secondary (B) incubation 
times of the insulin IRMA.
During optimisation of the primary incubation (A), the secondary 
incubation was held at 1 h and during optimisation of the 
secondary incubation (B), the primary incubation was held at 
2 h.
TABLE 5.8
COUPLING OF POLYCLONAL ANTI-INSULIN TO SEPHAROSER CL-4B
IgG offered (mg)* 0.025 0.050 0.100 0.150 0.200
IgG coupled (mg)* 0.014 0.021 0.030 0.044 0.056
% uptake of IgG 56 42 30 29 28
*mg IgG per mg gel.
Tor details of coupling reaction see Chapter 2, Section 5.3.
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Figure 5.15
Optimisation of the coupling ratio of IgG: solid-phase (A) and the 
mass of solid-phase added per tube (B) in the insulin IRMA.
A -1 mg solid-phase/tube 
B - solid-phase prepared with 0.1 mg IgG/mg gel.
The effect of varying the mass of solid-phase added per tube was also examined. 
Similar assay sensitivity was achieved with either 0.5 mg or 1 mg solid-phase 
(Figure 5.15B). A mass of 0.5 mg was chosen since the data suggested that this 
was likely to result in consistently lower zero dose binding levels and had the added 
advantage of greater economy of solid-phase.
Wash Cycles
100 pi aliquots of standards (0-100 mU/1) and 125l-IDl/C10 (100 000 cpm) were 
incubated for 2 h followed by a second incubation with solid-phase coupled 
polyclonal anti-insulin (0.5 mg) for 1 h prior to washing and counting. After wash 
cycles 3,4,5 and 6 the assay was counted and standard curves constructed 
(Figure 5.16). Four wash sequences were required in order to attain maximum 
sensitivity without reducing the assay range.
125I-Labelled Antibody
The effect of varying the mass of 125I-labelled antibody added per tube was 
assessed by incubating standard and 125I-ID1/C10 (100 pi) for 2 h prior to the 
addition of 0.5 mg solid-phase coupled polyclonal anti-insulin and a further 
incubation of 1 h followed by washing (x4) and counting. The results are shown 
in Figure 5.17. The specific activity of the 12^ I-ID1/C10 used was 0.44 MBq/pg, 
which was equivalent to 4.9 ng antibody/100 000 cpm in subsequent experiments. 
Compared with the use of 100 000 cpm in the previous experiments, the addition of 
50 000 cpm resulted in improved sensitivity with no apparent change in the assay 
range. Addition of 200 000 cpm allowed measurement of insulin over a wider range 
of concentrations (up to 100 mUA) with a slight reduction in sensitivity.
Since clinical utility required that the assay measure insulin up to 100 mU/1, the 
effect of adding 100 000 cpm or 200 000 cpm was re-evaluated in conjunction with 
sample volumes of 50 pi and 100 pi. The assay was performed as described above.
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Figure 5.16
Optimisation of number of washes required, prior to counting, in 
the insulin IRMA.
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Figure 5.17
Optimisation of the mass of i^I-IDl/ClO added per tube in the 
insulin IRMA..
Sensitivity of less than 1 mU/1 combined with a range up to 100 mU/1 was achieved 
with either 100 jul sample and 200 000 cpm 125I-ID1/C10 or 50 jllI sample and 
100 000 cpm 125I-ED1/C10 (Figure 5.18).The former combination was preferred as 
greater precision should be possible when pipetting larger volumes (100 pi vs 50 pi) 
and quantitating higher count rates (200 000 cpm vs 100 000 cpm).
2.4 Assay Validation 
Matrix Effects
To establish the effect of different matrices on the insulin IRMA, blood samples 
from three volunteers (A, B and C) were collected as serum, plasma-heparin 
(2 mg/10 ml blood) and plasma-EDTA (10-20 mg/10 ml blood), all with and 
without Trasylol (4 000 U/10 ml blood). Insulin standard curves were constructed 
in each of the above, together with hormone-free serum (HFS) and assay buffer 
(Figure 5.19).
The pattern of curves obtained from standards diluted in each matrix were 
indistinguishable between individuals. No difference was observed between serum 
and plasma in either the presence or absence of Trasylol and serum was chosen as 
the sample matrix. Similarly, there was no detectable difference in the standard 
curves whether standards were diluted in buffer or HFS. Standards were therefore 
prepared in assay buffer and stored at -70°C for future use.
Stability of Insulin in Whole Blood and Serum
To determine the stability of insulin in whole blood and serum, blood samples were 
collected from five volunteers and treated as follows:
(i) A reference sample, designated zero time, was allowed to stand at room 
temperature for 30 minutes prior to separation and immediate freezing of the 
serum.
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Figure 5.18
Evaluation of two sample volumes (50 pi and 100 pi) in 
conjunction with two masses of ^I-ID1/C10 (100 000 cpm and 
200 000 cpm) in the insulin IRMA.
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Figure 5.19
The effect of sample matrix on the insulin IRMA.
(ii) A second sample of blood was treated as described in (i) but the serum was 
divided into five aliquots which were allowed to stand at room temperature for 
a further 0.5, 1, 2, 4 or 6 hours before freezing.
(iii) Five further aliquots of whole blood were allowed to stand at room 
temperature for 0.5, 1, 2, 4 or 6 hours (in addition to the 30 minutes required 
by the reference sample) prior to separation and immediate freezing of the 
serum.
These experimental samples were assayed simultaneously and the results calculated 
as the concentration of insulin measured at each time point expressed as a percentage 
of the concentration of insulin measured at zero time (ie, % insulin remaining). The 
results for each of the five volunteers are shown separately with the median values at 
each time point being connected (Figure 5.20). Two-way analysis of variance 
(ANOVA) supported the view that no significant degradation of insulin occurred in 
whole blood or serum up to six hours storage at room temperature.
Recovery of Insulin from Serum
The recovery of insulin from serum was evaluated by adding standard insulin to
each of four individual sera. Ten replicates were performed for each dose level in
each individual serum and the percentage recovery calculated from the equation:
% Recovery = Measured Insulin - Serum Insulin x 100
Added Insulin
The results obtained are summarised in Table 5.9 and indicate that insulin was 
recovered quantitatively over the working range of the assay.
Parallelism Between Standards and Endogenous Serum Insulin
Serum samples from four patients with cirrhosis of the liver were diluted with assay 
buffer and measured in the insulin IRMA. The results from each individual (A-D), 
plotted together with the standard curve, are shown in Figure 5.21. Sequential
1 0 8
140 r
120
gp 100
*s
*3
g 80vu
a
a  60
VieHH
40
20
A
- r
A
Time (h)
N>#g
;s
*3
S4>t-
120
100 —&
80
60
40
20
Median
0
86420
Time (h)
Figure 5.20
Stability of insulin in whole blood (A) and serum (B).
TABLE 5.9
INSULIN IRMA RECOVERIES
Insulin added
(mU/1)
% Recovery ±SD
A* B C D
10 86.6±3.5 101.0±2.8 104.5±1.9 97.5+4.5
25 91.8±3.0 101.8±2.3 95.6±2.9 95.4±2.6
50 98.3±2.4 94.5±4.1 98.0±2.5 96.7±3.9
100 109.4±2.3 98.5±1.5 105.7±1.2 110.7±4.0
*A-D = individual sera.
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Figure 5.21
Parallelism between standards and endogenous serum insulin in 
four patients JA-D).
dilution of all four patient samples produced results which were parallel to the 
standard curve over its working range.
Stability of Insulin to Repeated Freeze-Thaw Cycles
Insulin was added to pooled human serum at four dose levels (25, 50, 70 and 
90 mU/1) and each resulting pool was divided into aliquots and frozen at -30°C. 
Separate aliquots of each pool were then subjected to 0, 1, 2, 3 or 4 freeze-thaw 
cycles prior to assay in the insulin IRMA. The results (Figure 5.22), evaluated by 
two-way analysis of variance indicated a significant difference (p<0.05) in measured 
insulin concentrations between freeze-thaw cycles. However, the coefficient of 
variation (CV) between the values for each dose level were lower than the 
corresponding intra-assay coefficients of variation suggesting no difference between 
measured insulin concentrations in serum samples after four freeze-thaw cycles.
Stability of Insulin in Frozen Samples
Blood samples were collected from five volunteers and the serum separated as 
described in Chapter 2, Section 3.3. The serum from each subject was divided into 
aliquots and stored at -30°C until required for assay. Single aliquots from each 
volunteer were thawed and assayed at various time intervals over a six month period 
(Figure 5.23). Two-way analysis of variance indicated that there was no significant 
degradation of insulin in frozen samples stored at -30°C for up to six months.
Cross-Reaction of Intact, Split and Des-Amino Proinsulins in the 
Insulin IRMA
The pattern of cross-reaction for intact, split and des-amino proinsulins is shown in 
Figure 5.24. The percentage cross-reaction of each form at two dose levels (10 and 
300 pmol/1) is shown in Table 5.10.
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Figure 5.22
Stability of insulin to repeated freeze-thaw cycles.
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Figure 5.23
Stability of insulin in frozen samples.
c3O
PQ
£
100
10
1
.1
10 100 1000 100001
Insulin 
Intact 
32-33 split 
Des 31-32 
65-66 split 
Des 64-65 
56-57 split 
Des 57-65
Insulin / Proinsulin (pmol/l)
Figure 5.24
Cross-reaction of intact, split and des-amino forms of proinsulin 
in the insulin IRMA.
TABLE 5.10
PERCENTAGE CROSS-REACTION OF INTACT, SPLIT AND DES- 
AMINO PROINSULINS IN THE INSULIN IRMA
% Cross-reaction
Proinsulin (pmol/1)
Proinsulin form 10 300
Intact 85.2 57.7
32-33 split 70.4 60.8
Des 31-32 68.5 49.5
65-66 split 73.5 61.9
Des 64-65 83.3 66.9
56-57 split 61.1 57.7
Des 57-65 79.6 59.8
The Final Insulin IRMA
Figure 5.25 shows a typical standard curve and within assay precision profile for 
the optimised insulin IRMA. The sensitivity of the assay was 0.3 mU/1 (CV 22%) 
(121) with a range of 0.8->100 mUA (CV <10%). The inter-assay coefficients of 
variation were calculated using quality control (QC) samples prepared at five dose 
levels and the results are shown in Table 5.11.
2.5 Correlation of Insulin RIA and IRMA
The insulin IRMA, developed as described above, was compared with the routine 
RIA in the Institute of Biochemistry at Glasgow Royal Infirmary. The RIA 
involved the incubation of sample and anti-insulin (raised in Strain 2 guinea-pigs as 
described in Chapter 3, Section 1) overnight at 4°C followed by the addition o f 1251- 
insulin and a further incubation of 3 hours at room temperature. SepharoseR CL-4B 
coupled anti-guinea-pig IgG was then added and the assay mixed continuously on 
an orbital shaker for 30 minutes prior to three washes as described in Section 2.1 of 
this chapter. The RIA was performed by MLSO staff in the above department.
Cross-Reaction of Intact, Split and Des-Amino Proinsulins in the 
Insulin RIA
The pattern of cross-reaction of intact, split and des-amino proinsulins in the insulin 
RIA is shown in Figure 5.26. The percentage cross-reaction of each form at two 
dose levels (10 and 300 pmol/1) is shown in Table 5.12.
Correlation of One Hundred Patient Samples Measured in Both the 
RIA and IRMA
One hundred patient samples measured in the routine RIA, at Glasgow Royal 
Infirmary, covering a range of insulin concentrations from 2.4 to 97.2 mU/1 were 
also measured in the IRMA. There was a strong positive correlation between the
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Figure 5.25
A representative standard curve (A) and within assay precision 
profile (B) for the optimised insulin IRMA.
TABLE 5.11
INTER-ASSAY COEFFICIENTS OF VARIATION FOR THE INSULIN IRMA
Insulin %CV Number of samples
(mU/1)
13 1.8 4
25 3.9 60
50 4.6 60
70 3.7 60
90 5.6 60
100
Insulin
Intact 
32-33 split 
Des 31-32 
65-66 split 
Des 64-65 
56-57 split 
Des 57-65
10 100 10001 10000
Insulin / Proinsulin (pmol/l)
Figure 5.26
Cross-reaction of intact, split and des-amino forms of proinsulin 
in the insulin RIA.
TABLE 5.12
PERCENTAGE CROSS-REACTION OF INTACT, SPLIT AND DES- 
AMINO PROINSULINS IN THE INSULIN RADIOIMMUNOASSAY
% Cross-reaction
Proinsulin (pmol/1)
Proinsulin form 10 300
Intact 107.4 86.2
32-33 split - 90.1
Des 31-32 - 90.1
65-66 split - 80.1
Des 64-65 - 92.1
56-57 split 136.8 85.1
Des 57-65 - 91.6
results from each assay (r=0.96) and the slope of the regression line was calculated 
to be 0.87, indicating that the IRMA results were 13% lower than those from the 
RIA (Figure 5.27). This difference could be accounted for in part by the lower 
cross-reaction of the various forms of proinsulin in the IRMA compared with the 
RIA (Tables 5.10 and 5.12 respectively).
3 DEVELOPMENT OF A PROINSULIN IRMA
3.1 Production of Monoclonal Antibodies for Use in a Proinsulin 
IRMA
In an attempt to produce McAbs specific for proinsulin three fusions were 
performed with proinsulin as immunogen (Chapter 4, Table 4.1). The initial fusion, 
performed on 19.7.85, did not yield any stable antibody-secreting hybridomas. 
This failure was attributed in part to the poor quality 125I-proinsulin, purified by gel 
filtration, used for screening (Chapter 4, Section 1). An alternative method of 
purifying 125l-proinsulin, reverse-phase HPLC, was developed (Section 1.2 of this 
chapter) and two further hybridisation experiments performed. The first, performed 
on 6.6.86, yielded one McAb reactive with C-peptide and proinsulin (PD4/H4) and 
two reactive with insulin and proinsulin (PF1/B9 and PF2/B5). A second fusion, 
performed on 10.4.87, yielded three McAbs specific for proinsulin (PH5/B5, 
PI2/G4 and PI3/B10) and one which reacted with insulin and proinsulin (PH4/B1).
3.2 Evaluation of Monoclonal Antibodies for Use in a Proinsulin 
IRMA
The C-peptide and proinsulin McAbs were evaluated for use in a proinsulin IRMA 
in conjunction with a polyclonal guinea-pig anti-insulin and the insulin McAbs 
available at the time of their production. The following three sections in this chapter 
deal with the proinsulin assays developed with the above McAbs as they were 
produced. A short summary of each section is outlined on the following page.
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Figure 5.27
Correlation of one hundred patient samples analysed in both the 
insulin RIA and IRMA.
(i) Section 4 Proinsulin IRMA with monoclonal anti-C-peptide.
This section describes the evaluation of the McAb reactive with 
C-peptide in conjunction with a polyclonal guinea-pig anti-insulin 
and various insulin McAbs produced in the same and earlier 
fusions. The desired assay sensitivity was not achieved with any 
combination of antibodies and the factors investigated in an 
unsuccessful attempt to improve the sensitivity are oudined.
(ii) Section 5 P roin su lin  IRM A-1 with p ro in su lin -sp ec ific
monoclonal antibody.
This section describes the evaluation of the highest avidity McAb 
specific for proinsulin, PH5/B5, in conjunction with a polyclonal 
guinea-pig anti-insulin and the various insulin McAbs produced 
previously, in addition to the one produced in the same fusion 
experiment (PH4/B1). The optimisation of a proinsulin IRMA 
utilising the proinsulin-specific McAb (PH5/B5) coupled to 
solid-phase and the insulin McAb (PH4/B1) labelled with 125I is 
described. The assay involved a primary incubation of 125I-anti- 
insulin with sample followed by a secondary incubation with 
solid-phase coupled anti-proinsulin. The interference of insulin 
in this assay, which rendered it unsuitable for clinical use, is also 
outlined.
(iii) Section 6 P roinsu lin  IRM A-2 with p ro in su lin -sp ecific
monoclonal antibody.
The assay described in this section utilises the same McAbs as 
the one described in Section 5, but the order of addition of the 
reagents was reversed. This resulted in an assay in which 
proinsulin was immunoextracted from the sample by solid-phase
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coupled anti-proinsulin prior to the addition of the 125I-labelled 
anti-insulin. This attempt to abolish the interference of insulin 
was successful and the clinical validation of this assay is 
outlined.
4 PROINSULIN IRMA WITH MONOCLONAL ANTI-C-PEPTIDE
4.1 Evaluation of Monoclonal Antibodies for Use in a Proinsulin 
IRMA
The C-peptide McAb (PD4/H4), produced in the fusion performed on 6.6.86, was 
evaluated in conjunction with the two insulin McAbs (PF1/B9 and PF2/B5) 
produced in the same fusion as well as a polyclonal guinea-pig anti-insulin and one 
of the three insulin McAbs produced in a previous hybridisation experiment in 
which insulin was used as immunogen.
Comparison of Anti-C-Peptide Coupled to Solid-Phase or Labelled 
with 125I
The C-peptide McAb (PD4/H4) was either labelled with 125I or coupled to solid- 
phase and evaluated in conjunction with the insulin McAb PF1/B9 similarly coupled 
to solid-phase or labelled with 12^ I. The use of the C-peptide McAb labelled with 
125I appeared to result in a more sensitive assay (Figure 5.28). Identical results 
were obtained with McAb PF2/B5 which has a similar avidity and epitope specificity 
to PF1/B9. Subsequent experiments were performed with McAb PD4/H4 labelled 
with 125I rather than coupled to solid-phase.
Comparison of Polyclonal or Monoclonal Anti-Insulins Coupled to 
Solid-Phase
Monoclonal antibody PD4/H4 was labelled with 125I and assessed in conjunction 
with three different insulin antibodies coupled to Sepharose^ CL-4B. The
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Figure 5.28
Comparison of monoclonal anti-C-peptide iodinated or coupled 
to solid-phase. Standard (200 jxl) and 12^ I-labelled McAb/100 
000 cpm in 100 |il were incubated for 24 h at 4°C followed by a 
second incubation with solid-phase coupled McAb for 3 h at 
room temperature.
antibodies used were:
(i) A polyclonal guinea-pig anti-insulin
(ii) Anti-insulin McAb PF1/B9 produced in the same fusion. This antibody reacts 
with the insulin A-chain loop and has an avidity constant of <1.2 x 10** 1/mol.
(iii) Anti-insulin McAb ID4/E5 produced using insulin as immunogen. This 
antibody reacts with an epitope outside the A-chain loop and has an avidity 
constant of 2.1 x 109 1/mol.
The results (Figure 5.29) indicated that the polyclonal solid-phase was superior to 
either monoclonal solid-phase in terms of assay sensitivity. The lower avidity McAb 
(PF1/B9) appeared to result in a more sensitive assay than the higher avidity 
ID4/E5. This suggests that the epitopes recognised by antibodies PD4/H4 and 
ID4/E5 lie close together spatially on the proinsulin molecule or that once bound, the 
PD4/H4 McAb alters the conformation of the epitope recognised by McAb ID4/E5.
Subsequent experiments were performed using 125I-labelled anti-C-peptide 
(PD4/H4) in conjunction with solid-phase coupled polyclonal anti-insulin.
4.2 Assay Optimisation
Clinical use required that the assay measure fasting levels of proinsulin 
(<10 pmol/1) (33) and therefore various parameters were examined in an attempt to 
maximise the sensitivity of the assay.
Sample Volume
The effect of increasing the sample volume from 100 pi to 200 pi was evaluated by 
incubating standard (100 |il or 200 [il) and i2^I-PD4/H4 (100 000 cpm in 100 pi) 
for 24 h prior to a second incubation with 1 mg solid-phase coupled polyclonal anti­
insulin for 3 h. A sample volume of 200 pi appeared to improve the assay 
sensitivity (Figure 5.30) and was adopted for subsequent experiments.
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Figure 5.29
Evaluation of 125I-anti-C-peptide monoclonal in conjunction 
with polyclonal and monoclonal anti-insulins in an IRMA to 
measure proinsulin.
100 fil aliquots of standard and 125l-PD4/H4 (100 000 cpm) 
were incubated for 3.5 h prior to a second incubation with solid- 
phase coupled anti-insulin (1 mg) for 2 h.
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Figure 5.30
Comparison of two sample volumes (100 p.1 and 200 jxl) in the 
proinsulin IRMA.
125I-Labelled Antibody
The effect of adding various masses of ^^I-labelled antibody per tube was assessed 
using two preparations with different specific radioactivities (approximately 0.44 
and 0.93 MBq/jig). The assay was performed as described in the previous section 
using a sample volume of 200 p,l. The same pattern of results was obtained with 
both preparations (Figure 5.31) but the antibody labelled to a specific activity of 
0.44 MBq/jig appeared to result in improved sensitivity.
Calibration of Proinsulin Standard Material
The standards used in the above experiments were prepared from stock material 
reconstituted for use as an immunogen and consequently lacking in accuracy. 
Therefore, intact proinsulin standards obtained from Professor C N Hales, were 
used as a reference for secondary calibration of the above material. The assay was 
performed as described in previous sections except that the sample volume was 
reduced to 100 pi to maximise use of the reference material. The value originally 
assigned to the 'in-house' standards required to be multiplied by 0.56 to give the 
comparative proinsulin concentration to the reference (Figure 5.32). The standard 
recalibration led to an improvement in the assay sensitivity by a factor of 2.
Comparison of Intact and Split Proinsulin Standards
32-33 split and 65-66 split proinsulin standards, also obtained from Professor 
C N Hales, were assayed in parallel with the intact proinsulin standard to evaluate 
differences in immunoreactivity between the three forms. It has been shown 
previously that in an immunometric assay system using anti-C-peptide antisera, 
intact proinsulin immunoreactivity was approximately one hundred times lower than 
that of the two split forms (39). However, in the assay described here intact 
proinsulin exhibited greater immunoreactivity than either split form (Figure 5.33).
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Figure 5.31
Effect of adding different masses of 125I-PD4/H4 per tube.
A - specific activity = 0.93 mBq/fig 
B - specific activity = 0.44 mBq
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Figure 5.32
Calibration of 'in-house' proinsulin standards against those 
obtained from Professor C N Hales.
100
Intact 
32-33 split 
65-66 split
0 .01 .1 101 100
Proinsulin (nmol/1)
Figure 5.33
Immunoreactivity of intact, 32-33 split and 65-66 split 
proinsulins in the proinsulin IRMA.
The above data show that the maximum sensitivity achieved using the C-peptide 
McAb (PD4/H4) to measure proinsulin, was approximately 20-40 pmol/1. This 
suggested that the development of a more sensitive proinsulin assay required a 
McAb of higher avidity.
5 PR O INSULIN IRM A-1 WITH PR O INSULIN-SPECIFIC  
MONOCLONAL ANTIBODY
The third hybridisation experiment performed using proinsulin as immunogen 
produced four McAbs, all of which were of higher avidity than the antibodies 
produced in the previous fusion (ie, those assessed in Section 4 of this chapter). 
Three of the antibodies were specific for proinsulin (PH5/B5, PI2/G4 and PI3/B10) 
and one reacted with insulin and proinsulin (PH4/B1).
5.1 Evaluation of Monoclonal Antibodies for Use in a Proinsulin 
IRMA
The highest avidity proinsulin-specific McAb PH5/B5 (Chapter 4, Section 2.3) was 
iodinated and evaluated in conjunction with solid-phase coupled polyclonal (guinea- 
pig; 0.03 mg IgG/mg gel) and monoclonal (PH4/B1; 0.022 mg IgG/mg gel) anti­
insulin. The assay involved incubating standard (200 |il) and 125I-PH5/B5 
(100 000 cpm in 100 |il) for 24 h followed by a second incubation with solid-phase 
coupled anti-insulin (1 mg) for 3.5 h prior to washing (x6) and counting. The solid- 
phase coupled monoclonal antibody resulted in a more sensitive assay and was used 
in preference to the solid-phase coupled polyclonal antiserum (Figure 5.34).
Similar assay sensitivities were achieved when the anti-proinsulin monoclonal was 
iodinated or coupled to solid-phase, although the use of this antibody as a solid- 
phase reagent resulted in a narrower working range (Figure 5.35). However, 
practical considerations dictated that the anti-proinsulin monoclonal be used as the 
solid-phase reagent as the hybridoma secreting the anti-insulin monoclonal 
(PH4/B1) did not grow well in vivo. Therefore, all subsequent experiments were
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Figure 5.34
Evaluation of 125I-labelled monoclonal anti-proinsulin, in
conjunction with a polyclonal and monoclonal anti-insulin, in an
IRMA to measure proinsulin.
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Figure 5.35
Evaluation of monoclonal anti-proinsulin iodinated or coupled to 
solid-phase (SP).
Assay details as in text for Figure 5.1 with the monoclonal anti­
insulin being used as partner antibody.
anti-insulin solid-phase = 0.022 mg IgG/mg gel
anti-proinsulin solid-phase = 0.007 mg IgG/mg gel
performed with the combination 125I-labelled anti-insulin (PH4/B1) and solid-phase 
coupled anti-proinsulin (PH5/B5).
5.2 Assay Optimisation
2^^I-Labelled Anti-Insulin
Monoclonal antibody PH4/B1 was iodinated to three specific radioactivities 
(1.00, 0.44 and 0.26 MBq/pg) and assessed in the proinsulin IRMA performed as 
described in Figure 5.29 with 200 pi aliquots of standard. The standard curves 
obtained were similar, with the antibody labelled to a specific radioactivity of 
0.44 MBq/pg giving slightly better sensitivity (Figure 5.36A). 125I-PH4/B1 
(0.44 MBq/pg) was then added at masses equivalent to 25 000, 50 000, 100 000 
and 200 000 cpm per tube. A mass equivalent to 50 000 cpm appeared to result in a 
slight improvement in sensitivity in comparison with 100 000 cpm used previously 
(Figure 5.36B).
Solid-Phase Coupled Anti-Proinsulin
Four solid-phase antibody reagents were prepared at different coupling ratios of 
IgGrgel. The quantity of IgG coupled per mg gel increased as the quantity offered 
increased, but the overall percentage uptake of IgG by the gel decreased before 
reaching an apparent plateau (Table 5.13). This pattern of results was similar to that 
observed for the insulin assay (Section 2, Table 5.8). When these solid-phases 
were evaluated in the proinsulin IRMA as described in the section above 
(using 50 000 cpm instead of 100 000 cpm), a coupling ratio of 0.024 mg IgG per 
mg gel was found to be optimal (Figure 5.37).
Incubation Times
The assay involved a primary incubation with 200 pi standard and 100 pi l2^l- 
PH4/B1 (50 000 cpm) followed by a secondary incubation with solid-phase coupled
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Figure 5.36
Evaluation of anti-insulin iodinated to three specific activities
(A) and the effect of varying the mass of one of the preparations 
(0.44 mBq) added per tube (B).
TABLE 5.13
COUPLING OF MONOCLONAL ANTI-PROINSULIN TO 
SEPH AR O SEr CL-4B
IgG offered (mg)* 0.012 0.024 0.050 0.100
IgG coupled (mg)* 0.002 0.003 0.005 0.006
% uptake of IgG 16.7 12.5 10 10
*mg IgG per mg gel.
For details of coupling reaction see Chapter 2, Section 5.3.
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Figure 5.37
Optimisation of the coupling ratio of IgG:solid-phase.
PH5/B5 (1 mg) prior to washing (x6) and counting. Initially, optimisation of the 
primary incubation was performed at 3, 6, 16 and 24 hours (Figure 5.38). The 
sensitivity and range of the assay did not appear to change from 3 to 24 hours and 
seven incubation times between 0.5 and 6 hours were evaluated (Figure 5.38 B 
and C). A reaction time of 1 h appeared optimal in terms of assay sensitivity. 
Evaluation of the second incubation between 0.5 and 4 hours indicated that 
maximum sensitivity was achieved after 0.5 h (Figure 5.39).
One or Two Incubation Steps
The two-step assay protocol described above (1 h + 0.5 h) was compared with a 
one-step assay in which all the reagents were added simultaneously and incubated 
for 1.5 h (Figure 5.40). The latter technique markedly reduced the assay sensitivity 
and the two-step protocol was subsequently adopted.
Wash Cycles
200 p.1 aliquots of standards (0-660 pmol/l) and 100 |il 125I-PH4/B1 (50 000 cpm) 
were incubated for 1 h followed by a second incubation with solid-phase coupled 
PH5/B5 (1 mg) for 0.5 h prior to washing and counting. The assay was counted 
after each wash cycle (1-8) and standard curves constructed (Figure 5.41). For 
maximum sensitivity to be achieved, six wash cycles were mandatory.
5.3 Assay Validation
Matrix Effects
To establish the effect of different matrices on the proinsulin IRMA, blood samples 
from three volunteers (A, B and C) were collected as serum, plasma-hepann 
(2 mg/10 ml blood) and plasma-EDTA (10-20 mg/10 ml blood), all with and 
without Traysylol (4 000 U/10 ml blood). Standard curves were constructed with
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Comparison of a one-step or two-step assay protocol.
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Figure 5.41
Optimisation of the number of washes required, prior to 
counting, in the proinsulin IRMA-1.
proinsulin standards diluted in assay buffer, HFS and each of the above test sera 
(Figure 5.42). The pattern of curves obtained from standards diluted in each matrix 
were similar for all three individuals with no difference observed between serum and 
plasma in either the presence or absence or Trasylol. Therefore, serum was chosen 
as the sample matrix. There was also no difference in the standard curves obtained 
when standards were diluted in buffer or HFS. Standards were subsequently 
prepared in assay buffer and stored at -70°C for future use.
Stability of Proinsulin in Whole Blood and Serum
To determine the stability of proinsulin in whole blood and serum, blood samples 
were collected from five volunteers and treated as described in the corresponding 
part of Section 2.4. The samples were assayed simultaneously and the results 
calculated as the concentration of proinsulin measured at each time point expressed 
as a percentage of the concentration of proinsulin measured at zero time 
(% proinsulin remaining). The results from each of the five volunteers are shown 
separately with the median values at each time point being connected (Figure 5.43). 
Two-way analysis of variance showed that there was a significant degradation of 
proinsulin in whole blood (p<0.0001) and serum (p<0.001). Analysis of the data 
by the Students paired t-test indicated that proinsulin levels in whole blood 
decreased significantly after 2 hours at room temperature (p<0.01) and after 4 hours 
in serum at room temperature (p<0.01). Therefore, it was recommended that blood 
samples were allowed to clot at room temperature for 30 minutes prior to separation 
and the serum be frozen within a further 30 minutes if proinsulin was to be 
measured.
Recovery of Proinsulin from Serum
Recovery of proinsulin from serum was evaluated by adding known quantities of 
standard proinsulin to each of three individual sera and one pool of human serum. 
Two replicates were performed for each dose level in each serum and the percentage
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Effect of different matrices on the proinsulin IRMA-1.
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Stability of proinsulin in whole blood (A) and serum (B).
recovery calculated from the equation:
% Recovery = Measured proinsulin - Serum proinsulin x 100
Added Proinsulin
The results obtained are summarised in Table 5.14 and indicate that proinsulin was 
recovered quantitatively over the working range of the assay.
The Effect of Insulin on the Proinsulin IRMA
The effect of insulin on the proinsulin IRMA was investigated by diluting proinsulin 
standards with buffer or insulin standards. Standard curves were constructed in the 
presence of different concentrations of insulin (Figure 5.44). The effect of adding 
25 and 50 mU/1 insulin was to shift the standard curve to the right suggesting that 
the insulin was competing with proinsulin for antibody binding sites. The 
monoclonal anti-proinsulin does not react with insulin (Chapter 4, Table 4.2), 
therefore the insulin must be competing with proinsulin for binding to the 125I- 
labelled monoclonal anti-insulin. Insulin interference was not abolished by 
increasing the mass of 125I-anti-insulin added per tube (Figure 5.45). Therefore this 
assay was considered to be unsuitable for use with clinical samples.
6 P R O IN S U L IN  IRM A -2 W ITH  P R O IN S U L IN -S P E C IF IC  
MONOCLONAL ANTIBODY
In an attempt to abolish the interference of insulin in the proinsulin IRMA, the assay 
was reversed, ie, proinsulin was immunoextracted from standards or samples by 
incubation with solid-phase coupled monoclonal anti-proinsulin prior to washing 
(to remove insulin) and a second incubation with l2^I-anti-insulin. All subsequent 
assays were performed using the WHO proinsulin standard, code 84/611, which 
only became available during this study.
1 2 0
TABLE 5.14
RECOVERY OF PROINSULIN FROM SERUM
Proinsulin added 
(pmol/l)
% Recovery ±SD
A B C D
7.3 107.1±10.8 104.1±8.1 132.2±29.4 72.5±4.7
13.2 101.6±5.5 107.8±5.8 113.1±10.0 93.0±2.6
66.0 104.9±15.3 119.9±0.1 108.4±5.4 100.2±13.9
120.0 97.6±22.8 127.1±2.5 88.4±2.8 92.4±6.2
*A-C = individual sera D = pooled human serum
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Figure 5.44
Effect of insulin (25 and 50 mU/l) on the proinsulin IRMA-1.
200 jxl proinsulin standard (diluted in buffer or insulin) and 100 
|il 12^I-PH4/B1 (50 000 cpm) were incubated for an hour 
followed by a second incubation with solid-phase coupled 
PH5/B5 (1 mg) for 0.5 h. The assay was washed six times 
prior to counting.
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Figure 5.45
Effect of insulin on the proinsulin IRMA-1 : varying the mass of 
125I-PH4/B1 added per tube.
Assay details as for Figure 5.44 but 100 mU/l insulin was used 
to dilute proinsulin standards.
6.1 Assay Optimisation
Incubation Times
The primary incubation involved mixing 200 pi aliquots of standard and solid-phase 
coupled PH5/B5 (1 mg) for 0.5 h followed by three washes with assay buffer. 
125i_p h 4/B1 (50 000 cpm in 100 pi) was then added and incubated for 1 h prior to 
six washes with 0.2% Tween 20/0.9% saline. The primary incubation was 
complete after 0.5 h while the second incubation was optimal at 1 h (Figure 5.46). 
Increasing the length of the second incubation beyond 1 h caused a sharp rise in the 
zero dose binding resulting in decreased assay sensitivity.
Solid-Phase Coupled Anti-Proinsulin
The effect of varying the amount of solid-phase added per tube was evaluated at four 
masses, 0.25, 0.5, 1 and 2 mg. The assay was performed as described above. 
A mass of 0.5 mg was optimal in terms of assay sensitivity (Figure 5.47A).
125I-LabeIIed Anti-Insulin
The effect of adding masses equivalent to 25 000, 50 000,100 000 or 200 000 cpm 
125I-PH4/B1 per tube was evaluated and the results are shown in Figure 5.47B. 
The standard curves obtained were superimposable and a mass of 200 000 cpm was 
chosen for subsequent experiments as this was likely to result in greater accuracy in 
the quantitation of radioactivity.
W ash Cycles
The number of wash sequences required after the second incubation prior to 
counting, was evaluated in the presence and absence of insulin (100 mU/l). 
Proinsulin standards were diluted in buffer or buffer containing insulin, and 200 pi 
aliquots incubated with solid-phase coupled PH5/B5 (0.5 mg) for 0.5 h prior to six
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Figure 5.46
Optimisation of the primary (A) and secondary (B) incubation 
steps in the proinsulin IRMA-2.
During optimisation of the primary incubation (A), the secondaiy 
incubation was held at 1 h and during optimisation of the 
secondary incubation (B), the primary incubation was held at 
0.5 h.
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Figure 5.47
Optimisation of the mass of solid-phase (A) and 125I-labelled 
antibody (B) added per tube in the proinsulin IRMA-2.
A - 125I-PH4/B1 was 50 000 cpm.
B - solid-phase coupled PH5/B5 was 1 mg.
washes with assay buffer. 125I-PH4/B1 (200 000 cpm in 100 p.1) was then added 
and incubated for 1 h prior to three or six washes with 0.2% Tween 20/0.9% saline 
and counting. Assay tubes were only counted after three and six washes as previous 
experiments had shown six to be optimal (Section 5, Figure 5.41). The assay 
sensitivity was improved from approximately 10 pmol/l to less than 2 pmol/l by 
increasing the number of wash cycles from three to six respectively (Figure 5.48).
The effect of four or six wash cycles between the primary and secondary incubation 
steps was evaluated as described above using undiluted proinsulin standards and six 
wash cycles after the second incubation. There was no difference in the standard 
curves obtained (Figure 5.49) and six wash cycles was adopted as this was likely to 
result in consistently lower zero dose binding levels.
6.2 Assay Validation
The effect of insulin (1000 mU/l) on the redeveloped proinsulin IRMA is shown in 
Figure 5.50A. An increase in the percent of 125I-anti-insulin bound was observed at 
the lower end of the standard curve in the presence of insulin, in contrast to the 
reduction seen in the previous assay (Section 5, Figure 5.45). The WHO insulin 
standard (66/304) is known to contain a trace amount of proinsulin as determined by 
gel filtration chromatography. Therefore 4 ml insulin standard (1000 mU/l) was 
absorbed with 60 mg SepharoseR CL-4B coupled monoclonal anti-proinsulin (2 h at 
room temperature) and used, in parallel with buffer and unabsorbed insulin 
(1000 mU/l), to dilute proinsulin standards (Figure 5.50B). Absorption of the 
insulin standard with the proinsulin-specific McAb markedly reduced the observed 
effect of insulin on the assay, as shown by the decrease in the percent of 125I-anti- 
insulin bound at the lower end of the standard curve. This corresponded to an 
apparent reduction in the concentration of proinsulin contamination from 
approximately 10 pmol/l (pre-absorption) to approximately 1 pmol/l (post­
absorption).
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Optimisation of number of wash sequences required after the 
second incubation of the proinsulin IRMA-2 prior to counting.
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Figure 5.49
Optimisation of the number of wash sequences required between 
the first and second incubations of the proinsulin IRMA-2.
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Figure 5.50
Effect of insulin on the proinsulin IRMA-2 before (A) and after
(B) absorption with a solid-phase coupled proinsulin-specific 
monoclonal antibody.
Reactivity of Split and Des-Amino Proinsulins in the Proinsulin 
IRMA
The pattern of reactivity of split and des-amino proinsulins in the proinsulin IRMA 
is shown in Figure 5.51. The percentage reactivity of each form at two dose levels 
is shown in Table 5.15. The assay described does not react with 32-33 split or des 
31-32 proinsulins except when they are present in extremely high concentrations 
(>1 nmol/1). 56-57 split proinsulin showed the greatest reactivity relative to intact 
proinsulin (70.8 to 75.0%). The other three forms exhibited similar reactivities 
relative to intact proinsulin: des 57-65 (54.2-68.8%), des 64-65 (53.3-64.6%) and 
65-66 split (54.2-55.0%). As the two forms 56-57 split and des 57-65 do not occur 
physiologically (40,118) the proinsulin assay effectively measures intact proinsulin, 
65-66 split and des 64-65 proinsulins.
Recovery of Intact Proinsulin from Serum
Recovery of intact proinsulin from serum was evaluated by adding known quantities 
of standard proinsulin to each of four individual sera. Ten replicates were 
performed for each dose level in each individual serum and the percentage recovery 
calculated from the equation:
% Recovery = Measured proinsulin - Serum proinsulin x 100
Added proinsulin
The results obtained are summarised in Table 5.16 and indicate that intact proinsulin 
was recovered quantitatively from serum.
Recovery of Split and Des-Amino Proinsulins from Serum
Recovery of the split and des-amino forms of proinsulin were evaluated in one 
serum at two dose levels. Ten replicates were performed at each dose level for each
1 2 3
form of proinsulin. The percentage recovery was calculated as described for intact 
proinsulin and the results summarised in Table 5.17.
Parallelism Between Intact Proinsulin Standards and Endogenous 
Serum Proinsulin
Serum samples from four patients, selected because they had proinsulin 
concentrations greater than 70 pmol/l, were diluted with assay buffer and measured 
in the proinsulin IRMA. The results from each patient (A-D) were plotted together 
with the standard curve (Figure 5.52). All four samples diluted in parallel with the 
standards.
Stability of Proinsulin to Repeated Freeze-Thaw Cycles
Intact proinsulin was added to pooled human serum at four dose levels (15, 35, 
105 and 305 pmol/l) and each resulting pool was divided into aliquots and frozen 
at -30°C. Separate aliquots of each pool were then subjected to 0, 1, 2, 3 or 4 
freeze-thaw cycles prior to assay in the proinsulin IRMA. The results (Figure 5.53) 
were subjected to two-way analysis of variance which indicated that there was no 
significant difference in proinsulin concentrations after four freeze-thaw cycles.
Stability of Proinsulin in Frozen Samples
Blood samples were collected from five volunteers and the serum separated as 
described in Chapter 2, Section 3.3. The serum from each subject was divided into 
aliquots and stored at -30°C until required for assay. Single aliquots from each 
volunteer were thawed and assayed at various time intervals over a five month 
period (Figure 5.54). Two-way analysis of variance indicated that there was no 
significant degradation of proinsulin in frozen samples stored at -30°C up to five 
months.
1 2 4
TABLE 5.17
RECOVERY OF SPLIT AND DES-AMINO PROINSULINS FROM SERUM
Proinsulin form Proinsulin added 
(pmol/l)
% Recovery ±SD
Intact 7.3 98.6±6.2
66.0 110.6±8.7
65-66 split 5.3 96.6±5.2
52.6 93.4±7.7
Des 64-65 7.5 104.5±10.7
60.0 95.2±8.7
56-57 split 8.0 97.1±6.6
64.0 94.2±8.2
Des 57-65 8.7 101.5±11.6
69.9 90.7±6.4
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Figure 5.52
Parallelism between intact proinsulin standards and endogenous 
serum proinsulin in four patients (A-D).
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Figure 5.53
Stability of proinsulin to repeated freeze-thaw cycles.
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Figure 5.54
Stability of proinsulin in frozen samples.
The Final Proinsulin IRMA
Figure 5.55 shows a typical standard curve and within assay precision profile for 
the optimised proinsulin IRMA. The sensitivity of the assay was 1.2 pmol/l 
(CV 22%) with a range of 3 to >1200 pmol/l (CV<10%). The inter-assay 
coefficients of variation were calculated using QC samples prepared at five dose 
levels and the results are shown in Table 5.18.
6.3 Comparison of the Three Proinsulin IRMA's Developed
The final proinsulin IRMA was compared with those described in Sections 5 and 4 
(Figures 5.56 parts A and B respectively). The assay protocols are outlined in 
Table 5.19.
The assay described in Section 5 (125I + SP) resulted in better sensitivity than the 
final assay apparently due to the lower zero dose binding achieved. This cannot be a 
function of the solid-phase or 125I-labelled antibody as the same preparations were 
used in both assays. The only difference between the assays is the order of addition 
of the reagents and therefore the length of time the solid-phase is incubated with 
125I-labelled antibody, ie, one hour in the final assay compared with 30 minutes in 
the other. When this incubation was reduced to 30 minutes in the final assay 
(Section 6.1, Figure 5.46), the zero dose binding was lowered but the binding 
levels at each dose of proinsulin were lowered by the same factor, resulting in no 
increase in sensitivity. Therefore, the most likely reason for the reduced sensitivity 
of the final proinsulin IRMA is that the proinsulin, once bound to the solid-phase, is 
either altered structurally such that it has a lower affinity for the 2^^I-labelled 
antibody or a proportion of the bound proinsulin is unavailable to bind to the 
iodinated antibody. However, the more sensitive assay was not clinically useful as 
the presence of insulin interfered with the assay causing a shift of the standard curve 
to the right (Section 5, Figure 5.44-5.45).
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Figure 5.55
A representative standard curve (A) and within assay precision 
profile (B) for the optimised proinsulin IRMA-2.
TABLE 5.18
INTER-ASSAY COEFFICIENTS OF VARIATION FOR THE PROINSULIN  
IRM A -2
Proinsulin % c v n
3 12.1 5
15 12.5 52
35 11.5 52
105 7.5 52
305 7.9 52
b ;'"'
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Figure 5.56
Comparison of the final proinsulin IRMA with those described 
in Section 5 (A) and Section 4 (B). Details of assay in text.
TABLE 5.19
PROTOCOLS FOR THE ASSAYS COMPARED IN FIGURE 5.56
A n t i - p r o in s u l in 1 
(SP + 125X)
A n t i - p r o i n s u l in 2 
(12SI + SP)
A n t i - C - p e p t id e 3
200  pi standard 
+
200 pi SP-PH5 (0.5 mg)
30 min
Wash x 6 with assay buffer
1
+ 100 111 125I-PH4/B1 
(200 000  cpm)
1 1 h
Wash x6 with 0.2% 
Tween 20/0.9% saline
200 pi standard 
+
100 pi 125l-PH4/Bl 
(200 000 cpm)
lh
+ 200 pi SP-PH5 
(0.5 mg)
30 min
Wash x6 with 0.2% 
Tween 20/0.9% saline
200 pi standard 
+
200 pi SP-PD4/H4 
30 min
Wash x 6 with assay 
buffer
I
+ 100 pi 125I-PH4/B1 
(200 000 cpm)
1 h
Wash x6 with 0.2% 
Tween 20/0.9% saline
1 Assay described in Section 6 .
2Assay described in Section 5.
2Assay using antibody evaluated in Section 4.
As the final assay described here, using the solid-phase anti-proinsulin, does not 
measure 32-33 split proinsulin, it was considered advantageous to re-evaluate the 
C-peptide McAb (PD4/H4) which had previously been shown to be capable of 
detecting intact, 65-66 split and 32-33 split proinsulins (Section 4, Figure 5.33). 
Therefore the C-peptide McAb was coupled to solid-phase and re-assessed using the 
primary proinsulin standard WHO 84/611 and the 125I-labelled monoclonal anti­
insulin (PH4/B1), both of which were unavailable when the C-peptide McAb was 
originally assessed. The sensitivity of the original assay described in Section 4 was 
approximately 20-40 pmolA. The use of the above reagents improved the sensitivity 
to approximately 3-10 pmol/1. As 32-33 split proinsulin has been shown to be the 
major circulating form of this hormone (32), an assay with a sensitivity in this range 
should be capable of measuring this form in the fasting state.
In conclusion, it would appear that there is some potential for the development of a 
proinsulin IRMA using the monoclonal anti-C-peptide (PD4/H4) as described 
above, but this would require further optimisation and clinical validation studies to 
be performed.
7 DISCUSSION
The availability of biosynthetic human proinsulin has resulted in the more 
widespread development of assays for proinsulin. Comparison of the proinsulin 
IRMA described in this chapter with other assays utilising 125I as a label (30, 31, 
32, 35, 36, 37, 38) shows that it is as good as the best assays available (32) in 
terms of sensitivity but has the advantage of being the only assay which can be 
performed within one working day.
The data presented in Section 2 of this chapter confirm that two-site IRMA 
techniques can offer the advantages of improved specificity and sensitivity, coupled 
with wider working ranges and shorter incubation times when compared with RIA
1 2 6
techniques. Furthermore, the ultimate sensitivity achieved in an IRMA compared 
with an RIA is less dependent on the avidity of an antibody, for when two McAbs 
PD4/H4 and PH5/B5 were compared in an IRMA to measure proinsulin, in 
conjunction with the same partner antibody, the difference in sensitivity of the 
resulting assays was of the order of 10 pmol/1 (Figure 5.56B). In contrast, when 
the same two antibodies were compared in an RIA, McAb PH5/B5 showed 
displacement of 125I-proinsulin with cold proinsulin at doses of approximately 
10 nmol/1 whereas McAb PD4/H4 did not exhibit displacement of 12^I-proinsulin 
with doses of cold proinsulin up to 60 nmol/1 (Chapter 4, Figure 4.6).
It is also clear from the data in this chapter that not only does a two-site IRMA 
require the availability of two antibodies which bind to different epitopes on the 
molecule to be measured, but that these antibodies must be capable of binding to the 
molecule simultaneously (Section 2.2, Table 5.7).
Finally, it was shown that the epitope specificity of a McAb may be as important as 
the avidity in determining its usefulness in a two-site IRMA technique.
1 2 7
CHAPTER 6 
CLINICAL APPLICATION
1 Co --.ii.
{2.^ . I n  m d f  J  - 0
1 NORMAL PHYSIOLOGY
1.1 Introduction
Clinical validation of the insulin and proinsulin IRMA's was performed by 
measuring concentrations of insulin and proinsulin in serum from normal adult 
subjects under a variety of conditions. Glucose was measured by the hexokinase 
method and C-peptide using the commercially available Medgenix kit. Measurement 
of glucose and C-peptide was performed by MLSO staff in the Institute of 
Biochemistry at Glasgow Royal Infirmary. Unless otherwise stated, results are 
expressed as median values with range. Statistical analyses were performed using 
the Wilcoxon Signed Rank and Mann-Whitney U Tests. To convert insulin 
concentrations from pmol/1 to mU/1 divide by 7.57 (calculated assuming a molecular 
weight of 5734 for insulin).
1.2 Twenty-Four Hour Profiles 
Methods
Serum samples were collected from six male volunteers at 30 minute intervals from 
1400 h one day to 1330 h on the following day. The content and timing of meals 
was standardised such that all subjects ate the same quantity of food at the same 
time.
The secretion rates of insulin and proinsulin into the peripheral circulation were 
calculated by deconvolution (122). The half-lives and distribution volumes of 
insulin and proinsulin used in the calculation were 3.9 minutes (24) and
17.2 minutes (23), and 12.5 1 (122) and 9.3 1 (123) respectively. The insulin and 
proinsulin serum concentration profiles were also analysed by cross-correlation 
(124). These analyses were performed by Dr D R Matthews at the Diabetes 
Research Laboratories, Radcliffe Infirmary, Oxford.
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R esu lts
Details of the six volunteers are shown in Table 6.1. All results are arranged in 
order of increasing subject age and body mass index (BMI). The glucose profiles 
are shown in Figure 6.1. The corresponding profiles of serum insulin and 
proinsulin concentrations and secretion rates, together with the analogous 
proinsulin/insulin ratios expressed in percentage terms, are shown in Figure 6.2.
Glucose, insulin and proinsulin concentrations rose in response to feeding 
(Figures 6.1 and 6.2). The number of glucose and insulin peaks observed varied 
between individuals, but for any one patient the pattern of insulin peaks mirrored 
that observed for glucose. The proinsulin profile was similar to insulin but 
individual peaks were not as distinct and there appeared to be a delay in the increase 
of proinsulin concentrations relative to insulin following the ingestion of food. This 
was confirmed by cross-correlation (Figure 6.3) which indicated that proinsulin 
concentrations increased later than insulin with a lag time of approximately 
30 minutes. This estimation may in part be an artefact of the 30 minute sampling 
intervals adopted. More correctly the lag time should be reported as being between 
1 and 30 minutes.
The sum of the glucose concentrations over the 24 hour period was similar for all 
six patients and ranged from 239-263 nmol/1 /24 h. However, the total amount of 
insulin secreted over the same period was highest in patients 1 and 2 (140 and 
138 nmol respectively) and decreased progressively (117, 104, 87 and 87 nmol) in 
patients 4, 5, 6 and 3 respectively (Table 6.2). This decrease in total insulin 
secretion was, in general, reflected in the post-prandial peak insulin concentrations 
achieved. The total amount of proinsulin secreted did not vary in parallel with 
insulin (Table 6.2). Under basal conditions, from 0200-0700 h, the total quantity of 
insulin and proinsulin released gave a completely different pattern of results from the 
total 24 h secretion data (Table 6.2).
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TABLE 6.1
TWENTY-FOUR HOUR PROFILE PATIENT DETAILS
Patient number Age (years) BMI
1 29 22.9
4 33 22.9
2 33 26.0
5 33 27.0
6 37 27.2
3 40 28.1
Patients have been listed in order of increasing age and BMI (kg/m^).
Figure 6.1
Twenty-four hour glucose profiles.
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Figure 6.2
Twenty-four hour profiles of insulin and proinsulin serum 
concentrations and secretion rates together with the 
corresponding proinsulin/insulin ratios expressed in percentage 
terms.
Ins = insulin PI = proinsulin pm/L = pmol/1
PI/I % = proinsulin/insulin ratio expressed as a percentage.
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The ratio of proinsulin/insulin secretion expressed as a percentage (Pi/Ins %) was 
calculated for the total secretion over 24 hr and in the basal state. In each of the six 
individuals the ratio was higher in the basal state, although the magnitude of the 
increase varied between patients. The Pi/Ins % ratios were also calculated for each 
time point of the study using both the concentration and secretion rate data 
(Figure 6.2). In both series of data the Pi/Ins % ratio decreased significantly in 
response to feeding (Table 6.3). The ratios then gradually increased to pre-meal 
values, but even under basal conditions, 0200 - 0700 h, there were fluctuations in 
the observed ratios (Figure 6.2).
D iscussion
The data presented here compare well with previously published material in two 
respects. Firstly, the observation that more than one glucose peak occurs following 
the ingestion of food and the exact number varies between individuals. Secondly, 
the synchronous nature of post-prandial glucose and insulin pulses (125, 126). The 
reported 13 minute oscillations of serum insulin during basal conditions (127) could 
not be observed due to the 30 minute sampling interval employed in this study.
1.3 Fasting Data
Methods
Serum samples were collected from healthy laboratory personnel after an overnight 
fast of at least ten hours.
Results
Serum glucose, insulin, proinsulin and C-peptide concentrations were compared 
between non-obese males (n = 17) and both non-obese females (n = 17) and obese 
(n = 6) males. The data is presented in Table 6.4 and Figure 6.4.
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TABLE 6.3
SERUM GLUCOSE CONCENTRATIONS AND PROINSULIN/INSULIN  
PERCENTAGE RATIOS BEFORE AND AFTER FEEDING DURING THE 
TWENTY-FOUR HOUR STUDY
Patient Number
BREAKFAST Pre 5.1 5.1 4.7 5.0 4.8 5.3
Glucose (mmol/1) Post 6.8  5.6 4.9 5.8 5.2 7 .4
p = 0.05
Pl/Ins % Pre 6.3 3.9 2.9 5.1 6 .6  3.4
(concentration) Post 1.2 1.4 1.7 2.2 4.6 1.2
p = 0.05
Pi/Ins % Pre 3.3 2.1 1.5 2.4 3.6 2.0
(secretion) Post 0.7 0.8 0.7 1.2 2.3 0.7
p = 0.05
LUNCH Pre 5.0 5.3 4.5 4.9 4.7 4.9
Glucose (mmol/l) Post 5.6 4.9 5.4 5.5 5.8 7.0
NS
Pl/Ins % Pre 9.0 6.7 6.0 6.8 11.3 3.4
(concentration) Post 4.1 2.0 1.1 4.4 3.3 1.0
p = 0.05
Pl/Ins % Pre 4.2 2.7 2.4 2.9 6.1 1.3
(secretion) Post 1.9 1.0 0.6 2.5 1.6 0.5
p = 0.05
DINNER Pre 4.6 4.6 4.7 4.9 4.6 4.5
Glucose (mmol/l) Post 4.8 5.4 5.0 4.2 5.0 5.1
NS
Pl/Ins % Pre 2.9 5.1 4.9 12.3 9.9 8.1
(concentration) Post 4.5 1.1 0.9 3.2 2.1 1.8
p = 0.05
Pl/Ins % Pre 6.8  2.5 2.9 7.2 5.5 4.5
(secretion) Post 2.3 0.7 0.4 1.6 1.0 1.0
p = 0.05
TABLE 6.4
FASTING CONCENTRATIONS OF GLUCOSE, INSULIN, PROINSULIN AND 
C-PEPTIDE IN NON-OBESE FEMALES AND MALES AND OBESE MALES
Non-obese 
females 
(n = 17)
Non-obese 
males 
(n = 17)
Obese 
males 
(n = 6)
Age 32 33 40.5*
(years) (21-47) (26-57) (37-44)
BMI 21.7** 23.8 28.3***
(18.5-25.6) (19.9-26.3) (27.0-31.4)
G lucose 4.7 4.7 5.0
(mmol/l) (4.1-6.2) (4.0-6.0) (2 .6 -6 .2 )
Insulin 36 39 93**
(pmol/1) (17-75) (19-102) (41-195)
Proinsulin 1.56** 2.34 3.86
(pmol/1) (1.23-3.00) (1.40-5.73) (1.03-6.96)
C-peptide 410 410 680
(pmol/1) (120-750) (210-760) (270-1110)
*p = 0.05 ** p<0.05 *** p<0.01
Results are expressed as median values with the range shown in brackets. The non-
obese males acted as a control group against which the obese males and non-obese 
females were compared.
Figure 6.4
Fasting concentrations of glucose, insulin, proinsulin and C- 
peptide in non-obese females and males and obese males.
The non-obese males acted as a control group against which the 
non-obese females and obese males were compared. See Table
6.4 for statistical analysis.
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The ages of the non-obese male and female groups were similar and although the 
BMI of the two groups was significantly different the ranges were similar 
(Table 6.4). Proinsulin was the only analyte to show a significant difference in 
concentration between the two groups (Table 6.4 and Figure 6.4).
The non-obese and obese males differed significantly in BMI and although the ages 
of the two groups were significantly different at the 5% level of probability, the 
range of the obese group (37-44 yr) was encompassed within that of the non-obese 
group (26-57 yr). The median values of glucose, proinsulin and C-peptide were 
higher in the obese group but did not reach statistical significance. However, the 
fasting insulin concentrations of the obese males were significantly increased above 
those of the non-obese males (Table 6.4 and Figure 6.4).
The non-obese male and female groups were each subdivided into two groups 
(<35 yr and >35 yr) which were significantly different with respect to age but not 
BMI (Table 6.5). The glucose, insulin, proinsulin and C-peptide concentrations for 
each group are shown in Table 6.5 and Figures 6.5 and 6 .6 .
No significant differences were observed between the non-obese male sub-groups. 
However, the non-obese females over 35 years of age showed a significant decrease 
in fasting insulin and C-peptide concentrations but no difference in proinsulin or 
glucose concentrations.
D iscussion
The lower fasting serum proinsulin concentrations measured in non-obese females 
compared with non-obese males have not been reported previously. However, a 
larger population requires to be studied to establish the true significance of this 
observation.
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TABLE 6.5
FASTING CONCENTRATIONS OF GLUCOSE, INSULIN, PROINSULIN AND 
C-PEPTIDE IN NON-OBESE MALES AND FEMALES ACCORDING TO AGE
Male Fem ale
<35 >35 <35 >35
(n = 10) (n = 7) (n = 10) (n = 7)
Age
(years)
31
(26-34)
39**
(36-57)
28
(21-35)
38**
(36-47)
BM I 23.7
(19.9-26.0)
24.9
(20.5-26.3)
21.9
(18.5-25.6)
21.4
(20.8-23.8)
G lucose
(m m ol/l)
4.8 
(4.0-5.8)
4.5
(4.3-6.0)
4.8
(4.3-6.2)
4.6 
(4.1-5.4)
Insu lin
(pm ol/1)
45
(19-102)
39
(34-52)
49
(17-75)
28*
(21-36)
P ro insu lin
(pm ol/1)
2 29 
(1.50-5.73)
2.63
(1.40-4.98)
1.57
(1.23-3.00)
1.46
(1.36-2.09)
C -peptide
(pm ol/I)
460
(220-760)
410
(210-560)
440
(280-750)
270**
(120-410)
* p<0.005 ** p<0.01
Results are expressed as median values with the range shown in brackets. Within the 
male and female groups the >35 year sub-group was compared with the analogous 
<35 year sub-group.
Figure 6.5
Comparison of fasting concentrations of glucose, insulin, 
proinsulin and C-peptide in non-obese males <35 years and >35 
years.
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Figure 6.6
Comparison of fasting concentrations of glucose, insulin, 
proinsulin and C-peptide in non-obese females <35 years 
and >35 years.
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Hyperinsulinaemia, both in the basal state and under conditions which stimulate 
insulin secretion, is a common finding in obesity. The mechanisms involved appear 
to be a combination of increased insulin secretion and decreased hepatic extraction 
(128,129,130,131,132). The results obtained in this study did show a significant 
increase in basal serum insulin concentrations in obese compared with non-obese 
males. The serum proinsulin and C-peptide concentrations were also elevated but 
not to an equivalent degree and did not reach statistical significance. This data is 
consistent with the dual mechanism of hyperinsulinaemia in obesity as described 
above.
Glucose tolerance tends to deteriorate with increasing age (133, 134) but the effect 
on fasting glucose concentrations is small (135). Also, it has been suggested that 
factors other than age contribute to the glucose intolerance of the elderly (135, 136, 
137). However, in general, fasting and stimulated plasma insulin concentrations 
have not been found to decline with age and if anything tend to increase (133, 134, 
135, 136, 137). Therefore, the finding in this study of decreased fasting insulin and 
C-peptide concentrations in females over 35 years compared to those under 35 years 
of age is contrary to previous observations. The explanation for the lower serum 
concentrations of insulin is probably due to decreased secretion as the serum C- 
peptide concentrations are decreased by an equivalent factor. Again, a larger 
population covering a wider age range would be required to substantiate this 
finding. It should be noted that the corresponding male group exhibited similar 
trends to the females, although they did not reach statistical significance.
1.4 Oral Glucose Tolerance Test
Methods
Healthy laboratory personnel undertook a 75 g oral glucose tolerance test (OGTT) 
after an overnight fast of at least ten hours. Two basal serum samples were taken at
1 3 2
-15 and 0 minutes after which 75 g glucose, in 300 ml water, was drunk within five 
minutes, and a further four serum samples collected at 30, 60, 90 and 120 minutes.
Results
Glucose, insulin, proinsulin and C-peptide concentrations, at all time points of the 
OGTT, were compared within and between the two groups studied: non-obese 
males and females. The median age of the non-obese male group was 33 years, 
range 29 - 57 years, and the median BMI was 24.4, range 20.5 - 26.3. The non- 
obese female group did not differ significantly from this with a median age of 
36 years, range 27 - 42 years, and a median BMI of 21.5, range 20.8 - 25.6. 
The results are summarised in Table 6.6 and Figures 6.7 and 6 .8 .
In both groups glucose and insulin concentrations rose to give maximum values 
30 minutes after ingestion of the glucose load. Serum C-peptide concentrations 
peaked at 60 minutes in both groups while proinsulin concentrations peaked at 
90 minutes in the male group and were highest at 120 minutes in the female group, 
although the concentrations at 90 and 120 minutes were not significantly different 
(Table 6 .6). Only the glucose concentrations returned to basal values within the 
time course of the OGTT showing no significant difference from 90 minutes 
onwards.
The Pi/Ins % ratio in both groups fell to a nadir at 30 minutes and returned to basal 
levels at 90 minutes (Table 6.7). Thus the Pi/Ins % ratio profile mirrored the 
glucose profile throughout the time course of the OGTT.
The median proinsulin concentrations in the female group were lower than the male 
group at all time points of the OGTT but only reached statistical significance at -15, 
0 and 30 minutes. Glucose and C-peptide concentrations were not significantly 
different between the groups at any time point of the OGTT, and insulin exhibited a 
similar pattern except at 120 minutes at which point the insulin concentration was
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significantly higher in the female group (Table 6 .6). There was no significant 
difference between the Pi/Ins % ratios of the two groups at any time point.
D iscussion
The lower proinsulin concentrations observed in females compared with males at 
the -15, 0 and 30 minute time points of the OGTT are in agreement with the fasting 
data results (Table 6.4).
The decrease in the Pi/Ins % ratio during the initial stage of the OGTT followed by a 
gradual increase to values higher than those observed in the basal state has been 
reported previously (138, 139, 140).
1.5 Glucagon Stimulation Test
Methods
The samples analysed were those collected previously as part of a study to compare 
the oral glucose load and intravenous (iv) glucagon injection as stimuli to C-peptide 
secretion in normal men (141). In summary, ten healthy men were fasted overnight 
and a basal serum sample taken prior to a slow 1 mg iv injection of glucagon. Six 
minutes later a second serum sample was taken. Three weeks later each subject 
underwent a 75 g OGTT with serum samples collected before and 30, 60, 90 and 
120 minutes after glucose ingestion. Plasma glucose was determined by the glucose 
oxidase method and C-peptide by an RIA using reagents supplied by Novo 
Laboratories Ltd.
Results
One subject was excluded from the calculation of results as he exhibited abnormally 
high fasting and stimulated concentrations of proinsulin. All other analytes 
measured on this individual were within the normal ranges. Therefore, one sample 
from his series of specimens was assayed at a number of dilutions and also in the
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presence of 1% (v/v) mouse serum. The measured proinsulin concentrations did not 
dilute in a linear fashion, and the addition of mouse serum reduced the concentration 
of measured proinsulin to the lower end of the fasting range (Table 6 .8), consistent 
with the presence of heterophilic antibodies. The results from the remainder of the 
group are presented in Table 6.9 and Figures 6.9 and 6.10.
During the OGTT, glucose concentrations peaked 30 minutes after the ingestion of 
the glucose load and returned to basal values by 60 minutes. Insulin concentrations 
also peaked at 30 minutes but did not return to basal values by the end of the test. 
Proinsulin concentrations peaked at 60 minutes and remained elevated until the end 
of the test (Table 6.9 and Figure 6.9).
Glucose, insulin and proinsulin concentrations rose significantly in response to the 
intravenous injection of glucagon (Table 6.9 and Figure 6.10).
The Pi/Ins % ratios were calculated for the OGTT and the glucagon stimulation test 
and the results are shown in Table 6.9 and Figures 6.9 and 6.10 respectively. 
During the OGTT the Pi/Ins % ratio reached a trough at 30 minutes and returned to 
basal values by 90 minutes. A similar fall in the Pi/Ins % ratio was observed after 
the intravenous injection of glucagon.
D iscussion
The results obtained from the subject with abnormally high proinsulin 
concentrations but normal insulin, glucose and C-peptide concentrations suggest the 
presence of antibodies to murine immunoglobulin in the serum of this individual. 
These antibodies would only interfere with the proinsulin assay as it entails the use 
of two murine McAbs. The insulin assay utilises one murine McAb and a guinea- 
pig antiserum. The presence of these antibodies in the serum of normal individuals 
has been reported (142, 143) and mouse serum was subsequently incorporated in 
the proinsulin assay diluent in order to prevent a repeat of this phenomenon.
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TABLE 6.8
INVESTIGATION OF ABNORMALLY HIGH MEASURED SERUM  
PROINSULIN CONCENTRATIONS IN A SINGLE SUBJECT
Proinsulin concentration (pmol/1)
Sample
dilution
Assay diluent Assay diluent + 1% 
(v/v) mouse serum
neat 19.17 0.9
1:2 9.94 -
1:4 2.91 -
1:8 0.83 -
1:16 UD - "■
U D  = undetectable
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Figure 6.9
Serum glucose, insulin and proinsulin concentrations and 
proinsulin/insulin percentage ratios during a 75 g glucose 
tolerance test.
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Lower concentrations of proinsulin were observed during the 75 g oral glucose 
tolerance test in this group of individuals compared with the normal data presented 
in Table 6 .6 . In Chapter 5, Figure 5.43, it was shown that proinsulin 
concentrations were decreased in serum which had been incubated at room 
temperature for more than 4 h. It is possible that the samples in this study had been 
subjected to such conditions during the performance of the initial assays for insulin 
and C-peptide, and therefore some degradation of proinsulin may have occurred.
1.6 Insulin Tolerance Test
Method
Proinsulin and insulin concentrations were measured in serum samples taken during 
an insulin tolerance test (ITT) from seven patients investigated for possible pituitary 
insufficiency but who were shown subsequently to have normal anterior pituitary 
function. Human insulin (0.15 U/kg body weight) was injected intravenously and 
serum samples collected before and 30,45, 60, 90 and 120 minutes after injection.
Results
The results are summarised in Table 6.10 and Figure 6.11. Insulin concentrations 
rose to a peak 30 minutes after the intravenous injection of insulin and returned to 
basal values at 120 minutes. The glucose concentrations fell to a nadir at 30 minutes 
in response to the rise in serum insulin, and subsequently increased but did not 
return to fasting values by the end of the test. Proinsulin concentrations reached a 
nadir at 45 minutes and were not significantly different from basal values by 
120  minutes.
D iscussion
The observed suppression of proinsulin secretion by administration of exogenous 
insulin is consistent with previous publications (144, 145). It has also been
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Figure 6.11
Serum glucose, insulin and proinsulin concentrations 
during an insulin tolerance test.
The individual values for each patient are shown together 
with the median values.
suggested that in the diagnosis of insulinoma, the suppression of proinsulin rather 
than C-peptide by exogenous insulin gives better discrimination between patients 
with insulinoma and control subjects (146).
1.7 General Discussion
The data presented in the previous sections confirm that serum insulin and 
proinsulin concentrations, measured by the assays described in this thesis, conform 
to the expected pattern in normal adult subjects under the majority of conditions 
evaluated.
An interesting observation is that the release of proinsulin is delayed relative to 
insulin in response to the ingestion of food (Section 1.2, Figure 6.3), and 
consequently the ratio of Pi/Ins % falls rapidly in response to the initial rise in blood 
glucose concentrations after feeding (Table 6.3). The latter phenomenon was also 
observed during the OGTT (Section 1.4, Table 6.7) and glucagon stimulation test 
(Section 1.5, Table 6.9).
These data suggest the presence of two pools of insulin in the (3 cell, only one of 
which contains proinsulin. Under basal conditions the proinsulin-containing insulin 
pool ('Pool Pl-Ins') is released, but in response to glucose the non-proinsulin 
insulin pool ('Pool Ins') is released preferentially initially, thus causing a fall in the 
Pl/Ins % ratio. The basic concept of two pools of insulin, one of which is important 
in the fasting state and the other after feeding has been suggested previously (147).
During the OGTT (Table 6.7) and following feeding in the 24 h study (Table 6.3), 
the Pl/Ins % ratio gradually increases again after the initial fall. This would suggest 
that the release of 'Pool Ins' occurs with a finite time after which release of 
’Pool PI-Ins' once again becomes predominant. This would correlate with the first 
and second-phase release of insulin in response to glucose (148).
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From the 24 h profiles of the Pl/Ins % ratio (both concentration and secretion rate in 
Figure 6.2) it can be seen that even under basal conditions the ratio fluctuates 
suggesting intermittent release of insulin from 'Pool Ins'. This could be accounted 
for by the pulsatile nature of insulin release observed under basal conditions (127).
Further evidence for the existence of two pools of insulin comes from the relatively 
recent discovery that pancreastatin inhibits the first-phase insulin secretory response 
but has little or no effect on the more prolonged second phase (149). Pancreastatin 
could therefore inhibit the release of 'Pool Ins' but not 'Pool PI-Ins'. In addition it 
has been shown that pancreastatin co-localises to the secretory granules of insulin 
(150) and it has been suggested that chromogranin A may be a precursor of 
pancreastatin (151). It could be hypothesised that the conversion of chromogranin 
A to pancreastatin only occurs in the secretory granules which form 'Pool Ins' and 
not in those forming 'Pool PI-Ins'. This would provide a mechanism for the 
changeover from first to second phase responses. An increase in blood glucose 
concentrations would stimulate the release of 'Pool Ins' which contains 
pancreastatin, and the latter on reaching a certain threshold, would inhibit the further 
release of insulin from 'Pool Ins' thereby causing the glucose to stimulate release of 
insulin from 'Pool PI-Ins'. As 'Pool PI-Ins' is hypothesised to contain 
chromogranin A rather than pancreastatin, the concentration of pancreastatin would 
fall below the threshold value and leave the first phase response intact for 
stimulation by further rapid increases in blood glucose concentrations.
If the above hypothesis proves to be substantiated, then the presence of proinsulin in 
only one of the two existing pools of insulin will provide a valuable marker for the 
investigation of the roles of each pool under physiological conditions and the 
possible defects which occur prior to and during pathophysiological changes.
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2 ALTERED PHYSIOLOGY AND PATHOPHYSIOLOGY
2.1 Non-Insulin Dependent Diabetes Mellitus 
Method
Serum samples were collected from two patients with non-insulin dependent 
diabetes mellitus (NIDDM) during the course of a 75 g OGTT.
Results
Details of the two patients are shown in Table 6.11. Only one of the two patients 
was receiving an oral hypoglycaemic agent for control of blood glucose 
concentrations at the time of study (patient MW). The serum glucose, insulin and 
proinsulin concentrations as well as the Pl/Ins % ratios during the OGTT are shown 
in Table 6.12.
Both patients had high fasting blood glucose concentrations which remained 
elevated throughout the OGTT and peaked later than normal (Table 6 .6). Fasting 
concentrations of insulin and proinsulin were above the normal range (Table 6 .6) 
and insulin concentrations peaked later than normal. The concentrations of insulin at 
all time points of the OGTT were within or slightly above the normal ranges 
observed in this thesis (Table 6 .6). In contrast, proinsulin concentrations were 
higher than the normal range (Table 6 .6) at all time points except the 90 minute 
sample from patient MW. The Pl/Ins % ratios were similar except at 30 and 
60 minutes when they were above the normal range (Table 6.7). The expected fall 
in the Pl/Ins % ratio in response to an increase in blood glucose concentrations was 
impaired in both patients.
D iscussion
The recent report in the literature of uniformly decreased insulin concentrations at the 
30 minute sampling period in patients with NIDDM (139) was established utilising
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TABLE 6.11
DETAILS OF NON-INSULIN DEPENDENT DIABETIC PATIENTS
Patient Age BMI Duration of Medication 
initials NIDDM
(years)
SD 61 30.4 3 Nifedipine (10 mg tds)
MW 59 32.7 5 Metformin (850 mg/day)
TABLE 6.12
SERUM GLUCOSE, INSULIN AND PROINSULIN CONCENTRATIONS AND 
PROINSULIN/INSULIN PERCENTAGE RATIOS IN TWO PATIENTS WITH 
NIDDM DURING A 75 g ORAL GLUCOSE TOLERANCE TEST
Patient Time (mins)
initials
0 30 60 90  120
Glucose (mmol/1)
SD 6.8  10.0 14.1 - 13.6
MW 8.0 9.5 13.6 15.3 14.2
Insulin (pmol/1)
SD 184 351 549 684 582
MW 145 192 260 415 379
Proinsulin (pmol/1)
SD 12.21 15.04 27.20 37.89 48.56
MW 7.42 10.34 12.66 16.76 20.52
Pl/Ins %
SD 6 .6  4.3 5.0 5.5 8.3
MW 5.1 5.4 4.9 4.0 5.4
an insulin IRMA which showed no cross-reactivity with proinsulin. The insulin 
IRMA which was developed in this thesis exhibits 60-85% cross-reaction of 
proinsulin depending on the dose and form measured (Table 5.9) and this may be a 
contributory cause of the discrepancy in results.
The impairment in the fall of the Pi/Ins % ratio in response to increased blood 
glucose concentrations correlates with the known loss of first-phase insulin 
response in NIDDM patients (152) and could be explained by an abnormality in the 
release of insulin from 'Pool Ins' as discussed in Section 1.7 of this chapter. It is 
interesting to note that the patient on metformin did not have a Pl/Ins % profile more 
similar to the normal pattern (Table 6.7) than the patient not receiving medication. 
In this respect it would be interesting to evaluate NIDDM patients before and after 
starting drug therapy.
2.2 Oral Glucose Tolerance Test in Pregnancy 
Methods
Plasma samples were obtained from fifteen pregnant females, in the second or third 
trimester, who underwent a 75 g OGTT at the Metabolic Unit, Western General 
Hospital, Edinburgh. The patients had been referred to the Unit for a variety of 
reasons, for evaluation of glucose tolerance. Plasma glucose was measured by the 
glucose oxidase method by MLSO staff in the Metabolic Unit. The non-obese 
pregnant female group comprised healthy laboratory personnel whose results have 
been presented in Section 1.4 of this chapter.
Results
Details of the patients included in this study are shown in Table 6.13. The pregnant 
females were divided into groups on the basis of glucose tolerance and their BMI 
prior to pregnancy. Two patients were not included in these groups; one exhibited 
normal glucose tolerance but had been classified as having gestational diabetes in a
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TABLE 6.13
ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY : PATIENT DETAILS
G roup Patient
in itials
Age BMI Weeks gestation
Non-pregnant, RR 32 22.1 NA
normal glucose AC 28 21.5 NA
tolerance, non-obese DB 37 23.1 NA
AMcL 27 25.6 NA
JE 38 21.1 NA
HC 42 21 .0 NA
VN 29 23.3 NA
AK 36 20.8 NA
CG 41 21.4 NA
Pregnant, normal JF 28 19.9 UK
glucose tolerance, AC 32 25.3 22
non-obese MW 26 25.6 32
PS 35 19.4 UK
MM 18 21.8 29
KD 24 24.9 33
Pregnant, normal LA 31 27.3 35
glucose tolerance, CT 31 30.2 UK
obese KF 27 36.2 33
SD 22 27.2 31
Pregnant, impaired PC 32 27.6 28
glucose tolerance, NN 40 34.6 32
non-obese/obese EH 23 19.3 UK
Previous gestational 
diabetic
CB 27 21.6 30
Placental tumour LMcK 27 23.3 30
NA = not applicable UK = unknown
previous pregnancy, and the other was discovered to have a benign placental tumour 
following caesarian section performed pre-term because of foetal distress.
Individual patient results for glucose, insulin and proinsulin concentrations, as well 
as Pi/Ins % ratios are presented in Tables 6.14-6.17 respectively. Due to 
insufficient patient numbers, only two comparisons could be performed: non-obese 
pregnant vs non-pregnant females, and non-obese vs obese pregnant females. The 
results of these statistical analyses are shown in Tables 6.18 and 6.19 respectively.
Pregnant non-obese females had higher fasting glucose concentrations than non­
pregnant non-obese females, and during the OGTT their plasma glucose and insulin 
concentrations peaked at 60 minutes instead of 30 minutes (Tables 6.14, 
6.15 and 6.18).
In non-obese and obese pregnant females, plasma glucose and insulin 
concentrations were not significantly different at any time during the OGTT 
(Tables 6.14, 6.15 and 6.19). However, the obese group exhibited higher fasting 
concentrations of proinsulin which remained significantly elevated until 90 minutes 
after ingestion of the glucose load (Table 6.16 and 6.19). The Pi/Ins % ratio was 
also increased in the obese group but only reached statistical significance at 
0, 120 and 180 minutes (Tables 6.17 and 6.19).
One of the three patients with impaired glucose tolerance required exogenous insulin 
(patient PC, Table 6.14). The plasma insulin concentrations in this patient were 
lower than the other two patients with impaired glucose tolerance from 30-120 
minutes of the OGTT. However, the concentrations were comparable to those of 
the pregnant females with normal glucose tolerance (Table 6.15). The plasma 
proinsulin concentrations in patient PC were lower throughout the OGTT, than the 
other two patients with impaired glucose tolerance and were below (0-60 min) or at 
the lower end (90-180 min) of the range observed in the pregnant females with 
normal glucose tolerance. The Pi/Ins % ratio of patient PC in the fasting state was
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TABLE 6.14
SERUM/PLASMA GLUCOSE CONCENTRATIONS IN PREGNANT AND NON­
PREGNANT FEMALES DURING A 75 g ORAL GLUCOSE TOLERANCE TEST
G roup Patient
initials
Timei (mins)
0 30 60 90 120 150 180
Glucose (mmol/1)
Non-pregnant, RR 4.3 7.9 7.3 7.0 5.8
normal glucose AC 4.7 7.3 5.2 4.2 5.0 - -
tolerance, non-obese DB 4.7 8.1 8.0 7.5 5.2 . -
AMcL 4.3 6.7 5.8 4.2 4.5 - .
JE 4.7 7.5 7.8 5.2 4.0 - -
HC 4.0 5.3 4.4 3.8 4.1 - -
VN 4.8 9.3 9.6 7.1 5.8 - -
AK 4.1 5.4 5.0 4.2 3.7 . -
CG 4.1 6.1 4.0 3.9 4.5 - -
Pregnant, normal JF 5.0 8.3 9.7 7.6 6.3 5.5 5.5
glucose tolerance, AC 4.7 6.1 6.8 6.4 5.7 5.2 4.7
non-obese MW 4.7 7.9 7.9 7.5 7.3 5.8 4.9
PS 4.8 6.8 5.3 5.3 5.4 5.6 5.3
MM 4.8 6.5 7.6 5.6 4.0 3.6 4.1
KD 5.3 7.5 7.7 7.2 7.4 6.8 4.5
Pregnant, normal LA 4.5 10.3 7.3 9.5 7.2 5.3 3.7
glucose tolerance, CT 5.2 7.9 8.4 6.8 7.2 6 .6 4.7
obese KF 4.4 8.0 8.1 7.4 7.0 5.0 4.0
SD 4.8 8.7 9.8 7.4 4.3 4.8 4.3
Pregnant, impaired PC* 5.6 9.4 10.9 10.4 9.0 8.1 6 .6
glucose tolerance, NN 5.8 11.7 13.5 11.1 9.4 6.9 5.3
non-obese/obese EH 4.8 7.8 9.3 8.6 8.0 6.7 4.8
Previous gestational CB 4.5 8.2 9.4 6.9 7.0 8 .6 9.4
diabetic
Placental tumour LMcK 4.3 8.7 10.1 9.5 8.4 5.6 3.9
*Patient required insulin
TABLE 6.15
SERUM/PLASMA INSULIN CONCENTRATIONS IN PREGNANT AND NON­
PREGNANT FEMALES DURING A 75 g ORAL GLUCOSE TOLERANCE TEST
Group Patient
initials
Time (mins)
0 30 60 90 120 150 180
Insulin (pmol/1)
Non-pregnant, RR 51 452 444 366 251
normal glucose AC 25 331 277 102 103 - -
tolerance, non-obese DB 28 249 406 464 221 - -
AMcL 47 429 526 281 291 - _
JE 57 136 251 145 97 - -
HC 25 187 270 177 183 - -
VN 23 448 554 642 559 - -
AK 35 114 161 282 196 - -
CG 36 379 281 202 198 - -
Pregnant, normal JF 26 207 330 377 353 250 232
glucose tolerance, AC 40 363 740 580 290 127 94
non-obese MW 52 588 414 410 384 158 48
PS 36 476 141 124 258 134 60
MM 61 356 581 222 75 55 66
KD 78 525 541 418 497 367 68
Pregnant, normal LA 39 1060 364 581 453 191 94
glucose tolerance, CT 68 374 467 328 463 378 131
obese KF 97 620 1073 855 611 302 129
SD 76 721 1108 560 138 202 60
Pregnant, impaired PC* 76 472 472 500 529 502 300
glucose tolerance, NN 94 1012 101 1180 1025 436 201
non-obese/obese EH 88 977 977 922 1079 600 236
Previous gestational CB 40 528 612 389 321 451 590
diabetic
Placental tumour LMcK 102 921 1876 1782 1794 545 251
♦Patient required insulin
TABLE 6.16
SERUM/PLASMA PROINSULIN CONCENTRATIONS IN PREGNANT AND
NON-PREGNANT FEMALES DURING A 75g ORAL GLUCOSE TOLERANCE
TEST
Group Patient Time (mins)
initials
0 30 60 90 120 150 180
Proinsulin (pmol/1)
Non-pregnant, RR 1.23 4.53 5.41 6.50 5.99
normal glucose AC 1.31 4.59 9.82 8.06 8.57 - -
tolerance, non-obese DB 1.46 3.62 10.71 18.69 16.18 . -
McL 1.56 3.33 5.85 5.88 6.39 - .
JE 1.61 1.99 4.80 5.68 4.64 - -
HC 1.58 3.48 5.14 7.89 7.24 - -
VN 1.47 4.93 8.77 14.33 15.26 - .
AK 1.43 3.67 6.04 11.42 10.99 - .
CG 2.09 5.43 8.82 7.18 8.18 - -
Pregnant, normal JF « 2.62 5.93 9.32 12.01 10.25 8.57
glucose tolerance, AC 1.24 2.83 5.86 10.59 8.40 7.50 5.77
non-obese MW 2.85 7.35 8.44 9.44 11.79 8.08 3.60
PS 0.89 5.23 4.36 4.77 5.50 3.23 2.80
MM 1.79 3.18 7.76 8.80 5.03 4.09 4.00
KD 2.47 6.93 14.59 16.20 18.72 15.64 9.70
Pregnant, normal LA 2.18 25.27 23.44 45.92 57.70 33.61 18.14
glucose tolerance, CT 4.34 13.09 22.96 27.08 40.11 39.96 25.58
obese KF 5.68 23.23 39.15 51.32 66.47 43.28 25.07
SD 3.16 6.74 19.04 17.70 10.43 7.22 4.12
Pregnant, impaired PC* 0.80 1.14 3.51 7.13 6.87 7.11 5.86
glucose tolerance, NN 3.47 6.28 13.88 22.71 28.25 21.56 15.09
non-obese/obese EH 5.19 7.20 13.83 24.32 36.63 33.57 23.94
Previous gestational CB 0.66 6.23 13.72 15.94 13.40 17.18 20.00
diabetic
Placental tumour LMcK 3.98 28.70 81.11 153.11 203.11 161.51 85.54
*Patient required insulin
TABLE 6.17
PROINSULIN/INSULIN PERCENTAGE RATIOS IN PREGNANT AND NON­
PREGNANT FEMALES DURING A 75 g ORAL GLUCOSE TOLERANCE TEST
Group Patient
initials
Time (mins)
0 30 60 90 120 150 180
Proinsulin/Insulin
Non-pregnant,
%
RR 2.4 1.0 1.2 1.8 2.4
normal glucose AC 5.2 1.4 3.5 7.9 8.3 - -
tolerance, non-obese DB 5.2 1.5 2 .6 4.0 7.3 - -
AMcL 3.3 0.8 1.1 2.1 2 .2 - -
JE 2.8 1.5 1.9 3.9 4.8 . -
HC 6.3 1.9 1.9 4.5 4.0 - -
VN 6.4 1.1 1.6 2 .2 2.7 - -
AK 4.1 3.2 3.8 4.0 5.6 - -
CG 5.8 1.4 3.1 3.6 4.1 - -
Pregnant, normal JF . 1.3 1.8 2.5 3.4 4.1 3.7
glucose tolerance, AC 3.1 0.8 0 .8 1.8 2.9 5.9 6.1
non-obese MW 5.5 1.3 2 .0 2.3 3.1 5.1 7.5
PS 2.5 1.1 3.1 3.8 2.1 2.4 4.7
MM 2.9 0.9 1.3 4.0 6.7 7.4 6.1
KD 3.2 1.3 2.7 3.9 3.8 4.3 14.3
Pregnant, normal LA 5.6 2.4 6.4 7.9 12.7 17.6 19.3
glucose tolerance, CT 6.4 3.5 4.9 8.3 8.7 10.6 19.5
obese KF 5.9 3.7 3.6 6.0 10.9 14.3 19.4
SD 4.2 0.9 1.7 3.2 7.6 3.6 6.9
Pregnant, impaired PC* 1.3 0.4 0.7 1.4 1.3 1.4 2 .0
glucose tolerance, NN 3.7 1.1 1.4 1.9 2.8 4.9 7.5
non-obese/obese EH 5.9 1.2 1.4 2 .6 3.4 5.6 10.1
Previous gestational CB 1.7 1.2 2 .2 4.1 4.2 3.8 3.4
diabetic
Placental tumour LMcK 3.9 3.1 4.3 8.6 11.3 29.6 34.1
*Patient required insulin
TABLE 6.18
STATISTICAL ANALYSIS OF SERUM/PLASMA GLUCOSE AND HORMONE 
CONCENTRATIONS IN NON-OBESE PREGNANT COMPARED WITH NON­
PREGNANT FEMALES, WITH NORMAL GLUCOSE TOLERANCE, DURING A 
75 g ORAL GLUCOSE TOLERANCE TEST
Time (mins)
0 30 60 90 1 2 0
Glucose (mmol/1)
Non-pregnant 4.3 7.3 5.8 4.2 4.5
Pregnant 4.8 7.2 7.7 6.8 6.5
P <0.01 NS NS NS NS
Insulin  (pmol/1)
Non-pregnant 35 331 281 281 198
Pregnant 46 420 478 394 322
P NS NS NS NS NS
Proinsulin  (pmol/1)
Non-pregnant 1.47 3.67 6.04 7.89 8.18
Pregnant 1.79 4.20 6.85 9.38 10.10
P NS NS NS NS NS
Pi/Ins %
Non-pregnant 5.2 1.4 1.9 3.9 4.1
Pregnant 3.0 1.2 1.9 3.2 3.3
P NS NS NS NS NS
NS = not significant
Results are expressed as median values. The ranges are not shown, as individual 
concentrations are presented in Tables 6.12 - 6.15.
TABLE 6.19
STATISTICAL ANALYSIS OF SERUM/PLASMA GLUCOSE AND HORMONE 
CONCENTRATIONS IN NON-OBESE C O M P A R E D  W IT H  O B E S E  
PREGNANT FEMALES, WITH NORMAL GLUCOSE TOLERANCE, DURING A 
75g ORAL GLUCOSE TOLERANCE TEST
Time (mins)
0 30 60 90 120 150 180
Glucose (mmol/1)
Non-obese 4.8 7.2 7.7 6.8 6.5 5.6 4.8
Obese 4.7 8.4 8.3 7.4 7.1 5.2 4.2
P NS NS NS NS NS NS NS
Insulin (pmol/1)
Non-obese 46 420 478 394 322 146 67
Obese 72 672 770 571 458 252 107
P NS NS NS NS NS NS NS
Proinsulin (pmol/1)
Non-obese 1.79 4.20 6.85 9.38 10.10 7.79 4.89
Obese 3.75 18.16 23.20 36.10 48.91 36.79 21.61
P =0.05 =0.05 =0.01 =0.01 NS NS NS
Pi/Ins %
Non-obese 3.0 1.2 1.9 3.2 3.3 4.7 6.1
Obese 5.8 3.0 4.3 7.0 9.8 12.5 19.4
P =0.05 NS NS NS =0.01 NS =0.05
NS = not significant
Results are expressed as median values. The ranges are not shown as individual 
concentrations are presented in Tables 6.12 - 6.15.
the lowest measured in this study, but followed the expected pattern during the 
OGTT, falling to a nadir at 30 minutes and gradually rising to fasting values 
(Table 6.17).
The other two patients with impaired glucose tolerance had higher plasma insulin 
concentrations at all time points of the OGTT (Table 6.15) and increased plasma 
proinsulin concentrations from 90-180 minutes (Table 6.16) when compared with 
the non-obese pregnant females. The Pi/Ins % ratios were similar to the non-obese 
pregnant females with normal glucose tolerance throughout.
Patient CB who exhibited normal glucose tolerance at the time of testing, but was 
known to have had gestational diabetes during a previous pregnancy, appeared to 
have similar plasma insulin and proinsulin concentrations to the non-obese pregnant 
females with normal glucose tolerance from 0-120 minutes. At 150 and 
180 minutes the plasma glucose concentrations started to rise again and a 
corresponding increase in insulin and proinsulin concentrations was observed 
(Tables 6.14 - 6.16). This patient exhibited a low fasting Pi/Ins % ratio which fell 
in response to an increase in plasma glucose concentrations at 30, 150 and 
180 minutes thus following the expected pattern (Tables 6.14 and 6.17).
Patient LMcK had impaired glucose tolerance and was subsequently found to have a 
benign placental tumour. The plasma insulin and proinsulin concentrations, 
throughout the OGTT, were higher than the non-obese pregnant females with 
normal glucose tolerance and were increased from 60-120 minutes (insulin) 
and 30-180 minutes (proinsulin) when compared with the two patients 
(NNandEH) with impaired glucose tolerance (Tables 6.15 and 6.16). The 
Pi/Ins % ratios were increased at all time points of the OGTT except 0 when 
compared with either the non-obese pregnant females with normal glucose tolerance 
or those with impaired glucose tolerance. The decrease in the Pi/Ins % ratio at 
30 minutes was not as marked in this patient (Table 6.17).
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Discussion
Glucose tolerance is known to decrease in normal human pregnancy with a 
corresponding increase in plasma insulin concentrations (153, 154). While these 
trends were apparent in the data presented here, they did not reach statistical 
significance possibly due to the small number of patients studied.
It has also been shown that although the absolute concentration of plasma proinsulin 
is increased in late normal and gestational diabetic pregnancy, this does not account 
for the glucose intolerance as the Pi/Ins % ratio is unchanged (153, 155). This 
observation was confirmed with the data presented above. The only group to show 
an increase in the Pi/Ins % ratio was the obese pregnant female group who had 
normal glucose tolerance.
The results presented in Table 6.17, the Pi/Ins % ratios, exhibit a number of 
interesting observations which merit discussion. The Pi/Ins % ratio was 
significantly higher in the obese compared with the non-obese pregnant females. In 
three of the four patients in this group the fall in the ratio at 30 minutes was not as 
great as that of either non-obese pregnant or non-pregnant females. This profile is 
similar to that observed for the two patients with NIDDM (Table 6.12) although the 
impairment of the decrease at 30 minutes is not so great. Therefore these three 
obese pregnant females are similar to the two patients with NIDDM both in their 
obesity and Pi/Ins % ratio profiles during an OGTT. Obesity is already known to 
be a common factor in patients with NIDDM (156) and as an impaired Pi/Ins % ratio 
profile may prove to be another common factor it would be interesting to establish 
whether the profile in these patients returned to normal post-partum, thus indicating 
whether pregnancy, which is known to be diabetogenic (153) had revealed this trait.
Two of the patients with impaired glucose tolerance (NN and EH) showed a normal 
Pl/Ins % ratio profile during the OGTT while the absolute plasma concentrations of
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both these hormones were raised. This is consistent with impaired glucose tolerance 
in pregnancy being due to insulin resistance (153) rather than a deficiency or 
abnormality of insulin secretion.
Finally, the patient with impaired glucose tolerance who required administration of 
exogenous insulin (patient PC) exhibited a Pi/Ins % ratio profile which followed the 
expected pattern, but the absolute ratios were lower at all time points. This profile 
differs from those observed for patients with NIDDM or the obese pregnant female 
group. In Section 1.7 of this chapter it was hypothesised that two different pools of 
insulin existed, 'Pool Ins' and 'Pool PI-Ins'. Taking this hypothesis a step further, 
if two different types of (3 cell existed which corresponded to the two pools of 
insulin, then it could be possible that 'Pool Ins' (3 cells are involved in the 
pathogenesis of NIDDM while 'Pool PI-Ins' p cells are those initially involved in 
the pathogenesis of insulin-dependent diabetes mellitus (IDDM).
2.3 Insulinoma
M ethods
Archive samples from three patients investigated for insulinoma, and subsequently 
proven positive following surgery, were assayed for insulin and proinsulin.
Results
Plasma glucose, insulin, proinsulin and C-peptide concentrations as well as the 
Pi/Ins % ratios of a number of fasting samples from each patient are shown in 
Table 6.20. All patients were hypoglycaemic at the time of sampling and C-peptide 
concentrations (when assayed) were within the normal range. Only patient WT 
exhibited clearly raised fasting concentrations of insulin whereas all three patients 
had fasting proinsulin concentrations outwith the normal range, although in patient 
NK the concentration was only marginally elevated. Patient GS was the only one 
with an abnormal Pi/Ins % ratio.
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TABLE 6.20
PL A SM A  G L U C O SE , IN S U L IN , P R O IN S U L IN  AND C -P E P T ID E  
CONCENTRATIONS AND THE PROINSULIN/INSULIN PERCENTAGE RATIOS 
IN FASTING SAMPLES FROM PATIENTS WITH INSULINOMA
Patient
in itia ls
Sex G lucose
(m m ol/1)
Insu lin
(pm ol/1)
P ro insu lin
(pmol/1)
C -peptide P i/In s  
(pmol/1) %
GS Female 95 87.44 350 92.0
1.9 102 84.50 390 82.8
WT Female 1.5 255 12.69 5.0
- 204 11.92 - 5.8
NK Male 1.9 81 6.81 300 8.4
1.7 53 7.59 300 14.3
1.1 121 6.51 550 5.4
1.4 82 7.90 400 9.6
Normal* Female 4.1-6.2 17-75 1.23-3.00 120-750 1.2-6.9
range Male 4.0-6.0 19-102 1.40-5.73 210-760 2.3-16.7
*Established from the fasting and OGTT data presented in this thesis.
However, the diagnosis of insulinoma is not made on the basis of a raised fasting 
insulin concentration. It is the fact that the insulin concentration is inappropriate in 
relation to the degree of hypoglycaemia which is important. This can be expressed 
as an amended insulin/glucose ratio (AI/G) and is calculated from the 
equation (157, 158):
AI/G = insulin (mU/D
glucose (mmol/1) - 1.7
An AI/G of greater than 30 is consistent with insulinoma.
Plasma proinsulin and insulin concentrations were measured in samples taken from 
patient GS during an insulin suppression test. These results, together with the 
previously available glucose and C-peptide data are presented in Table 6.21. There 
was incomplete suppression of both plasma proinsulin and C-peptide concentrations 
following administration of exogenous insulin.
The insulin and proinsulin concentrations, together with the Pi/Ins % ratios in 
samples taken from patient WT during pancreatic portal venous sampling, are 
shown in Table 6.22. Unfortunately, there was not a sufficient volume of the 
sample measured previously as having the highest insulin concentration to permit 
measurement of proinsulin. However, in the remaining samples the one with the 
highest insulin concentration also had the highest proinsulin concentration although 
the ratio of Pl/Ins % was lowest. It is also interesting to note that the Pi/Ins % ratio 
was less than 50% of that observed in the periphery in all the samples taken during 
this procedure except for the sample collected from the right gastric vein.
D iscussion
It is generally accepted that measurement of fasting proinsulin concentrations is 
useful in the diagnosis of insulinomas, especially in those cases where patients
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TABLE 6.21
PLASMA GLUCOSE, INSULIN, PROINSULIN AND C-PEPTIDE 
CONCENTRATIONS IN A PATIENT WITH INSULINOMA 
DURING AN INSULIN SUPPRESSION TEST
Time
(m in)
G lucose
(m m ol/1)
Insulin
(pm ol/1)
P ro insu lin
(pmol/I)
C -peptide
(pmol/I)
0 3.1 129 41.59 430
30 1.2 12550 49.56 470
45 0.5 5280 39.13 380
60 0.9 924 35.26 350
90 1.6 681 32.46 280
120 2 .0 285 35.37 330
The patient was GS.
TABLE 6.22
PLASMA INSULIN AND PROINSULIN CONCENTRATIONS IN A PATIENT 
DURING PANCREATIC PORTAL VENOUS SAMPLING
Sample
number
Location Insulin
(pmol/1)
Proinsulin
(pmol/1)
Pi/Ins %
1 Splenic vein 563 12.31 2 .2
3 Splenic vein 684 13.57 2 .0
4 Splenic vein 637 14.59 2.3
5 Portal vein 1195 14.39 1.2
6 Portal vein 1191 17.20 1.4
7 Portal vein 1030 18.32 1.8
9 Superior/common 
pancreatic vein
725 12.75 1.8
10 Left gastric vein 1759 17.01 1.0
11 Superior mesenteric vein 2160 19.72 1.0
12* Right colic vein >7570 - -
13 Gastro-epiploic vein 5674 31.02 0.5
14 Right gastric vein 328 14.04 4.3
15 Superior pancreatico­
duodenal vein
1528 19.94 1.3
Peripheral vein 204 11.92 5.8
*There was not sufficient sample remaining to re-measure the insulin concentration 
or measure the proinsulin and C-peptide concentrations. The patient was WT.
exhibit low plasma insulin concentrations during fasting (19, 146, 159, 160, 161). 
When inappropriately high concentrations of insulin and/or proinsulin in the 
presence of hypoglycaemia, after an overnight or more prolonged fast, have not 
been clearly demonstrated additional test can confirm the diagnosis of insulinoma. 
One of these tests, the insulin suppression test, involves administration of 
exogenous insulin to induce hypoglycaemia and simultaneous measurement of 
serum C-peptide or proinsulin concentrations. Normal subjects show marked 
suppression of both C-peptide and proinsulin concentrations whereas insulinoma 
patients show diminished or absent suppression (145, 157). The data shown in 
Table 6.21 is consistent with the diagnosis of insulinoma.
A technique to enhance the localisation of insulinomas has been developed which 
involves catheterisation of the portal and splenic veins and venous sampling for 
measurement of insulin. In this way, the tumour can be located by the presence of 
higher concentrations of insulin in the veins draining the tumour than in the veins 
draining uninvolved pancreas. This technique has been used successfully for 
tumours which otherwise proved difficult to locate although some problems have 
been encountered (162). This technique was used to locate the tumour in patient 
WT (Table 6.20).
The higher Pi/Ins % ratio found in the sample taken from the right gastric vein is 
due to a decreased concentration of insulin. This is probably a result of enzymatic 
degradation of insulin due to the fact that this vein drains the lesser curvature of the 
stomach and the pyloris.
2.4 Mendenhall's Syndrome
Methods
Archive fasting and OGTT samples from a 14 year old boy with Mendenhall’s 
Syndrome were assayed for insulin and proinsulin.
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Results
The clinical and biochemical features of this patient have been described 
previously (163).
The fasting plasma sample had a glucose concentration of 17.8 mmol/1 with insulin 
and proinsulin concentrations of 1997 pmol/1 and 27.04 pmol/1 respectively. The 
sample was assayed at several dilutions in the insulin assay and was found to dilute 
in parallel with the standards (Table 6.23).
The plasma glucose, insulin, proinsulin and C-peptide concentrations together with 
the PI/INS % and PI/CP % (proinsulin/C-peptide) ratios during the OGTT are 
shown in Table 6.24. Plasma glucose, insulin and C-peptide concentrations peaked 
at 30 minutes with proinsulin showing a peak at 60 minutes. The Pi/Ins % and 
PI/CP % ratios showed the expected decrease at 30 minutes followed by a gradual 
rise. However, while the PI/CP % ratios were within the normal range, the Pi/Ins 
% ratios were markedly lower.
D iscussion
Mendenhall's Syndrome is known to be a state of insulin resistance (163, 164, 165) 
and this accounts in part for the high circulating concentrations of insulin due to 
decreased degradation and clearance. An increase in insulin secretion in the basal 
state would also appear to contribute to the high circulating insulin concentrations as 
evidenced by the increased fasting C-peptide concentrations observed. This in turn 
would account for the decreased Pi/Ins % ratios while the PI/CP % ratios are within 
the normal range, although they are at the lower end. The marginally elevated 
proinsulin concentrations are probably due to decreased clearance caused by the 
insulin resistance. The first-phase insulin secretion appears to be intact as the Pi/Ins 
% ratio falls as expected at 30 minutes during the OGTT and thereafter rises as the 
insulin concentrations fall and the proinsulin concentrations increase.
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TABLE 6.23
MEASUREMENT OF INSULIN CONCENTRATION IN SERIALLY DILUTED 
PLASMA FROM A BOY WITH MENDENHALL’S SYNDROME
Sample dilution Measured insulin concentration (pmol/1)
1:5 408
1:10 205
1:20 98
1:40 48
TABLE 6.24
SERUM GLUCOSE, INSULIN, PROINSULIN AND C-PEPTIDE CONCEN­
TRATIONS AND PR O INSULIN/INSULIN AND PRO INSULIN/C-PEPTIDE  
PERCENTAGE RATIOS IN A BOY WITH MENDENHALL'S SYNDROME  
DURING A 75 g ORAL GLUCOSE TOLERANCE TEST
Time
(min)
Glucose
(mmol/1)
Insulin
(pmol/1)
Proinsulin
(pmol/1)
C-peptide
(pmol/1)
Pi/Ins
%
PI/CP
%
0 11.7 2410 8.04 2 300 0.33 0.35
5 18.9 2873 7.48 5 500 0.26 0.14
30 30.1 9093 13.33 10 200 0.15 0.13
60 29.9 7753 21.61 4 100 0.28 0.53
90 24.4 5516 15.09 3 900 0.27 0.39
: i-if '.-n~ V;v ■ ;y O-yy n vv.y;.; rMi
It is hypothesised that the increased insulin secretion observed in this patient is due 
to release of insulin from 'Pool Ins' rather than 'Pool PI-Ins' as the basal 
concentrations of proinsulin are only marginally elevated in comparison to the C- 
peptide concentrations. This would result from the continuous glucose challenge 
resulting from the observed hyperglycaemia. The constant hyperinsulinaemia could 
then result in a down-regulation of receptors which in turn would aggravate the 
existing situation. It is not known whether a continuous glucose challenge in 
normal individuals would result in the same pattern of secretion and therefore no 
conclusions can be made concerning a possible defect of insulin secretion in this 
syndrome.
In view of the recent description of a third-phase of insulin release, observed in 
intact islet or whole pancreas preparations in response to a continuous glucose 
challenge (166, 167), it is interesting to speculate whether this syndrome exhibits an 
in vivo expression of this phenomenon and if so, whether the insulin response 
observed is abnormal.
2.5 Oral Glucose Tolerance Test in Cirrhosis 
Methods
Three groups of patients underwent a standard 75 g OGTT. The normal control 
group comprised healthy laboratory personnel whose results have been presented in 
Section 1.4 of this chapter. The inpatient control group were selected randomly 
from patients admitted to the Department of Surgery at Glasgow Royal Infirmary, 
for procedures unrelated to hepatic, renal and gastro-intestinal disease. Typically 
they were receiving treatment for varicose veins and hernias. The cirrhotic patients 
were all biopsy-proven.
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Results
Details of the three patient groups are shown in Table 6.25. The cirrhotic and 
inpatient control groups were matched for age, and both were older than the normal 
control group. All of the normal control group exhibited normal glucose tolerance 
whereas in the inpatient control group four (44%) had impaired glucose tolerance 
and two (22%) were classified as diabetic. A similar distribution was observed in 
the cirrhotic group where seven patients (50%) had impaired glucose tolerance and 
three (21%) were diabetic.
The glucose, insulin, proinsulin and C-peptide concentrations of the three groups 
during a 75 g OGTT are shown in Table 6.26 and Figure 6.12. The glucose, 
proinsulin and C-peptide profiles of the age-matched inpatient control and cirrhotic 
groups were similar at fasting and at all time points of the OGTT. However, 
compared to the younger normal control group, both groups exhibited significantly 
increased concentrations of glucose and proinsulin from 30 to 120 minutes during 
the OGTT and significantly decreased concentrations of C-peptide at 30 minutes 
(cirrhotic group) and 30 and 60 minutes (inpatient controls).
Insulin concentrations at fasting and during the OGTT were similar in the inpatient 
control and cirrhotic groups except at 90 minutes when the cirrhotic patients had a 
significantly increased plasma insulin concentration. The inpatient and normal 
controls only differed at 120 minutes when the former group had significantly 
higher insulin concentrations. In contrast, the cirrhotic group exhibited fasting 
hyperinsulinaemia and also showed significandy increased insulin concentrations at 
60, 90 and 120 minutes during the OGTT when compared with the normal control 
group.
The Pi/Ins % and PI/CP % (proinsulin/C-peptide) ratios for the three groups during 
the OGTT are shown in Table 6.27. The Pi/Ins % ratios are interesting for they
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Figure 6.12
Plasm a glucose, insulin, proinsulin and C-peptide 
concentrations in patients with cirrhosis during a 75 g oral 
glucose tolerance test.
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only detect the inpatient control group as being different from the normal controls. 
At first sight, the cirrhotic group would appear to have a normal Pi/Ins % profile, 
but this results from increases in both insulin and proinsulin concentrations. A more 
accurate reflection of actual events is given by the PI/CP % ratios which detect both 
the inpatient and cirrhotic groups as being similar and different from the normal 
control group. Both groups showed an increased fasting PI/CP % ratio but this did 
not reach statistical significance. The increased ratios observed during the OGTT 
however, were significant. The normal controls exhibited a decrease in the PI/CP % 
ratio at 30 minutes (p<0.01) and a return to basal values at 60 minutes until the end 
of the test. Both the inpatient and cirrhotic group failed to show the decrease at 
30 minutes and exhibited raised PI/CP % ratios from 60 minutes until the end of the 
test (p<0.05).
D iscussion
The observed prevalence of abnormal glucose tolerance in the cirrhotic patients in 
this study was higher than has been reported previously (168). However, the 
similar prevalence found in the inpatient control group suggests that other factors 
may also have contributed to the higher incidence observed in this study.
The hyperinsulinaemia of the cirrhotic group, when compared with the normal 
control group, both at fasting and following ingestion of a glucose load is in 
agreement with other studies (140, 169, 170, 171, 172, 173, 174). Similarly 
hyperproinsulinaemia at fasting and after a glucose load has been reported (171). 
The data presented here is consistent with hyperproinsulinaemia following a glucose 
load, but although the cirrhotic group showed median fasting proinsulin 
concentrations twofold greater than the normal control group (171) this was not 
statistically significant. One group did not find any difference in serum proinsulin 
concentrations at fasting and following a glucose load (140) and it was suggested 
that this was due to the fact that their assay did not measure 32-33 split and
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des 31-32 proinsulin. As their assay, although an RIA, exhibited similar specificity 
to the one used in this study, their explanation for not detecting 
hyperproinsulinaemia in cirrhotic patients does not appear to be valid.
The majority of investigations have reported C-peptide concentrations at fasting 
and/or following a glucose load to be normal (170, 171) or increased (140, 169,
171, 172, 173, 176). The results obtained in this study are in accordance with those 
that found normal fasting C-peptide concentrations (170), but differ from all 
previous investigations in finding that the C-peptide concentrations during an OGTT 
are decreased in cirrhotic patients compared with normal controls.
All previous studies have only compared cirrhotic patients with normal healthy 
control subjects who in many instances were laboratory personnel (170, 171,
172, 173) or not specified (140, 176). Only one group stated that the control as 
well as the cirrhotic group were hospitalised during the study (172). In addition to 
the comparison of the cirrhotic group with a normal control group, this study also 
compared them with an equivalent inpatient population selected at random.
When the inpatient and normal control groups were compared, the inpatient group, 
like the cirrhotic patients, exhibited glucose intolerance, increased proinsulin 
concentrations and decreased C-peptide concentrations during an OGTT. They only 
differed from the control group with respect to insulin concentrations at 120 minutes 
of the OGTT. Therefore, in comparison with the inpatient control group, the 
cirrhotic patients only appeared to be abnormal in having fasting hyperinsulinaemia 
and increased insulin concentrations at 60 and 90 minutes during the OGTT.
The hyperinsulinaemia cannot be explained by increased secretion as fasting C- 
peptide concentrations are normal and are decreased in response to an OGTT 
compared to normal controls. A decrease in the insulin response to glucose has also 
been shown by Greco et al (174) who measured insulin in portal and peripheral 
blood following a glucose load. Whereas peripheral hyperinsulinaemia was
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observed, the concentrations of insulin in portal blood were lower than in control 
subjects. Johnston et al (177) also suggested the presence of mild p cell deficiency 
in cirrhosis. Therefore the hyperinsulinaemia observed must be due to decreased 
degradation rather than increased secretion. This is substantiated by other groups 
who have shown a decreased fractional uptake of insulin by human cirrhotic liver 
(178) and a longer half-life for insulin in cirrhotic rat liver (179). A number of other 
studies also concluded that the hyperinsulinaemia of cirrhosis was due to decreased 
degradation rather than increased secretion (170, 177, 180) but the majority of 
studies have concluded that both hypersecretion and diminished degradation are 
responsible (140, 169, 171, 172, 173, 176). It has also been suggested that 
hyperproinsulinaemia contributes substantially to the increased concentrations of 
insulin (171). This study found increased concentrations of proinsulin in patients 
with cirrhosis but conclude that it does not contribute to the increased insulin 
concentrations as the inpatient group which showed an equivalent increase in 
proinsulin did not exhibit the same extent of hyperinsulinaemia.
It has been reported that patients with cirrhosis of the liver have an impaired first- 
phase but not second-phase, insulin response (181). The data presented here is 
consistent with this as the PI/CP % ratios did not show the expected decrease at 
30 minutes during an OGTT. This also correlates with the prevalence of IGT and 
diabetes observed.
In conclusion, the data in this study suggest that cirrhosis of the liver is associated 
with glucose intolerance, hyperinsulinaemia and hyperproinsulinaemia. The 
hyperinsulinaemia is attributable to diminished degradation. However, an inpatient 
population exhibited the same characteristic features as the cirrhotic patients except 
for the hyperinsulinaemia. Therefore, it is suggested that only the 
hyperinsulinaemia is truly secondary to development of cirrhosis of the liver and 
other factors may be involved in causing the glucose intolerance, 
hyperproinsulinaemia and diminished insulin response during an OGTT.
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CHAPTER 7 
GENERAL DISCUSSION
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When the aims of this thesis were originally proposed, the main difficulty envisaged 
was the production of insulin and C-peptide antibodies of sufficiently high avidity to 
permit the development of a two-site IRMA capable of measuring the low 
concentrations of proinsulin found in human serum in the basal state. It was hoped 
that production of a proinsulin-specific McAb would be possible and that use of 
such an antibody in an assay to measure proinsulin would overcome the problems 
associated with cross-reaction from insulin and C-peptide.
It soon became apparent that these views were rather simplistic. Although it had 
been suggested that proinsulin in human serum was heterogeneous (40), it was not 
known to what extent this reflected intact proinsulin and the various conversion 
intermediates. Also, the shortage of well-defined proinsulin standards did not 
permit characterisation of the proinsulin assays which had been developed (33, 34) 
and it was assumed that all the forms of proinsulin were measured equally. It was 
only with the introduction of biosynthetic human proinsulin that the situation was 
clarified and previous extracted pancreatic proinsulin standards were shown to 
behave differently to the biosynthetic proinsulin standards in the assays available 
(182, 183). The extracted pancreatic standards appeared to comprise partially 
hydrolysed rather than intact proinsulin and this led to the suggestion that the major 
circulating form of proinsulin was possibly one or both of the conversion 
intermediates rather than the intact molecule (183). At about the same time it was 
also shown that polyclonal and monoclonal antibodies specific for proinsulin reacted 
with an epitope which involved the B-C chain junction, and therefore these 
antibodies could not be used in an assay to measure the 32-33 split/des 31-32 forms 
of proinsulin.
It was therefore decided that the assays developed in this thesis would reflect the 
specificity of the antibodies developed as there was no indication as to which form 
of proinsulin should be measured. The final assay developed measured intact and
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65-66 split/des 64-65 proinsulin and was sufficiently sensitive to measure fasting 
serum concentrations of proinsulin.
A two-site insulin IRMA was also developed, using a polyclonal and monoclonal 
anti-insulin, and was shown to cross-react to a lesser extent with all forms of 
proinsulin than the locally established RIA.
During the work performed to produce antibodies to insulin and proinsulin and the 
subsequent development of the assays, a number of interesting observations were 
made. It would appear that the polyclonal antibody response to a molecule the size 
of insulin may not be as heterogeneous as expected. The data presented in 
Chapter 3 indicated that the antibodies raised to insulin in a number of animal 
species appeared to be restricted to a single, or small number, of epitopes and that 
certain epitopes on the molecule were immunodominant. When the 
immunodominant epitope was masked due to conjugation to a carrier protein, the 
immune response either failed or was directed against a different epitope. Similar 
evidence was obtained from hybridisation experiments where it was noted that the 
McAbs produced in any one fusion appeared to be restricted with respect to the 
epitope recognised. The fusion using insulin as immunogen resulted in three 
McAbs of apparently identical specificity. Likewise, the two fusions with 
proinsulin produced either McAbs against C-peptide or a proinsulin-specific 
determinant but not both.
The practical constraints of the above finding were observed when the polyclonal 
anti-insulin was used to develop a two-site IRMA for insulin as only one of the two 
specificities of McAb produced could be used as a partner antibody.
Practical difficulties were also encountered when developing the proinsulin IRMA 
due to the presence of high molar concentrations of insulin compared to proinsulin 
in clinical samples. This required that proinsulin be reacted with a solid-phase
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coupled proinsulin-specific McAb, to permit the removal of insulin, prior to the 
addition of the radiolabelled insulin McAb thus abolishing possible interference.
It would appear that the sensitivity of the proinsulin assay cannot be further 
improved with the use of 125]-iabelled antibodies, unless an amplification step was 
included, as the zero dose binding tubes gave a count rate which was only 200- 
300 cpm above the background count rate.
The aim of this thesis which was not met was the production of suitable antibodies 
to permit the development of an immunoassay for C-peptide. The C-peptide McAb 
produced was shown to be of too low avidity for use in RIA techniques to measure 
either proinsulin or C-peptide, although latterly it was shown to have potential for 
the development of a proinsulin IRMA.
C-peptides are known to be poor immunogens (184, 185, 186) and require 
conjugation to a carrier protein prior to immunisation. Even then, the production of 
high avidity antisera is difficult (185). The cost of human C-peptide restricted the 
quantity which could be purchased and required that conjugation techniques be 
evaluated in a model system. Although some initial groundwork was performed, 
due to the limited time available, this work was not completed.
If the original aims of this thesis were to be reassessed at this point in time with 
respect to antibody production and assay development, they would probably reflect 
the recent achievement by W J Sobey et al (32) in developing IRMA’s for each of 
the forms of proinsulin as well as an insulin-specific IRMA. However, in view of 
the recent reports in the literature of antibodies specific for the A-C junction of the 
proinsulin molecule (187) and the B30 residue of human insulin (188), it may be 
possible to develop an improved IRMA which would be specific for 32-33 split/ 
des 31-32 proinsulin. In addition, it would be interesting to establish whether it is 
possible to develop a two-site assay for a molecule the size of C-peptide. It would 
also be proposed that alternative detection systems be evaluated in an attempt to
1 5 5
improve the sensitivity of the various proinsulin assays, thus allowing more accurate 
and precise measurement of proinsulin in the basal state.
The final two aims of this thesis were related to the clinical application of the assays 
developed. Proinsulin and insulin concentrations were measured during fasting and 
various dynamic function tests under both physiological and pathophysiological 
conditions. From the data collected, a number of interesting observations were 
made which merit further investigation.
The finding that females have lower concentrations of intact proinsulin than males at 
fasting and during an OGTT requires the investigation of larger numbers to 
determine the true significance of this observation. It would also be interesting to 
measure the concentration of 32-33 split/des 31-32 proinsulin in the same groups to 
assess whether a similar pattern resulted. If the differences were found to be 
significant they would have major implications for studies involving the 
measurement of proinsulin as male and female groups would have to be investigated 
separately.
The most interesting finding was that insulin appeared to be released from two 
pools, only one of which appeared to contain intact proinsulin. It would be useful 
to ascertain whether the same apparent distribution occurs for the proinsulin 
conversion intermediates. However, in the studies performed in this thesis, the 
above observation enabled the use of Pi/Ins % and PI/CP % ratios, in conjunction 
with the raw insulin, proinsulin and C-peptide concentration data, to detect abnormal 
patterns of insulin release from one or both pools.
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It is suggested that the future aims of this work might encompass the following 
proposals:
(i) Observation of the Pi/Ins % and PI/CP % ratio profiles, from normal 
volunteers and patients with NIDDM, over the first 30 minutes of an OGTT 
using various sampling intervals. It should then be possible to determine the 
maximum sampling interval from which a clinically useful profile can be 
obtained.
(ii) Using the conditions determined above, establishment of normal Pi/Ins % and 
PI/CP % ratio profiles in a large group of normal volunteers.
(iii) Investigation of larger numbers of patients with IGT, NIDDM and IDDM 
during an OGTT to evaluate whether characteristic profiles can be determined 
for each group.
(iv) Study of a group of people known to be at risk of developing NIDDM and/or 
IDDM to ascertain whether characteristic changes occur in the Pl/Ins % and/or 
PI/CP % profiles over the years preceding the clinical manifestations of 
diabetes.
(v) Study of newly diagnosed NIDDM patients with respect to their Pl/Ins % and 
PI/CP % profiles during an OGTT. Investigation of whether any changes 
occur as they proceed from treatment by diet alone, to drug therapy and if 
necessary, administration of exogenous insulin.
From the results of the above studies it would be hoped that it may be possible to 
detect those people who are at risk of developing insulin or non-insulin dependent 
diabetes mellitus. This might be useful in the future if prophylactic treatment for the
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prevention of diabetes became available. It also might be possible to determine 
guidelines to evaluate which patients with NIDDM can be successfully treated by 
diet, drugs and/or insulin and to assess when and if these requirements change.
It would also be interesting to investigate the Pl/Ins % and PI/CP % ratios in 
response to insulin secretagogues other than glucose to determine if differences 
occur in the pattern of insulin secretion depending upon the stimulus received. 
Again investigation of normal volunteers, patients with NIDDM/EDDM and those in 
the prediabetic period may possibly provide useful markers for those at risk of 
developing diabetes.
Finally, the possible role of pancreastatin in the regulation of insulin secretion and 
the clinical relevance of the third-phase of insulin secretion, especially in the context 
of the boy with Mendenhall's Syndrome, would be an interesting topic of 
investigation.
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